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The nucleotide excision repair (NER) pathway is a central DNA repair mechanism to repair a 
variety of bulky DNA lesions. Accumulation of these types of damage all over the genome 
results in the development of a cancer prone mutator phenotype, as it can be seen in patients 
with the autosomal recessive disease xeroderma pigmentosum, and their high frequency of 
ultraviolet induced skin tumors. It is known that decreased NER level are a risk factor for 
several cancer entities. Several components of the NER pathway already serve as biomarkers 
for cancer risk and treatment success. The endonucleases XPF/ERCC1 and XPG are the core 
components of the incision complex of NER. XPF/ERCC1 is also involved in the repair of 
DNA interstrand crosslinks (ICL). Due to the essential roles of this complex, patient cells 
retain at least one full-length allele and residual repair capabilities, rendering them unsuitable 
for XPF variant analyses. 
In the course of this thesis, the CRISPR/Cas9 technology was established in the laboratory 
and applied to generate an XPF knockout in a fetal lung fibroblast cell line (MRC5Vi cells), 
to analyze the unknown functional relevance of physiologically occurring, spontaneous XPF 
mRNA splice variants. Furthermore, functional roles of XPF point mutants in NER and ICL 
repair were investigated.  
The successfully generated XPF knockout cells were markedly sensitive to UVC, cisplatin, 
and PUVA (psoralen activated by UVA) and had reduced repair capabilities for NER and ICL 
repair as assessed by reporter gene assays. Using the knockout cells it was shown that human 
XPF is predominately involved in homologous recombination repair but dispensable for non-
homologous end-joining. Notably, while ERCC1 was stably expressed in the cytosol, it was 
not detectable in the nucleus without its heterodimeric partner XPF, implicating the necessity 
of functional XPF to retain ERCC1 in the nucleus. Overexpression of wildtype XPF reversed 
these effects. Functional analyses revealed two XPF splice variants with residual repair 
capabilities (XPF-201 and XPF-003) in NER, as well as ICL repair. XPF-201 lacks the first 
12 amino acids of the protein, while XPF-003 is severely C-terminally truncated. 
Interestingly, another variant, XPF-202, which differs to XPF-003 in the first 12 amino acids 
only, had no repair capability whatsoever, suggesting an important role of this protein region. 
It might be involved in interacting with other proteins of the DNA repair machinery.  
Splice variants of XPF and XPG, already characterized during my master thesis, were 
identified to exert dominant negative effects on NER, when stably overexpressed in wildtype 
cells. Additionally, the newly generated KO cells represent a highly promising tool for 
Abstract 
XIII 
mechanistic studies. In this cellular background without XPF expression, point mutants 
showed different catalytic activities compared to reconstituted in vitro systems, which are 
limited by the artificial combination of recombinant proteins, or patient cell lines retaining at 
least one full-length allele.  
Finally, it was shown that the XPF and XPG splice variants varied in their inter-individual 
expression in healthy donors, as well as in various tissues. Together with their residual repair 
capability, dominant-negative effects, and different expression levels, functionally relevant 
spontaneous splice variants of XPF and XPG present promising prognostic marker candidates 
for individual cancer risk, disease outcome, and therapeutic success. Association studies and 
translational research within clinical trials will have to confirm this assumption in the future. 
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The genetic information necessary for growth, development, functioning, and reproduction of 
all known living organisms, except RNA viruses, is coded in the deoxyribonucleic acid 
(DNA). According to a central dogma, DNA is transcribed into messenger RNA (mRNA), 
and mRNA is then translated into proteins (protein biosynthesis), which fulfill all sorts of 
different functions in the cell (Crick, 1970). A living organism is constantly exposed to 
different exogenous and endogenous DNA damaging agents that can alter the genomic 
sequence, causing impairment of protein function, resulting in accumulation of defective 
proteins, and finally leading to a mutator phenotype (reviewed in Bertram, 2000). On the one 
hand, this is an evolutionary engine, but on the other hand can cause carcinogenesis in case of 
mutated tumor suppressor genes (Goh et al., 2011; Hoeijmakers, 2009; Hollstein et al., 1991).  
1.1 UV irradiation and the skin 
Electromagnetic radiation with a range from 100-400nm, UV light, is a commonly known, 
very potent mutagen, and can be subdivided into UVA, UVB and UVC (reviewed in Seebode 
et al., 2016).  
1.1.1 Penetration 
UVC irradiation (100-280nm) comprises the shortest wavelength, but the highest energy and 
lies in the absorption maximum of DNA (245nm). Anyhow, the largest portion of UVC 
irradiation is blocked by the ozone-containing stratosphere and would be absorbed by the 
corneal barrier of the skin (stratum corneum) if it would reach the earth’s surface. UVB  
(280-315nm) and UVA (315-400nm) irradiation are able to penetrate the atmosphere and 
cause damage to the DNA (Rastogi et al., 2010). UVA irradiation is commonly known to be 
the factor that influences skin aging as it reaches deeper layers of the skin, the dermis, where 
elastic and collagen fibers are located, whereas UVB can only penetrate into the deepest 




Figure 1: Penetration depth and effects of UV irradiation 
The left panel shows a histological cut of human skin (hematoxylin eosin staining, x40), while the right panel 
shows a schematic view of the penetration depth of UV and visible light through the skin. UVC irradiation  
(100-280nm) is blocked by the stratosphere and does not reach the earth’s surface. UVB irradiation (280-315nm) 
penetrates into the stratum basale and can directly be absorbed by the DNA leading to the generation of bulky 
DNA lesions (6-4PPs and CPDs). UVA irradiation (315-400nm) reaches the dermis mainly causing the 
formation of reactive oxygen species, which then result in strand breaks, abasic sites, oxidative damage or base 
modifications. Illustration by Dr. rer. nat. Christina Seebode.  
1.1.2 UV induced DNA lesions 
While UVA only causes indirect DNA damage through the creation of free radicals, UVB and 
UVC directly lead to DNA lesions by crosslinking of adjacent pyrimidine bases and the 
formation of bulky adducts. This results in two lesions of different types, the cyclobutane 
pyrimidine dimers (CPDs) or 6,4- pyrimidine pyrimydone photoproducts (6-4PPs) (Lippke et 
al., 1981; Mitchell & Nairn, 1989) (see Figure 2). CPDs make up 75% of the lesions and 
contain a four membered ring arising from the coupling of the C=C double bonds of 
pyrimidines, while 6-4PPs (25%) lead to a crosslink of C6 of one pyrimidine and C4 of the 
other pyrimidine resulting in a stronger distortion of the DNA backbone (Vink & Roza, 2001; 
Yokoyama et al., 2012). 6-4PPs are more rapidly repaired in the cell (within six hours) than 
CPDs that still persist after 12 hours (50%) (Kobayashi et al., 2001). Therefore, CPDs are the 




Figure 2: UV-induced DNA lesions 
UVB irradiation can directly be absorbed by the DNA and leads to the formation of DNA photoproducts. 
Adjacent pyrimidine bases (thymidines (T) and cytosines (C)) are crosslinked and form CPDs and 6-4PPs with a 
ratio of 3:1 (from (Seebode et al., 2016)). 
In the course of replication, one possibility for cells to cope with these DNA damages, are 
translesion polymerases, if the damage has not been repaired before the cell enters the S-phase 
of the cell cycle. A typical UV signature mutation is the C to T or CC to TT transition that has 
been found in TP53 genes of squamous cell carcinomas (SCCs) (Brash et al., 1991). These 
signature mutations follow the A-rule, meaning that the translesion polymerase ƞ, which lacks 
a proof-reading function, complements the crosslinked pyrimidine bases with two adenines on 
the opposite strand (reviewed in Matsumura & Ananthaswamy, 2002). That is why 
evolutionary other pathways developed to repair DNA damage (see 1.2).  
1.1.3 The multistep carcinogenesis model 
As described by Hanahan and Weinberg, the accumulation of mutations is one of the 
hallmarks of cancer (reviewed in Hanahan & Weinberg, 2000). In the multistep 
carcinogenesis process, a key step is the mutational activation of oncogenes or inhibition of 
tumor suppressor genes, resulting in the loss of cell cycle control and apoptosis while leading 
to uncontrolled cell proliferation (reviewed in Soehnge et al., 1997).  
Different molecular mechanisms are involved in skin cancer development. Among other 
effects, UVB irradiation can promote cell proliferation through the MAPK (mitogen-activated 
protein kinase) pathway, via activating mutations of the RAS oncogene (reviewed in 
Melnikova & Ananthaswamy, 2005). Furthermore, activation of the sonic hedgehog (SHH) 
pathway components PTCH1 and SMO is a key feature of basal cell carcinoma (BCCs) 
driving cell proliferation and tumor growth (reviewed in Athar et al., 2014; Emmert et al., 
2014). UV signature mutations occurring in early stages of oncogenic transformations in the 
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skin can also be found in the TP53 gene in SCCs and BCCs, resulting in a defective p53 
protein, which is known to be the “guardian of the genome” (Ehrhart et al., 2003; Inciarte et 
al., 1976). The p53 protein is involved in multiple cellular processes and fulfills various 
functions amongst which are the activation of cell cycle checkpoints, DNA repair, and 
initiation of apoptosis (Fridman & Lowe, 2003; Greenblatt et al., 2003; Oren, 1999). The 
CDKN2A gene encodes for two strong tumor suppressors involved in cell cycle regulation. 
p16INK4A prevents phosphorylation of the retinoblastoma (RB) protein by CDK4/CDK6 and 
therefore progression from G1- to S-phase, while p14ARF stabilizes the cellular p53 level, 
thereby preventing oncogenic cell transformations (Emmert et al., 2014; Saridaki et al., 2003; 
Sharpless & Chin, 2003). 
Xeroderma pigmentosum (XP) patients, who have a high predisposition for skin cancer 
development, present a unique model disease to analyze the effects of unrepaired DNA 
lesions in skin carcinogenesis and accelerated skin cancer development (reviewed in Daya-
Grosjean, 2008) (see 1.3.1). 
1.2 DNA repair 
As previously mentioned, UV light was of great importance during the earliest steps of 
evolution as the ability of DNA to absorb UV light led to the development of long chain RNA 
molecules generating more complex organisms (Mulkidjanian et al., 2012). Therefore, UV 
induced mutations can be seen as an evolutionary engine in the development and progression 
of life. However, forced by evolutionary pressure, at some point all living organisms 
developed a complex network of DNA repair pathways to alleviate harmful effects of DNA 
damage and maintain genome integrity, the DNA damage response (DDR) (reviewed in 
Giglia-Mari et al., 2011).  
1.2.1 DNA damage response (DDR) 
The DDR is a complex network of cellular pathways that sense, signal and repair DNA 
lesions through activating cell cycle checkpoints and DNA repair pathways in response to 
DNA damage by surveillance proteins that monitor DNA integrity. The DDR consists of a 
phosphorylation cascade that is initiated by stalled replication forks or polymerases (reviewed 
in Giglia-Mari et al., 2011).  
The protein kinases ATM (PI3K-like kinases ataxia-telangiectasia mutated) and ATR (ataxia-
telangiectasia and Rad3-related), which are recruited and activated by double strand breaks 
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(DSBs) and replication protein A (RPA)-coated single stranded DNA (ssDNA), are key 
components of the DDR-signaling cascade in mammalian cells (reviewed in Bartek & Lukas, 
2007; Cimprich & Cortez, 2008; Shiloh, 2003). Subsequently, ATM and ATR phosphorylate 
the target protein kinases CHK1 and CHK2 and together reduce cyclin-dependent kinase 
(CDK) activity by various mechanisms, e.g. activation of p53 and p21 resulting in G1/S and 
G2/M cell cycle arrest (reviewed in Kastan & Bartek, 2004; Riley et al., 2008). Thereby, the 
time for DNA repair before replication and mitosis is prolonged. Furthermore, ATM and ATR 
also increase DNA repair protein activity by transcriptional or post-transcriptional 
modifications like phosphorylation, acetylation, ubiquitylation, or sumoylation (reviewed in 
Huen & Chen, 2008). If the damage cannot be removed, continuous activation of the DDR 
response triggers cell death via apoptosis or cellular senescence to prevent tumor formation 
(Campisi & d'Adda di Fagagna, 2007; Halazonetis et al., 2008). 
The nucleotide excision repair (NER), a special case of the DDR response, is a particularly 
important mechanism in the removal of mutations resulting from UV-induced DNA damage 
(see 1.2.2). 
1.2.2 DNA repair mechanisms 
Cells have developed a number of repair mechanisms to ensure genome integrity and cope 
with different sorts of DNA damage. This thesis mainly focusses on the repair of UV-induced 
DNA lesions, interstrand crosslinks, and DNA DSBs (reviewed in Lombard et al., 2005). 
1.2.2.1 Nucleotide excision repair (NER) 
In bacteria pyrimidine dimers formed by UV irradiation are reversed using a special light-
dependent process, called photoreactivation. A photolyase binds to the pyrimidine dimer and 
catalyzes a second photochemical reaction using visible light breaking the cyclobutane ring 
and reforming the two adjacent thymidylates (reviewed in Thoma, 1999).  
Prokaryotic NER only involves three proteins, UvrA, UvrB and UvrC, which carry out the 
complete process of damage recognition and excision. At the beginning, there is an energy-
independent distortion recognition factor (UvrA), followed by energy-dependent recognition 
of DNA damage using a DNA helicase (UvrB). This helicase creates an open preincision 
complex and subsequently an oligonucleotide is released by dual incision (Kisker et al., 2013; 
Sancar & Rupp, 1983). The new DNA strand is synthesized and sealed by DNA polymerase 
II. A direct reversal process performed by photolyases is present in prokaryotic organisms as 
well (reviewed in Zhang et al., 2013a). Photolyases can be found in prokaryotes, eukaryotes 
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and archaea, but are not present in higher mammals like humans. Hence, other highly 
conserved DNA repair processes developed among both prokaryotes and eukaryotes.  
The eukaryotic NER is one of the most versatile repair systems as it can recognize various 
different types of lesions, e.g. UV-induced lesions or intrastrand crosslinks and involves 
numerous factors (>30) (reviewed in Truglio et al., 2006). The DNA damage is sensed 
through a distortion present in the DNA structure (bulky lesions). Thus, different lesions can 
all be repaired by a common set of enzymes. It is increasingly evident that the overall strategy 
for NER in eukaryotes has many similarities to the process initiated by the UvrABC nuclease 
in prokaryotes.  
On the molecular level, the repair cascade is made up of several subsequent steps: lesion 
sensing, opening of a denaturation bubble, incision of the damaged strand, displacement of 
the lesion-containing oligonucleotide, gap filling (re-synthesis according to the 
complementary strand) and closing ligation of a nick (reviewed in Nouspikel, 2009; Scharer, 
2013) (see Figure 3). The damage recognition step is divided into two subpathways: 
transcription coupled repair (TCR) and global genome repair (GGR). TCR only works on 
actively transcribed genes (Mellon et al., 1987), while the GGR removes DNA lesions 
throughout the whole genome (Bohr et al., 1985).  
XPC preferably binds to DNA backbone distorting structures and its binding activity can 
further be stimulated by HR23B and Centrin2 (Krasikova et al., 2012). 6-4 PPs, lead to a 
strong distortion of the DNA backbone and can directly be recognized by the XPC-HR23B-
Cen2 complex (Araki et al., 2001). Additionally, HR23B protects XPC from proteolytic 
degradation. The formation of an XPC-HR23B complex with DNA is enhanced by the single 
strand DNA (ssDNA) binding protein RPA (Krasikova et al., 2008). As CPDs only slightly 
distort the DNA backbone, they are poorly recognized by XPC, although their removal 
depends on XPC recognition (Sugasawa et al., 1998). To further increase XPC’s affinity to 
the damaged DNA it can be polyubiquitinated and depends on the UV-DDB-ubiquitin ligase 
complex consisting of DDB1 and DDB2 (UV-damaged-DNA-binding protein 2 = XPE) 
(Sugasawa et al., 2005). In addition, damage recognition is facilitated by a stronger distortion 
of the DNA backbone due to binding of UV-DDB (Fujiwara et al., 1999). A stalled RNA 
polymerase II itself is the damage recognition factor in TCR independent of XPC. Together 
with the Cockayne syndrome (CS) proteins, CSA and CSB, it initiates the repair (Mu & 
Sancar, 1997).  
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During GGR as well as TCR, the basal transcription factor TFIIH is recruited via direct 
interaction with XPC-HR23B or by XPA, respectively (Park et al., 1995; Riedl et al., 2003). 
TFIIH consists of the CAK (CDK7; Cyclin H and MAT1) and core complex (XPD, XPB, 
p62, p52, p44, p34 and p8/TTDA) (see Figure 3). XPG is thought to be the eleventh subunit 
of TFIIH, while XPD connects the two subcomplexes (Chen et al., 2003) (reviewed in Compe 
& Egly, 2012; Egly & Coin, 2011). TFIIH performs the opening of a denaturation bubble (24- 
30 nucleotides (nts)) around the lesion. In NER the ATPase activity of XPB and the helicase 
activity of XPD are needed for the opening of the denaturation bubble (Coin et al., 2007). 
TFIIH is supported by XPA and RPA, two factors that have a high affinity for ssDNA, in 
displacing the XPC complex (Overmeer et al., 2011). Furthermore, RPA also assists TFIIH to 
open the DNA helix around the damage and protects the undamaged strand opposite the 
lesion (de Laat et al., 1998b; Lee et al., 2003). Together with XPA it is important for 
verifying the lesion and damage demarcation (reviewed in Fadda, 2016). 
After anchoring TFIIH to the site of DNA damage by XPA and RPA, the two endonucleases 
XPF/ERCC1 (5’) and XPG (3’) are recruited. TFIIH is responsible for XPG recruitment via 
its pleckstrin homology/phosphotyrosine-binding (PH/PTB) domain of subunit p62 (Dunand-
Sauthier et al., 2005; Gervais et al., 2004), while XPF/ERCC1 is recruited to the damage site 
through a direct interaction between the central domain of ERCC1 and XPA (Orelli et al., 
2010). XPF/ERCC1 is a heterodimeric endonuclease complex that cleaves upstream of the 
lesion, whereas XPG cleaves downstream (Mu et al., 1996; O'Donovan et al., 1994). Strand 
incision and repair synthesis of NER are highly coordinated with several subsequent steps.  
5’ incision by XPF/ERCC1 is necessary and sufficient for the initiation of repair synthesis as 
it generates a free 3’ OH group and a branched flap structure with a free 5’ end. On the other 
hand, 3’ incision by XPG is not necessarily needed to initiate polymerization by DNA 
polymerase δ or ε (Staresincic et al., 2009). Actually, efficient 3’ incision requires the 
presence and catalytic activity of XPF/ERCC1 (Tapias et al., 2004). Hence, 5’ incision has to 
precede the 3’ incision. Regardless, 3’ incision is needed for completion of repair synthesis.  
Depending on the lesion, the excised fragment is about 24-32nts in length (Evans et al., 
1997b). After displacement of the lesion-spanning oligonucleotide the gap is accurately filled 
by either of the replicative polymerases δ, ε, or κ according to the undamaged complementary 
strand (Ogi et al., 2010). The nick is then closed by ligase I and III together with XRCC1 




Figure 3: Schematic overview of the NER pathway 
(A) Global genome repair: 6-4PPs lead to a strong DNA distortion and are directly recognized by the XPC-
HR23B-Centrin2 complex (green), while CPDs can only be identified by XPC together with the DDB complex 
(DDB1, XPE) (B). (C) Lesion affinity of XPC and DDB is increased by ubiquitylation. (I) and (J). In TCR, 
repair is initiated by a stalling of the RNA polymerase II at the site of a lesion on the transcribed strand as well as 
interaction with CSA, CSB, and XAB2. (D) The basal transcription factor TFIIH, harbouring ATPase XPB and 
helicase XPD, is responsible for unwinding the dsDNA around the lesion. In case of TCR, RNAPII is replaced 
by TFIIH, XPA, and RPA. (E) XPC is replaced by XPA and RPA, while TFIIH is recruited. (F) The two 
endonucleases XPF/ERCC1 (5’) and XPG (3’) are recruited and incise the damaged DNA strand. (G) After 
recruitment of PCNA the gap is filled by DNA polymerase δ, ε, or κ. (H) Ligase I or III seal the nick between 
the newly synthesized and free 5’ phosphate at the XPG restriction site. (K) The ten/eleven-subunit complex 
TFIIH is composed of a core associated to the CAK through the XPD subunit (purple). The core (rose) is made 
up of XPB, p62, p52, p44, p34, and p8/TTDA, while the CAK (blue) contains Cdk7, Cyclin H, and MAT1. XPG 
is proposed to present the eleventh subunit and is a component of TFIIH. Illustration by Dr. rer. nat. Christina 
Seebode, adapted from (Egly & Coin, 2011; Nouspikel, 2009). 
1.2.2.2 Interstrand Crosslink Repair 
DNA interstrand crosslinks (ICLs) can be caused by various endogenous metabolites, 
environmental exposures, and cancer chemotherapeutic agents with at least two reactive 
chemical groups (reviewed in Clauson et al., 2013). Thereby, two nts of opposite DNA 
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strands can be covalently bound preventing strand separation during replication or 
transcription by blocking the replication fork or RNA polymerase. This results in highly 
cytotoxic ICLs and until now repair pathways are not completely defined. In principle, 
damage recognition can either be replication-bound (blocked replication fork) or non-
replication bound (blocked RNA polymerase). The basic mechanism is shown in a schematic 
overview below (see Figure 4) (Bhagwat et al., 2009; Kottemann & Smogorzewska, 2013; 
Moldovan & D'Andrea, 2009; Niedernhofer et al., 2004; Sengerova et al., 2011). After 
damage recognition, the endonucleases XPF/ERCC1 and Mus81/Eme1 are thought to cut the 
lesion-containing (parental) strand, thereby unhooking one daughter duplex from the damage, 
forming a DNA DSB. Subsequently, translesion synthesis by error-prone damage-tolerating 
polymerases takes place. Afterwards, the NER pathway, especially the excision complex 
consisting of XPF/ERCC1 and XPG repairs the overhanging strand. During S-phase the sister 
chromatid is synthesized via homologous recombination (HR). Especially the exact 
mechanisms of non-replication-bound repair, which is mainly coordinated by NER proteins, 
needs to be further investigated and a lot of open questions, still remain. For example there is 
an ongoing discussion whether XPF/ERCC1 is the only required endonuclease for ICL repair 
(Fisher et al., 2008; Kuraoka et al., 2000) or whether other proteins are needed for processing 
of intermediate states of ICL repair, e.g. other endo- or exonucleases (Clauson et al., 2013; 




Figure 4: Schematic overview of interstand crosslink repair (ICL) 
The interstrand crosslink (ICL) of two DNA strands is repaired by a multistep process, coordinated by the 
Fanconi anemia complex (not shown) by a yet unclear mechanism. An ICL can either by detected in a replication 
bound (stalled replication fork) or replication-independent context (stalled RNA polymerase). (A) The 
endonucleases XPF/ERCC1 and Mus81/Eme1 are thought to cut the lesion-containing strand, thereby unhooking 
the damage. (B) A translesion polymerase is recruited and fills the resulting gap around the ICL (TLS = 
translesion synthesis). (C) The overhanging ICL is repaired by the NER excision complex consisting of the 
XPF/ERCC1 and XPG endonucleases. (D) During S-phase the sister chromatid is synthesized via homologous 
recombination (HR). As the endonuclease XPF/ERCC1 is involved in two steps of ICL repair it is of special 
importance (A and C). Illustration by Dr. rer. nat. Christina Seebode, adapted from (Moldovan & D'Andrea, 
2009). 
1.2.2.3 DNA double strand repair pathways 
This thesis focusses on the endonucleases XPF/ERCC1 and XPG, which have originally been 
detected in NER. Mutations in ERCC1 or XPF can cause very severe phenotypes as well in 
humans as in mice, which cannot solely be explained by defects in NER or ICL repair often 
showing accelerated aging. Orthologs of XPF/ERCC1 like DmERCC1-MEI9 in Drosophila 
melanogaster or Rad1-Rad10 in Saccharomyces cerevisiae have been implicated in DSB 
repair (Baker et al., 1978; Fishman-Lobell & Haber, 1992; Ivanov & Haber, 1995) due to 
their ability to remove non-homologous 3’ single-stranded flaps (Al-Minawi et al., 2008; 
Niedernhofer et al., 2001; Sargent et al., 1997). Furthermore, different studies reported about 
the moderate sensitivity of XPF/ERCC1 deficient mammalian cells to DSB inducing agents 
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and ionizing radiation, suggesting an important function of XPF/ERCC1 in one or more sub-
pathways of DSB repair (Ahmad et al., 2008; Mogi & Oh, 2006; Murray et al., 1996; Wood 
et al., 1983).  
There are two major pathways of DSB repair in eukaryotes: the correct HR mediated repair 
(HRR) and the error-prone nonhomologous end joining (NHEJ) (Brugmans et al., 2007). As 
HRR recovers lost sequence information from a sister chromatid it can only take place during 
S or G2 phases of the cell cycle. During NHEJ, two broken ends are connected by ligation, not 
restricting it to proliferating cells (reviewed in Karran, 2000). In HRR, the XPF/ERCC1 
heterodimeric complex is thought to function through the error-prone single-strand annealing 
(SSA) sub-pathway, gene conversion, and homologous gene targeting in yeast and mammals 
(Adair et al., 2000; Fishman-Lobell & Haber, 1992; Ivanov & Haber, 1995; Niedernhofer et 
al., 2001; Sargent et al., 2000), while for NHEJ the complex is only involved in the Rad52- 
and Ku70/Ku86-independent microhomology-mediated end-joining (MMEJ) sub-pathway 
(Ahmad et al., 2008; Bennardo et al., 2008; Ma et al., 2003; McVey & Lee, 2008; Yan et al., 
2007). Unfortunately, these studies primarily focus on mice, yeast, and hamster cells, and 
until now human XPF/ERCC1 has only been assumed to be involved. 
1.3 DNA repair deficiency disorders 
Mutations in components of the different DNA repair pathways can result in various clinical 
entities and diseases. A rare genetic disorder arising from defects in one of the NER 
components is XP (reviewed in Kraemer et al., 1987). There is no prevalence for ethnic 
groups and it appears all over the world. 
1.3.1 Xeroderma pigmentosum 
In 1874, Hebra and Kaposi were the first to describe XP as patients with “parchment skin” 
(Hebra & Kaposi, 1874). XP is a rare autosomal recessive disorder that affects the repair of 
DNA damage caused by UV light (see Figure 3). Worldwide the prevalence of XP is very low 
and varies in different regions (North America/Northern Europe 1:1.000.000, North 
Africa/Middle East 1:50.000, Japan 1:22.000) (Ben Rekaya et al., 2009; Hirai et al., 2006; 
Kleijer et al., 2008; Kraemer & Slor, 1985; Messaoud et al., 2010; Soufir et al., 2010). The 
DNA repair mechanism impaired in this disease is the NER, affecting the genes XPA to XPG 
or the translesion polymerase η (reviewed in Lehmann et al., 2011).  
Introduction 
12 
XP patients exhibit high sun sensitivity and freckling from birth on leading to a strongly 
increased risk for skin cancers (reviewed in Kraemer et al., 1987) (see Figure 5). 
Development of non-melanoma skin cancer (NMSC) is 10.000-fold increased and occurs at a 
median age of nine years compared to 67 years in the general population (Bradford et al., 
2011). Tumors are preferentially located at sun-exposed areas (face, head, neck, or the back of 
the hands). The median age for melanoma is 22 years in contrast to 55 in the general 
population and the risk is 2.000-fold increased. Melanoma preferentially occur on the 
extremities (Kraemer et al., 1994). XP is an interesting model disease for fast-forward skin 
carcinogenesis as well as accelerated aging. In the healthy population, skin cancer is rare 
before the age of 20. Typically, melanomas develop between the age of 30-50, while non-
melanoma skin cancer is most prominent in elderly people (reviewed in de Vries & Coebergh, 
2004; Madan et al., 2010). Therefore, studies of XP patients provide a molecular foundation 
to demonstrate the UV induced origin of mutations of cancer suppressing genes in NMSCs as 
well as melanoma (Couve-Privat et al., 2004; Giglia et al., 1998; Wang et al., 2009a). 
Interestingly, XP cells show normal killing after exposure to X-rays, while they are 
hypersensitive to UV irradiation. X irradiation is also used as a therapy for tumors in XP 
patients (DiGiovanna et al., 1998; Giannelli et al., 1981), suggesting that the repair of x-ray 
induced damage is independent from NER. 
Kraemer et al. could show that experiments fusing different strains of XP patient fibroblasts 
lead to a higher DNA repair rate than of either strain’s unfused cells, indicating 
complementary corrections in the fused cells. Thereby, they identified five complementation 
groups, meaning that there are at least five mutation causing genes decreasing DNA repair 
among these fibroblast strains (Kraemer et al., 1975a; Kraemer et al., 1975b). To date, seven 
XP complementation groups, XP-A to XP-G as well as a variant form (defect in translesion 




Figure 5: Picture of two XP patients with typical clinical features 
(A) This patient shows the typical freckling in sunexposed areas together with a severe sun burn of the face and 
several non-melanoma skin cancers of the face (nose, lips, cheek). (B) This picture shows the same patient a few 
years later. Due to tumor resection he has lost his nose, shows scarring of the face, and new precancerous 
lesions. (C) This female patient has also lost her nose due to an invasive tumor, (D) but additionally also shows 
melanoma skin cancer in sunexposed areas, like the arms. 
Among the different complementation groups there is a large difference in frequency with 
XP-C and XP-A being the most prominent ones, and XP-B being quite rare. Furthermore, 
they differ in the severity of the symptoms like the number of skin cancers or neurological 
involvement (see Table 1). The general belief has been that heterozygous carriers of XP show 
no clinical symptoms and have a normal DNA repair capability. Anyhow, XP heterozygous 
mice have a higher susceptibility for skin and internal organ cancers (Cheo et al., 2000), 
which also suggests an effect in humans. A clinical study (NCT00046189) addressing this 
issue is currently going on at the National Institute of Health (NIH). 
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Table 1: XP complementation groups 
The table shows the frequency of the different XP complementation groups and gives information on skin cancer 
number, neurological involvement, repair capability, the defective gene and chromosomal location (from 
(Lehmann et al., 2014a)). 
 
1.3.2 Other associated disorders 
Mutations in the CSB/ERCC6 and CSA/ERCC8 genes encoding proteins involved in the TCR 
DNA repair pathway can cause another rare autosomal recessive congenital disorder, 
Cockayne syndrome (CS) (reviewed in Cleaver et al., 2009). The disease was first described 
in 1936 by Edward Cockayne (Cockayne, 1936) and has an incidence of less than one case 
per 250.000 live births in Northern Europe. In 65% of the cases the mutations lie in CSB, 
while CSA is affected in 35% of the cases (reviewed in Laugel, 1993). Clinical hallmarks of 
the disease are microcephaly and growth failure, photosensitivity, hearing loss, cataracts, 
retinal dystrophy, developmental delay, and premature aging (Hoeijmakers, 2009). 
Cerebrooculofacioskeletal (COFS) syndrome represents the prenatal extreme form of CS and 
is clinically characterized by microcephaly, cataract and/or microphthalmia, arthrogryposis, 
severe psychomotor developmental delay, height-weight growth delay and facial 
dysmorphism (prominent metopic suture, micrognathism) (Pena & Shokeir, 1974). 
Additionally, cutaneous photosensitivity, peripheral neuropathy, sensorineural hearing loss 
and pigmentary retinopathy can be observed. Mutations can mainly be found in the 
CSB/ERCC6 gene; however, one case has been linked to the ERCC1 gene (Faridounnia et al., 
2015; Jaakkola et al., 2010). To date, fewer than 20 cases have been confirmed. 
Another extremely rare disease is the XPF-ERCC1 (XFE) progeroid syndrome (Niedernhofer 
et al., 2006). The patient presented with dwarfism, cachexia, and microcephaly, sun-
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sensitivity, learning disabilities, hearing loss, and visual impairment. The progeroid features 
of accelerated aging led to an early death at the age of 16. 
1.3.3 Genotype-phenotype-correlation 
The genotype-phenotype correlation of DNA repair deficiency disorder patients is highly 
complex. Patients can show combined symptoms of different diseases, e.g. XP and CS. These 
patients exhibit XP symptoms like photosensitivity and increased risk for cutaneous 
malignancies in combination with CS symptoms like neurologic abnormalities (Emmert et al., 
2006; Kraemer et al., 2007; Lehmann et al., 2014a), and belong to XP complementation 
groups B, D, F, or G. All these genes encode for proteins important for interactions with 
TFIIH (see Figure 3). Currently, it is believed that a transcription defect may be the reason for 
neurologic impairment (reviewed in van Gool et al., 1997). Furthermore, oxidative processes 
involving mitochondria caused by the generation of free radicals could be the basis of 
neurodegeneration in XP patients (reviewed in Bohr et al., 2002; Jeppesen et al., 2011). 
Figure 6 shows the complex genotype-phenotype interactions of the mutations in the different 
XP genes (A-G plus the variant form), CSA and CSB as well as TTD-A (part of the TFIIH 
complex) and TTDN1 (unknown function). COFS syndrome, XFE, Fanconi anemia (FA), and 
trichothiodystrophy (TTD) can also derive from defects in NER proteins. For example, XP-G 
patients can be subdivided into three categories showing either typical XP symptoms, XP with 
late onset CS symptoms, or XP with severe CS symptoms. Patients who express at least one 
full-length allele of XPG can be found in the XP only group. On the other hand, XP-G 
patients with late-onset CS symptoms show several different types of mutations; however, all 
of these patients either express a mutant full-length protein or splice variants (in the following 
also referred to as isoforms) with residual functions in NER or the ability to interact with 
TFIIH (reviewed in Scharer, 2008). 
Likewise, different mutations in the XPF gene can result in distinct clinical outcomes: either 
cancer, as in XP, or progeroid symptoms, as in XFE syndrome. This may be explained by 
effects of the mutation on NER as well as ICL repair, thereby primarily resulting in cell death 
and senescence in response to DNA damage, leaving fewer possibilities for accelerated 
carcinogenesis but enhanced aging. Classic XP-F patients that mainly show mild symptoms 
only suffer from a defect in NER causing less cell death, but allowing mutation accumulation 




Figure 6: 12 clinical entities and 14 molecular defects show the complex genotype-
phenotype correlation of DNA repair deficiency disorders 
Different mutations in various genetic regions of DNA repair proteins can lead to 12 different clinical entities. In 
turn, mutations in different genes can cause the same clinical entity. TTD = trichothiodystrophy, COFS = 
cerebro-oculo-facial-skeletal syndrome, UV’S = UV sensitive syndrome. Illustration by Dr. rer. nat. Christina 
Seebode, modified from (Schubert & Emmert, 2016). 
1.4 Multiple functions of the XPG and XPF/ERCC1 endonucleases 
The specialty of the two endonucleases XPG and XPF/ERCC1 is not only founded in their 
coordinated interplay during the dual incision step of NER, but also in the fact that they have 
many other functions besides excision during NER. For example, XPG as well as XPF are 
involved in basal transcription via interaction with TFIIH (Ito et al., 2007; Le May et al., 
2012), and also in ICL repair (reviewed in Clauson et al., 2013). As shown in XPF/ERCC1 - 
deficient patient cells, neither the components of the FA signaling pathway, nor components 
of homologous recombination (HR) can be recruited (Bhagwat et al., 2009). Furthermore, 
genome-wide association studies of single nucleotide polymorphisms (SNPs) and protein 
expression analysis implicate the XPF and XPG genes as potential marker for skin cancer risk 
as well as for disease outcome (Li et al., 2013a). This thesis focuses on spontaneous mRNA 




The human gene encoding for xeroderma pigmentosum group G was identified as ERCC5 
(Cleaver et al., 1999; MacInnes & Mudgett, 1990). The XPG gene is located on chromosome 
13q32.3-q33.1 and encodes for a 136kDa protein, organized into 15 exons and 14 introns. So 
far, several spontaneous mRNA splice variants, due to alternative splicing, have been 
identified in the healthy population, whose amounts vary in different tissues (Emmert et al., 
2001).  
The XPG endonuclease is involved in multiple processes from DNA repair to basal 
transcription due to its interplay with TFIIH. XPG’s function during NER is highly conserved 
among different species. The yeast homolog of human XPG, Rad2, displays an evolutionary 
conserved endonuclease activity (Habraken et al., 1993). 
XPG belongs to the FEN 1 (flap endonuclease 1) protein family of structure-specific 
endonucleases and harbors two highly conserved nuclease domains (Scherly et al., 1993). 
Members of the FEN 1 family cleave a variety of substrates containing ss/dsDNA junctions 
including 5’ single-stranded overhangs and bubble structures. The XPG protein sequence 
shows two conserved N and I nuclease regions that XPG shares with other nucleases, e.g. 
Rad2. Furthermore, XPG has unique domains that are responsible for its specific functions 
during NER. The spacer region (about 600 amino acids (aa)) includes a conserved, highly 
acidic patch and separates the N and I region (see Figure 7). In the ternary structure, after 
protein folding, these two regions come close together and form the active center for XPG’s 
endonuclease function. The spacer is also partly involved in the interaction with other 
proteins, e.g. TFIIH and RPA (Dunand-Sauthier et al., 2005; Thorel et al., 2004). The C-
terminal region, beyond the I region is engaged in protein-protein interactions, e.g. with 
TFIIH, while the PIP-box motif mediates interaction with PCNA (Gary et al., 1997). Two 
distinct interaction patches between XPG and TFIIH suggest a strong functional interaction. 
Furthermore, the C-terminus contains two strong nuclear localization signals (NLSs) (Knauf 





Figure 7: Schematic overview of XPG and its domains 
The N and I domains (light blue-green) form the catalytic center of the XPG endonuclease. They are separated 
by a spacer region in the primary sequence, but come close together in the ternary structure after protein folding. 
The PIP-box motif (PCNA binding motif) (orange) and nuclear localization signals (NLS-A N-terminal, NLS-B 
and NLS-C) (green) are located at the C-terminal region. Interaction regions with TFIIH (XPB, XPD), RPA and 
PCNA are indicated by black bars. The D1 and D2 boxes are conserved in higher eukaryotes (grey). Modified 
from (Scharer, 2008). 
XPG plays a key role during GGR as well as TCR, by displaying a structural endonuclease 
activity. On the one hand, XPG performs the 3’ downstream cut and on the other hand its 
presence is necessary for the binding of the endonuclease XPF/ERCC1 and its previous 5’ cut 
(Staresincic et al., 2009). Furthermore, it stabilizes TFIIH by forming a complex with TFIIH, 
XPA and RPA leading to a constitutive recruitment of XPF to NER complexes (Ito et al., 
2007; Wakasugi et al., 1997). XPG can only reveal its catalytic function once XPF-ERCC1 
has made the 5’ incision, as the 3’ incision is triggered by a conformational change of the 
damaged structure (Hohl et al., 2003; Staresincic et al., 2009).  
Indicated by a complex genotype-phenotype relationship in patients with defects in XPG, 
resulting in different clinical entities like XP, CS and XP/CS, XPG might have important 
roles outside of NER. Besides its role during NER, XPG is also involved in basal 
transcription via its interaction with TFIIH. The architecture of TFIIH was found to be highly 
dependent on interaction with XPG (see Figure 3K), therefore impaired interaction due to 
mutations in XPG could result in dissociation of CAK and core, suggesting an XPG function 
independent of the nuclease activity (Arab et al., 2010; Ito et al., 2007) (see Figure 3K). 
Moreover, XPG as well as XPF are present at the promoter and terminator forming loop 
structures that are demethylated and DNA is relaxed by small cuts produced by these 
endonucleases (Le May et al., 2012).  
Additionally, XPG as well as other NER factors are involved in the repair of oxidative DNA 
damage like ROS that lead to damages like 8-oxo-guanine, a non-bulky lesion, or bulky 
lesions like 8,5’-cyclopurine-2’-deoxynucleoside (Slupphaug et al., 2003). These lesions are 
primarily repaired by the short patch base excision repair (BER) (reviewed in Berquist & 
Wilson, 2012). Interestingly, NER seems to provide a backup repair mechanism for BER as 
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XPG is involved in TCR of oxidative lesions via interaction with TFIIH (Klungland et al., 
1999) stimulating the initial step of BER (Melis et al., 2013). Additionally, XPG is not only 
involved in transcription, but has also been reported to interact with the replisome (Gilljam et 
al., 2012) and to be involved in chromatin organization (Le May et al., 2012).  
1.4.2 XPF/ERCC1 
The human XPF (ERCC4) gene (OMIM: 278760) encodes for a 916 aa protein that is part of 
the heterodimer XPF/ERCC1 cleaving 5’ of UV induced lesions with the chromosomal 
location 16p13.2-p13.1 (Brookman et al., 1996; Sijbers et al., 1996a). The ERCC1 gene 
(OMIM: 126380) encodes for a 297 aa protein and is located on chromosome 19q13.32 
(Sijbers et al., 1996b). These two proteins are paralogs probably arisen by gene duplication of 
the conserved Helix-hairpin-Helix (HhH2) protein-interaction and nuclease domains (Gaillard 
& Wood, 2001). Interestingly, also for XPF and ERCC1 several spontaneously occurring 
physiological mRNA splice variants have been postulated (www.ensembl.org (Friboulet et 
al., 2013; Gerhard et al., 2004; Matlin et al., 2005)).  
In eukaryotes, the XPF/ERCC1 heterodimeric protein complex is evolutionary conserved. 
Orthologs comprise Rad1/Rad10 in Saccharomyces cerevisiae, Xpf/ercc1 in mice, and Mei-
9/Ercc1 in Drosophila (Baker et al., 1978; Fishman-Lobell & Haber, 1992; reviewed in de 
Buendia, 1998). These nucleases belong to a family of structure specific nucleases also 
including MUS81/Eme1 and SLX4-SLX1, which are related through structural similarities 
(Hanada et al., 2006; reviewed in Heyer, 2004). Even XPF and ERCC1 show sequence 
similarities with each other in their HhH2 domains (Gaillard & Wood, 2001). This domain is 
involved in dimerization as well as DNA binding (de Laat et al., 1998a) (Doherty et al., 1996; 
Su et al., 2012). 
XPF and ERCC1 function together as a heterodimer, where the catalytic activity lies in the 
XPF subunit, while ERCC1 presents the DNA binding unit. The nuclease specifically cuts 
junctions between ss/dsDNA, where the single strand departs 5’ to 3’ from the junction 
(Bessho et al., 1997; de Laat et al., 1998a; Evans et al., 1997b). The endonuclease complex 
XPF/ERCC1 has a core function in NER, but also plays a key role in ICL repair (De Silva et 
al., 2002), in which context it is also involved in HR at DNA replication forks (Al-Minawi et 
al., 2009). Furthermore, there have been extensive studies on the complex functions of 
XPF/ERCC1 -besides NER and ICL repair- for example to assess its role in sub-pathways of 
homology-directed double strand repair via SSA, gene conversion, and homologous gene 
targeting (Adair et al., 2000; Niedernhofer et al., 2001; Sargent et al., 1997).  
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For XPF there is an even more complex genotype-phenotype correlation than for XPG. 
Defects in XPF have been associated with several disorders including XP, XP/CS complex 
phenotype, CS, FA, and XFE (see Figure 7 and Figure 9) (Ahmad et al., 2010; Bogliolo et al., 
2013; Hayakawa et al., 1981; Kashiyama et al., 2013; Niedernhofer et al., 2006; Schubert et 
al., 2014). This highlights the importance of the XPF protein in different cellular pathways 
and may extend beyond DNA repair. Defects in ERCC1 have been associated with XP, CS, 
and even the severe COFS syndrome (see Figure 9) (Jaspers et al., 2007; Kashiyama et al., 
2013). 
XPF/ERCC1 is also involved in the removal of reactive oxygen species (ROS), which 
explains why XPF/ERCC1 deficient patients often display an accelerated aging phenotype 
through damage accumulation (Fisher et al., 2011b).  
 
Figure 8: Schematic overview of XPF/ERCC1 and their domains 
The colored bars depict functional protein domains (e.g. nuclease domain, Helix-hairpin-Helix (HhH2) motif). 
Green lines present putative NLS. The grey arrows indicate mutations leading to different disease entities, as 
well as a mutation hotspot (dotted line), while black arrows and lines highlight essential residues and protein 
interaction domains. Pink asterisk mark the essential residues for the interaction between XPF and ERCC1. 
Illustration by Dr. rer. nat. Christina Seebode, modified from (de Laat et al., 1998c; Fisher et al., 2011a; Li et al., 
1995; McNeil & Melton, 2012; van Duin et al., 1986). 
Indeed, XPF as well as XPG have been implicated in different other cellular processes. They 
are involved in transcription, even without genotoxic stress, by gene regulation through 
chromatin looping and triggering DNA methylation. While XPG induces DNA breaks and 
demethylation around the promoter region to catalyze the recruitment of the transcriptional 
repressor CTCF to promote gene looping, XPF only functions in stabilizing the structures (Le 
May et al., 2012). Moreover, XPF/ERCC1 also seems to be involved in telomere maintenance 
through the interaction with TRF2 and cleaving of 3’ overhangs of uncapped telomeres. This 
makes the complex a critical factor for genome stability (Munoz et al., 2005; Wan et al., 




1.4.3 XP-G and XP-F patients 
In order to study DNA repair, patient cell lines with defective components of repair pathways 
can be of great help to understand the function of these proteins, the basic mechanism and the 
influence of protein variants, e.g. splice variants. For the rare complementation group G less 
than 30 patients have been reported so far (Europe, Japan, North- and South America) 
(Lehmann et al., 2014b; Schafer et al., 2013; Soltys et al., 2013). The patient XP20BE 
belongs to the XP-G complementation group and showed clinical features of the XP/CS 
complex phenotype. The symptoms included sun sensitivity, microcephaly, 
hyperpigmentation, and mental impairment. The patient died at the age of six years 
(Moriwaki et al., 1996). He inherited a mutation from his father in exon one of the XPG gene 
that resulted in a premature termination codon. Furthermore, the maternal allele produces an 
unstable or poorly expressed mRNA. Moreover, the cDNA contained an mRNA species with 
a large splicing defect that encompassed a deletion from exon one to exon fourteen (Okinaka 
et al., 1997). Therefore, the largest XP20BE allele leads to synthesis of an extremely 
shortened protein (only 138 aa) and presents a usable model cell line to study variants of the 
XPG endonuclease.  
So far, a key limitation to study the functions of the XPF/ERCC1 complex has been the lack 
of an appropriate human XPF- or ERCC1-defective cell line. Up until now, patient cell lines 
were utilized to study the function of these proteins. However, due to the essential role of 
these genes, all mutations characterized in patients so far retained at least one full-length 
allele with residual functional capabilities (see Figure 9) (Schubert et al., 2014). Most XP-F 
patients show relatively mild symptoms of photosensitivity with occasional neurological 
abnormalities and there are only a few severely affected patients (Niedernhofer et al., 2006). 
Therefore, a suitable host cell line with a complete knockout is of great interest to investigate 




Figure 9: Schematic view of XPF/ERCC1 and mutations associated with DNA repair 
defective disorders 
Mutations in the genes coding for XPF or ERCC1 can lead to different clinical entities. Black font = XP, blue 
font = COFS, red font = CS, or XP/CS complex phenotype, green font = XFE. From (Kashiyama et al., 2013) 
1.5 Genome editing techniques 
The demand for targeted, fast, and customizable gene knockout has rapidly grown over the 
last decade. The molecular basis for gene editing relies on the cellular repair mechanisms of 
DSBs. These lesions can be repaired by HRR or NHEJ as mentioned above (Takata et al., 
1998) (see 1.2.2.3). HRR is an error-free process, but the cell depends on a template strand 
and therefore it only takes place in S, G2, or M phase of the cell cycle (reviewed in Szostak et 
al., 1983). DSBs are re-ligated through the NHEJ pathway in the absence of a repair template, 
resulting in insertion/deletion mutations leading to frameshift mutations and premature stop 
codons (Deltcheva et al., 2011). For genome editing it is critical to introduce a directed DSB 
in the target gene. Recently, notable attention has been paid to genome editing tools like zinc-
finger nucleases (ZFNs), meganucleases or bacterial transcription activator-like type III 
effector nucleases (TALENs). Those techniques have been used for targeted gene knockout 
(KO) in multiple fields (Wood et al., 2011).  
1.5.1 TALEN, Zinc finger and meganucleases 
ZFNs or TALENs function through tethering of endonuclease catalytic domains to modular 
DNA-binding proteins to induce targeted DSBs at specific genomic loci (Wood et al., 2011). 
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ZFNs are artificial restriction enzymes in which a zinc-finger DNA-binding domain is fused 
to a DNA-cleavage domain (Kim et al., 1996). In order to cleave DNA, the cleavage domain 
has to dimerize and thus one pair of ZFNs is required to target non-palindromic DNA sites 
(Bitinaite et al., 1998). 
TAL effectors are naturally occurring proteins from Xanthomonas, a plant bacterial pathogen. 
The central targeting domain contains a series of 33–35 aa repeats each recognizing a single 
base pair (bp). Specificity is determined by two hypervariable aa, the repeat-variable 
diresidues (RVDs) (Deng et al., 2012; Mak et al., 2012). Modular TALE repeats are linked 
together to recognize contiguous DNA sequences, similar to ZFNs. In contrast to ZFN 
proteins, no re-engineering of the linkage between repeats is necessary to construct long 
arrays of TALEs with the ability to basically target single sites in the genome. DNA binding 
domains can be coupled to various effectors, most importantly including cleaving domains of 
nucleases like FokI to induce targeted DSBs (Cermak et al., 2011; reviewed in (Gaj et al., 
2013). On the other hand, meganuclease technology utilizes naturally occurring homing 
endonucleases, e.g. I-CreI and I-SceI enzymes, to re-engineer their DNA-binding specificity 
to target novel sequences (reviewed in Chevalier & Stoddard, 2001).  
Meganuclease and TALEN based gene editing approaches have already been used in 
preclinical trials for XP gene therapy. For example, Dupuy et al. (Dupuy et al., 2013) applied 
engineered meganuclease and TALEN to perform a targeted correction of an XPC mutation in 
a patient cell line (XP4PA). After successful XPC gene correction, the full-length XPC 
protein was re-expressed resulting in full recovery of WT UV resistance and functional repair 
capabilities in the patient cell line.  
1.5.2 CRISPR/Cas9 
Notwithstanding, the above mentioned techniques are often inefficient, time consuming, 
laborious, and expensive (Wei et al., 2013). The Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR)/ CRISPR associated (Cas) nuclease 9 system is adapted from 
the adaptive bacterial immune system of Streptococcus pyogenes that evolved in bacteria to 
defend against invading plasmids and viruses. In this setting, a nuclease is guided by small 
RNAs to highly efficiently target specific DNA sequences (Cong et al., 2013; Li et al., 
2013b). In the CRISPR/Cas9 strategy, a DSB is induced by Cas9 cleavage and the target 
locus is typically repaired by the error-prone NHEJ or the error-free HRR. In the absence of a 
repair template, the NHEJ pathway re-ligates DSBs, resulting in insertion/deletion mutations 
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and therefore in frameshift mutations and premature stop codons as mentioned above 
(Deltcheva et al., 2011) (see 1.2.2.3).  
In the natural context, invading DNA from viruses or plasmids is cut into small fragments and 
incorporated into the CRISPR locus amidst a series of short repeats (around 20 bps). When 
the loci are transcribed, and transcripts are processed, small RNAs (crRNA – CRISPR RNA) 
are generated guiding the Cas9 effector endonuclease together with a tracrRNA to target 
invading DNA based on sequence complementarity. Upon another encounter, the Cas9 
complexed with a crRNA and separate tracrRNA then cleaves the foreign DNA containing 
the 20 nt crRNA complementary sequence adjacent to the PAM sequence. (Barrangou et al., 
2007; Jinek et al., 2012) (see Figure 10). 
 
Figure 10: Schematic overview of the CRISPR/Cas9 system of Streptococcus pyogenes 
Foreign invading DNA (A) is incorporated into the bacterial genome at the CRISPR loci during the acquisition 
phase (B). The CRISPR loci is transcribed, and processed into crRNA during crRNA biogenesis (C). If the cell 
is challenged with the same foreign invading DNA again, the Cas9 endonuclease complexed with a crRNA and 
separate tracrRNA cleaves foreign DNA containing a 20 nt crRNA complementary sequence adjacent to the 
PAM sequence (D). Illustration by Dr. rer. nat. Christina Seebode.  
For genome editing, synthetic guide RNAs have been simplified by fusing together the 
crRNA and tracrRNA of the CRISPR/Cas9 system (Jinek et al., 2012). This system can be 
applied to all tissues and cell types containing the mentioned DSB repair pathways. The 
advantage of the CRISPR/Cas9 system over ZFNs and TALENs lies in the markedly easier 
design, high specificity, efficiency, and applicability for high-throughput and multiplexed 
gene editing in a variety of cell types and organisms bringing the CRISPR/Cas9 technology to 
the fore of the genome editing field (reviewed in Boettcher & McManus, 2015). 
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1.5.3 Limitations and precautions 
Special attention has to be paid to nuclease off-target activity, which can be predicted by 
several online tools (Hsu et al., 2013; Pellagatti et al., 2015). However, a precise prediction of 
off-target sites due to tolerable mismatches, epigenomic effects, DNA methylation and 
chromatin structure is not possible yet. However, off-target mutations are less common in 
CRISPR/Cas9 systems compared to ZFNs, TALENs, and meganucleases analyzed by whole-
genome sequencing studies (Suzuki et al., 2014; Veres et al., 2014). In regard to cleavage 
efficiency, it has to be mentioned that ZFNs show relatively weak cleavage of chromosomal 
DNA, in comparison to 100% cleavage efficiency of TALENs in mammalian cell lines (Kim 
et al., 2010). Concededly, mismatched dimer formation of TALENs can cause high mutation 
rates (Kim et al., 2013). Interestingly, ZFNs are nearly equally effective in creating both 
deletions and insertions, while TALENs preferably induce deletions (Cornu et al., 2008).  
1.6 Alternative mRNA Splicing 
In prokaryotes the process of splicing cannot be observed, as their genes are not organized 
into exons and introns. Consequently, many bacteria contain polycistronic mRNA, meaning 
one mRNA that encodes for several proteins (reviewed in Kozak, 1983). In eukaryotic cells, 
all classes of RNA are co- or post-transcriptionally processed including mRNA splicing,  
5’ capping, and 3’ polyadenylation. All these processes occur in the nucleus before the 
mRNA is transported into the cytoplasm for protein biosynthesis (reviewed in Bentley, 2002). 
Pre-mRNA splicing is defined as the joining together of exons while removing the introns and 
is an essential part of eukaryotic gene expression as it presents a regulatory tool of the cell to 
produce multiple mRNA molecules from a single gene. The process of alternative splicing is 
highly coordinated, regulated and has an influence on the amount of information encoded in 
the transcriptome of the proteome (reviewed in McManus & Graveley, 2011). Usually, 
alternative splicing events can be grouped into four categories: 
1) alternative 5’ splicing sites 
2) alternative 3’ splicing sites 
3) cassette exons 
4) retained introns 
It is possible that two or more of these events come together or take place at multiple 
locations in a gene, thereby evolving extremely complex splicing patterns that give rise to 
different isoforms of a gene. Moreover, alternative splicing can function in quantitative gene 
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control by targeting RNAs for nonsense-mediated decay (reviewed in Matlin et al., 2005). In 
humans, 95% of all genes that consist of more than two exons are alternatively spliced to 
increase the diversity of the cell’s protein composition (Pan et al., 2008). Interestingly, 
especially for XP genes a number of physiologically occurring spontaneous mRNA variants 
could be identified. In particular, this applies for splice variants of the two endonuclease 
complexes XPF/ERCC1 and XPG (see www.ensembl.org). 
Hitherto, there have been several reports of intron-retaining splice variants of functional 
importance (Busse et al., 2009; Honda et al., 2012; Whiley et al., 2011) being a good rational 
to analyze the residual function of XPF/ERCC1 and XPG spontaneous mRNA splice variants. 
1.6.1 Mechanism of mRNA splicing 
Pre-mRNA splicing is a highly coordinated process involving different cis-acting elements. 
The 5’ splice site is characterized by the AG/GURAGU sequence (‘/’ defining the splice site), 
while the 3’ splice site contains a polypyrimidine patch followed by an AG dinucleotide at the 
actual splice site. Furthermore, the so-called branchpoint can be found upstream the 3’ splice 
site (reviewed in Sperling et al., 2008). 95% of splicing reactions are catalyzed by the major 
spliceosome consisting of five small nuclear ribonucleoprotein particles (snRNPs; U1, U2, 
U4, U5 and U6), each containing a small nuclear RNA (snRNA) and different proteins. 
Moreover, the spliceosome also contains 100-200 non-snRNP proteins (reviewed in Wahl et 
al., 2009). A number of other RNA binding proteins are involved in the splicing process, e.g. 
SR proteins (proteins with long stretches of serine and arginine residues) and hnRNPs 
(reviewed in Wang & Burge, 2008). The minor spliceosome processes a rare class of pre-
mRNA introns, denoted U12-type, consisting of less abundant snRNAs U11, U12, U4atac, 
and U6atac, together with U5. The minor spliceosome is also located in the nucleus like its 
major counterpart (Pessa et al., 2008). 
Figure 11 depicts the mechanism of major spliceosomal assembly. Firstly, U1 interacts with 
the 5’ splice site, while U2 binds to the 3’ polypyrimidine tract. The U4-U6-U5 tri-snRNP is 
pre-assembled from the U5 and U4/U6 snRNPs. Subsequently, it is recruited, generating the 
pre-catalytic B complex. Large rearrangements in RNA–RNA and RNA–protein interactions, 
leading to the destabilization of the U1 and U4 snRNPs, give rise to the activated spliceosome 
(reviewed in Will & Luhrmann, 2011). 
U1 snRNP binding to the 5' splice site and other non-snRNP associated factors is essential for 
first recognition and formation of the early (E) complex. U2 snRNP is recruited to the branch 
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region through interactions with the E complex component U2AF (U2 snRNP auxiliary 
factor). U2 snRNP becomes tightly associated with the branch point sequence to form 
complex A in an ATP-dependent reaction (Jamison et al., 1992). A duplex formed between 
U2 snRNP and the hnRNA branch region bulges out the branch adenosine specifying it as the 
nucleophile for the first transesterification (Query et al., 1994). The U2 snRNA is placed 
nearly opposite of the branch site, which results in an altered conformation of the RNA-RNA 
duplex. In detail, the altered structure of the duplex induced places the 2' OH of the bulged 
adenosine in a favorable position for the first step of splicing (Newby & Greenbaum, 2002). 
Afterwards, the U4/U5/U6 tri-snRNP is recruited to the assembling spliceosome to form 
complex B. Following additional conformational changes, complex C is activated for 
catalysis. U5 snRNP interacts with sequences at the 5' and 3' splice sites and U5 protein 
components interact with the 3' splice site region (Chiara et al., 1997). Finally, the intron is 
spliced out and ligation of the 5' and 3' exons leads to formation of a mature mRNA. 
 
Figure 11: Major spliceosomal assembly 
The spliceosomal complex is assembled on each pre-mRNA intron in a multi-step process. Thereto, the snRNPs 
U1, U2, U4, U5, and U6, together with various additional splicing factors, interact with the pre-mRNA. This 
results in the formation of "mature" spliceosomes (spliceosomal B complexes) which are then catalytically 
activated by subsequent steps involving complex structural and compositional rearrangements. In a first step the 
5' end of the intron is cleaved, generating the so-called spliceosomal C complex. In the following, this complex 
catalyzes cleavage at the 3' end of the intron, and ligation of the 5' and 3' exons to form a mature mRNA. From 
http://www.mpibpc.mpg.de/luehrmann [01.03.2017]. 
1.6.2 Splice site mutations and polymorphisms 
In approximately 15% of all diseases, point mutations lead to defective pre-mRNA splicing 
(Krawczak et al., 1992). These splice site mutations can have different consequences, e.g. 
decreased recognition of the adjacent exon consequently inhibiting splicing of the adjacent 
intron, exon skipping, and activation of cryptic splice sites or intron retention (Nakai & 
Sakamoto, 1994). As already mentioned, deep sequencing has shown that over 95% of human 
genes undergo alternative splicing, thereby requiring exon-intron boundary recognition. In the 
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case that SNPs are located in the splice sites this can influence exon configuration. 
Furthermore, these splice site SNPs can alter translation efficiency of the mRNA and lead to 
important changes in disease susceptibility (Field et al., 2005; Iwao et al., 2004). Splice 
junction sequences are highly important because changes in splice sites alter recognition 
efficiency of splicing factors, then leading to altered exon recognition events and changes in 
the composition of amino acids and protein domains. Changes of nucleotide sequences in 
splice sites weaken exon-intron junction strength (splice site strength score) and frequently 
lead to the breaking of consensus nts at splice sites (Fox-Walsh et al., 2005; Roca et al., 
2008). To simultaneously profile both gene expression levels and the types of isoforms that 
are being expressed next-generation RNA sequencing is an effective tool (reviewed in 
Marioni et al., 2008; Wang & Burge, 2008; Wang et al., 2009b). 
Despite their existence and sequence not much is known about the function of spontaneous 
splice variants of XP genes. In the context of residual catalytic activity and individual 
expression levels those variants could be able to modify a person’s individual NER and ICL 
repair capabilities. Additionally, these physiologically occurring variants, together with 
artificially generated point mutants, display interesting tools to investigate the relevance of 
functional protein domains. It can be suggested that individual expression levels of specific 
functionally relevant splice variants influence cancer risk, disease progression and therapeutic 
success. Interestingly, the XPC polyA-T polymorphism (PAT) has been associated with an 
increased risk for head and neck cancer, SCC, as well as melanoma (Blankenburg et al., 2005; 
Marioni et al., 2008; Shen et al., 2001; Wang & Burge, 2008; Wang et al., 2009b). Zhang et 
al. could show that the expression level of splice variants in different tissues is more suitable 
to distinguish between oncogene and non-oncogene samples than the primary gene transcript 
itself (Zhang et al., 2013b). Additionally, tumor-specific splice variants, in the case of 
BRCA1/2 or p53-inhibitor MDM2, are often overexpressed (Brinkman, 2004; Yi & Tang, 
2011). In human melanoma cell lines splice variants of the p53 protein could be observed to 
be augmented as well (reviewed in Wei et al., 2012). 
In view of these results, it is of great interest to characterize physiologically occurring 
spontaneous mRNA splice variants of the XPF/ERCC1 and XPG genes, making it the central 
aim of this thesis. 
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1.7 Aim of the study 
The NER pathway is a central DNA repair mechanism to repair a variety of bulky DNA 
lesions (e.g. pyrimidine photo products) independent of the cell cycle. Accumulation of these 
types of damage all over the genome results in the development of a cancer prone mutator 
phenotype as it can be seen in patients with the autosomal recessive model disease XP, their 
high frequency of UV-induced skin tumors (~1000 fold increase compared to the healthy 
population), and reduced life span (approximately 37 years). Furthermore, it is known that a 
decreased NER level is a risk factor for several cancer and tumor entities in the normal 
population, components of the NER pathway already serve as biomarker for the etiopathology 
of tumor diseases (e.g. XPG in melanoma), and the chemotherapeutic success of the 
treatment. The endonucleases XPF/ERCC1 and XPG are the core components of the NER 
incision complex and the heterodimer XPF/ERCC1 is also involved in repair of DNA ICLs. 
Currently, there is an ongoing discussion about ERCC1 and its ability to serve as a biomarker 
for personalized medicine. Our group and others already demonstrated that these three 
essential repair genes show a high number of physiologically occurring spontaneous 
alternative spliced transcripts with unclear functions and a difference in expression in several 
tissues (Emmert et al., 2001).  
 
Figure 12: Overview of the XPG spontaneous mRNA splice variants 
(A) Physiologically occurring spontaneous mRNA splice variants of the XPG endonuclease produce several C-
terminally truncated proteins (IsoII - IsoVI) missing one or more of the functional domains. On the other hand, 
variant 201 misses exons one - four (in frame) including one of the nuclease domains (N) and part of an 
interaction patch with TFIIH. 202 only lacks exon one, but in addition contains the immunoglobulin like variant 
motif of 484 aa, caused by splicing defects leading to a conjoined gene (see www.ensembl.org; (Emmert et al., 
2001)). (B) Reactivation of a reporter gene after treatment with UVC. A firefly plasmid containing specific 
lesions due to treatment with UVC was transfected into XP20BE primary fibroblasts and complemented with 
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plasmids encoding for XPG or its splice variants. The relative repair capability is calculated as the percentage 
(repair %) of the reporter gene activity (firefly luciferase) compared to the untreated plasmid, after normalization 
to an internal co-transfected control (Renilla luciferase). Data are presented as the mean ± SEM. The one-tailed, 
unpaired student’s t-test was applied, ∗∗ P < 0.01, ∗∗∗ P < 0.001. At least four independent experiments in 
triplicates were performed. 
During my master thesis, I characterized six spontaneous XPG splice variants and was able to 
identify two splice variants with residual repair capabilities (see Figure 12). These results 
suggest that other endonucleases may also take part in NER and could be reaction partners of 
the described splice variants. Furthermore, splice variants of the second endonuclease 
(XPF/ERCC1) involved during NER are of special interest. 
Therefore, the goal of my Ph.D. project was to elucidate the catalytic functions or negative 
influence of the alternative splice variants of the three genes XPF, ERCC1 and XPG during 
NER and ICL removal. So far, a key limitation to study the functions of the XPF/ERCC1 
complex has been the lack of an appropriate human XPF- or ERCC1-defective cell line. With 
regard thereto, generation of XPF and ERCC1 KO cell lines using the CRISPR/Cas9 tool was 
the first part of the project. Afterwards, this cell lines had to be characterized in regard to 
sensitivity against different genotoxins and repair capabilities. In a second step, the goal was 
to amplify and clone alternative splice variants of XPF and ERCC1 from WT human skin 
fibroblasts to elucidate catalytic and possible dominant negative effects, by functional testing 
using different repair assays (see Figure 13).  
The last step was the evaluation if and how the different transcript levels of the relevant 
spontaneous isoforms of the three genes are able to serve as prognostic factors for the 
individual UV-induced skin cancer risk. With these investigations the project provides an 
important contribution to the understanding of the molecular mechanisms in NER and ICL 
repair as well as the establishment of splice variants as new prognostic biomarkers regarding 
personalized medicine in terms of carcinogenesis of the skin. It can be summarized by the 
following bullet points: 
1) generation of an XPF and ERCC1 KO cell line using the CRISPR/Cas9 tool 
2) characterization of KO cells as a useful model cell line 
3) amplification and cloning of postulated alternative splice variants of XPF and ERCC1 
from normal human skin fibroblasts 
4) functional analysis of alternative splice variants of XPF and XPG 
5) implication of functionally relevant splice variants as prognostic marker for individual 




Figure 13: Overview of the XPF and ERCC1 spontaneous mRNA splice variants 
The XPF gene can be alternatively spliced into C- or N-terminally truncated physiologically occurring variants. 
While XPF-201 only lacks the first 12 amino acids, XPF-202 and XPF-003 are severely C-terminally truncated, 
lacking functional domains, e.g. the nuclease domain. ERCC1 also comprises C-terminally truncated splice 
variants (ERCC1-003, ERCC1-005, -007, -008, -011, and -013). Furthermore, ERCC1-002 and ERCC1-004 





2.1 Biological material 
2.1.1 Cell lines 
Cell lines that were used in this project are listed in Table 2. Primary human fibroblasts have 
been isolated from skin punch biopsies of healthy donors. They function as a source for 
physiological mRNA splice variant preparations. 
Table 2: Cell lines 
Cell line Source Distributor 
WT fibroblasts primary fibroblasts 
derived from healthy donor punch 
biopsies 
XP20BE XP patient fibroblasts 
Coriell Cell Repository, Camden New 
Jersey, USA 
MRC5Vi immortalized fetal lung fibroblasts 
gift from Sarah Sertic  
(Sertic et al., 2011) 
HeLa immortal cervical cancer cells ATCC Manassas Virginia, USA 
2.1.2 Bacteria 
Escherichia coli (E. coli) DH5 [F-, endA1, glnV44, thi-1, recA1, relA1, gyrA96, deoR, 
nupG, Φ80dlacZΔM15, Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λ–,] (Hanahan, 1983) 
were used for transformation and amplification of plasmid DNA. 
2.2 Consumable supplies 




 96 Microplate Promega, Mannheim GER 
Blotting paper extra thick Bio-Rad Laboratories, Munich GER 






) Greiner Bio-One, Frickenhausen GER 
CELLSTAR
®
CELLreactor™, Polypropylene Filter 
Top Tube 
Greiner Bio-One, Frickenhausen GER 
Cell strainer (40µm) VWR, Darmstadt GER 
Cryo boxes Nunc, Wiesbaden GER 
Cryo tubes 2ml Greiner Bio-One, Frickenhausen GER 
Dispenser multipette

 plus Eppendorf, Hamburg GER 
Dispenser tips (50l, 5ml) Eppendorf, Hamburg GER 
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Erlenmeyer flask (200ml, 500ml) VWR, Darmstadt GER 
Falcon tubes 15ml, 50ml Sarstedt, Nuembrecht GER 
Glass cover slips, round Roth, Karlsruhe GER 
Kimtech wipes Kimberly-Clarke Professional, Roswell USA 
Glass pipettes (5ml, 10ml, 25ml) Brand, Wertheim GER 
Neubauer cell counting chamber Brand, Wertheim GER 
Microscope slides Thermo Fisher Scientific, Braunschweig GER 
Mini TGX Gels Biorad, Munich GER 
Nitrocellulose, 0.45 M Protran BA85 Amersham Bioscience, Piscataway USA 
Parafilm
®
 Brand, Wertheim GER 
Pasteurpipettes (230nm) Brand, Wertheim GER 
PCR tubes Sarstedt, Nuembrecht GER 
Petri dishes  Greiner Bio-One, Frickenhausen GER 
Pipettes (10l, 100l, 200µl, 1000l) Eppendorf, Hamburg GER 
Pipette tips (10l, 100l, 1000l) Sarstedt, Nuembrecht GER 
Polystyrene round bottom tube BD Falcon, Heidelberg GER 
Reaction tubes (0,5ml, 1,5ml, 2,0ml, 5,0ml) Eppendorf, Hamburg GER 
Scalpel, disposable Feather, Osaka JPN 
Tissue culture multiwell plates (6-well, 24-well, 96-
well) 
Greiner Bio-One, Frickenhausen GER 
Tissue culture dish (10cm) Greiner Bio-One, Frickenhausen GER 
Toothpick Fackelmann, Hersbruck GER 
2.3 Equipment 
Table 4: Equipment 
Instrument Manufacturer 
3100-Avant Genetic Analyzer Applied Biosystems, Foster City USA 
7900HT Fast Real-Time PCR System Applied Biosystems, Foster City USA 
Analytical balance BP2100; MC1 Sartorius, Goettingen GER 
Autoclave DE-65 Systec, Wettenberg GER 
Benchtop centrifuge 5415C Eppendorf, Hamburg GER 
ChemoCam Imager 6.0 Intas, Goettingen GER 
CO2-Incubator Sanyo, Munich GER 
Double Distilled Water System Arium® 611VF Sartorius, Goettingen GER 
DU 640

 Spectrophotometer Beckmann, Munich GER 
Freezer -20, +4 combination Liebherr, Rostock GER 
Gel iX 20 Imager Intas, Goettingen GER 
Glomax
®
 Discover System Promega, Mannheim GER 
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Hera freeze -80°C freezer Heraeus Instruments, Hanau GER 
Ice machine ZBE 30-10 Ziegra, Isernhagen GER 
Incubator model 200 Memmert, Buechenbach GER 
Microscope Axiovert A1 Carl Zeiss, Oberkochen GER 
Microscope Axioskop 2 Carl Zeiss, Oberkochen GER 
Microscope Axiovert 100  Carl Zeiss, Oberkochen GER 
Microscope Axiovert Imager M1 Carl Zeiss, Oberkochen GER 
Microwave Panasonic, Hamburg GER 
Mini-PROTEAN Tetra Cell Bio-Rad Laboratories, Munich GER 
Mini-PROTEAN
®
 TGX™ Precast Protein Gels 4-
15% 
Bio-Rad Laboratories, Munich GER 
Mini Rocking Platform Biometra, Goettingen GER 
NanoVuePlus
®
 GE Healthcare, Buckinghamshire UK 
pH meter Schuett, Goettingen GER 
Pipetboy acu Integra Biosciences, Fernwald GER 
Power Supply Ease 500 Invitrogen, Karlsruhe GER 
Shaker Infors, Bottmingen SWZ 
Hera safe sterile bench Thermo Fisher ,Waltham MA, USA 
Thermomixer 5436 Eppendorf, Hamburg GER 
T Gradient Thermo Block Biometra, Goettingen GER 
ULT7150-9-M Cryogenic freezer Thermo Fisher, Waltham MA, USA 





 Transfer System Bio-Rad Laboratories, Munich GER 
UVC 500 Ultraviolet Crosslinker with five 8W 254nm 
UV lamps 
Amersham Bioscience, Piscataway USA 
Vortexer Vibrofix VF1 Electronic IKA Labortechnik, Staufem GER 
Water bath GFL, Großburgwedel GER 
2.4 Chemicals 






 qPCR Mix Plus (ROX) Solis Biodyne, Tartu EST 
Agarose Saekem

 Fluka Chemie, Neu-Ulm GER 
Ammonium persulfate (APS) Sigma-Aldrich, Taufkirchen GER 
Ampicillin  Sigma-Aldrich, Munich GER 
Aqua ad iniectabilia Braun, Melsungen GER 
Boric acid Sigma-Aldrich, Taufkirchen GER 
Bradford Mix Roti

 Roth, Karlsruhe GER 
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Bromphenol blue Sigma-Aldrich, Taufkirchen GER 
Calcium chloride (CaCl2) Merck, Darmstadt GER 
Complete ULTRA Tablets Mini EDTA Roche, Mannheim GER 
Dithiothreitol (DTT) Sigma-Aldrich, Munich GER 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, Taufkirchen GER 
DNase Qiagen, Hilden GER 
dNTP Mix (dATP, dCTP, dGTP, dTTP) Thermo Fisher Scientific, Braunschweig GER 
Ethanol absolute, 99,8% Merck, Darmstadt GER 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, Taufkirchen GER 
EGTA (ethylene glycol-bis(β-aminoethyl ether)-
N,N,N',N'-tetraacetic acid) 
Sigma-Aldrich, Taufkirchen GER 
Fluorescence mounting medium Agilent Technologies Inc., Santa Clara USA 
Formaldehyde 4% Serva, Heidelberg GER 
G418 disulfate salt Sigma-Aldrich, Taufkirchen GER 
Gene Ruler (100bp #SM0241, 1kb SM0311) DNA 
ladder 
Thermo Fisher Scientific, Braunschweig GER 
Glycine (C2H5NO2) Sigma-Aldrich, Taufkirchen GER 
Glycerol (C3H8O3) Merck, Darmstadt GER 
HD Green Intas, Goettingen GER 
Hepes PAA, Coelbe GER 
Hi-Di Formamide Applied Biosystems, Foster City USA 
Hoechst33342 Life Technologies, Eggenstein GER 
Isopropanol (C3H8O) Merck, Darmstadt GER 
LB Agar Life technologies, Darmstadt GER 
LB Broth Base  Life technologies, Darmstadt GER 
Magnesium Chloride (MgCl2) Merck, Darmstadt GER 
Marker VI, protein ladder Applichem, Chicago IL, USA 
Methanol (CH3OH) Mallinckrodt Baker, Griesheim GER 
N,N,N,N-tetramethyl-ethane-1,2-diamine (TEMED) Sigma-Aldrich, Taufkirchen GER 
Nonidet P40 Sigma-Aldrich, Taufkirchen GER 
Paraformaldehyde (PFA) Merck, Darmstadt GER 
PhosSTOP Phosphatase Inhibitor Cocktail Roche, Mannheim GER 
Phenylmethanesulfonylfluoride (PMSF) Sigma-Aldrich, Taufkirchen GER 
Ponceau S Sigma-Aldrich, Taufkirchen GER 
Potassium Chloride (KCl) Merck, Darmstadt GER 
Puromycin Invivogen, San Diego, CA USA 
Roti
®
-Free Stripping Buffer Roth, Karlsruhe GER 
Sodium chloride (NaCl) Merck, Darmstadt GER 
Sodium dodecyl sulfate (SDS) Roth, Karlsruhe GER 
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Sodium hydroxide (NaOH) Merck, Darmstadt GER 
Superfibronectin Sigma-Aldrich, Taufkirchen GER 
Trifluoroacetic acid (TFA) Merck, Darmstadt GER 
Tris-Base Merck, Darmstadt GER 
Triton X-100 Merck, Darmstadt GER 
Vectashield Mounting Medium for Fluorescence with 
DAPI 1:1200 
Vector Laboratories, Burlingham CA/USA 
-mercaptoethanol (C2H6OS) Merck, Darmstadt GER 
2.5 Buffers, solutions and media 
Frequently used buffers, solutions and media were prepared as listed below. 
Table 6: Buffers, solutions and media 
 Receipt/ Manufacturer 
Cell culture 
Dulbecco’s Modified Eagle Medium (DMEM) high 
glucose 
PAA, Coelbe GER 
FibroLife
®
 fibroblast medium Lifeline Cell Technology, Frederick MD, USA  
Freezing medium (fibroblasts) 
40% DMEM 
40% (v/v) FBS 
20% (v/v) DMSO 
Fetal Bovine Serume (FBS) Biochrom AG, Berlin GER 
Penicillin-Streptomycin (100x) PAA, Coelbe GER 
Trypanblue solution 0,4% Sigma-Aldrich, Taufkirchen GER 




89mM Boric acid 
2mM EDTA 
Protein biochemistry 
















Immunoblot transfer buffer, pH 8.3 
0.192M Glycine 
0.025M Tris-Base 
20% MeOH (v/v) 
0.01% SDS 
Ponceau S solution 
0.2% (v/v) Ponceau S 
3% (v/v) TFA 
4% paraformaldehyde (PFA) 
3.6g PFA 
8ml PBS 
8 drops 1M NaOH 
 dissolve stirring at 60°C  
 fill up to 50ml with PBS 








0,04% Brompehnol blue 
before use add 10% -mercaptoethanol (v/v) 
Additional commonly used buffers 
10x PBS, pH 7.2 
1.5M NaCl 
30mM KCl 
80mM Na2HPO4 x 2H2O 
10mM KH2PO4 
6x DNA loading buffer 
0.5 M EDTA 
50% (v/v) Glycerol  
0.01% Brompehnol blue 
2.6 Oligonucleotides 
The following oligonucleotides were utilized in this work. For cloning into pcDNA3.1(+) 
(XPF KpnI (5’- ttaGGTACC -3’), XbaI (5’- ttaTCTAGA -3’); ERCC1 HindIII (5’- 
ttaAAGCTT -3’), XhoI (5’- ttaCTCGAG -3’)), pcDNA3.1(-)mycHisA2 (XPF XbaI, KpnI; 
ERCC1 XhoI, HindIII), and pcDNA3.1(+)eGFP (XPF KpnI, XbaI; ERCC1 HindIII, XhoI) 
respective restriction recognition sequences were added.  
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Table 7: Oligonucleotides 
Gene Oligonucleotide 
Amplification primer XPF/ERCC1 and splice variants 
XPF_fwd 5’- ATGGAGTCAGGGCAGCC -3’ 
XPF_rev 5’- TCACTTTTTCCCTTTTCCTTTTGA -3’ 
XPF_rev_w/oStop 5’- CTTTTTCCCTTTTCCTTTTGATAC -3’ 
XPF201_fwd 5’- ATGGCGCCGCTGCTGGA -3’ 
XPF003_rev 5’- TTAACCCCACAAGATACCTTCCC -3’ 
XPF003_rev_w/oStop 5’- ACCCCACAAGATACCTTCCCCT -3’ 
ERCC1_fwd 5’- ATGGACCCTGGGAAGGACAAA -3’ 
ERCC1_rev 5’- TCAGGGTACTTTCAAGAAGGGCT -3’ 
ERCC1_rev_w/oStop 5’- GGGTACTTTCAAGAAGGGCTCGT -3’ 
ERCC1-003_rev 5’- TTACAGGCGGAAGCCACTGT -3’ 
ERCC1-003_rev_w/oStop 5’- CAGGCGGAAGCCACTGTGT -3’ 
ERCC1-005_rev 5’- TCACCTGAGGAACAGGGCA -3’ 
ERCC1-005_rev_w/oStop 5’- CCTGAGGAACAGGGCACA -3’ 
ERCC1-007_rev 5’- TTACAGATGAGGAAACTGAAGGC -3’ 
ERCC1-007_rev_w/oStop 5’- CAGATGAGGAAACTGAAGGCCA -3’ 
ERCC1-008_rev 5’- TTAAAATTGGAACTGAAGCTCAAC -3’ 
ERCC1-008_rev_w/oStop 5’- AAATTGGAACTGAAGCTCAACCAC -3’ 
ERCC1-011_rev 5’- GGCAGGGAGATGGAAGGAA -3’ 
ERCC1-011_rev_w/oStop 5’- TGGGGCAGGGGAGCC -3’ 
ERCC1-013_rev 5’- CAAGAAGGGCTCGTGCAG -3’ 
ERCC1-013_rev_w/oStop 5’- AGAAGGGCTCGTGCAGGAC -3’ 
Quickchange mutagenesis XPF 
QC_XPF_D668A_fwd 5’- CATCTGCAGATGTTTCCACTGCCACTCGGAA -3’ 
QC_XPF_D668A_rev 5’- CCGGCTTTCCGAGTGGCAGTGGAA -3’ 
QC_XPF_P85S_fwd 5’- GAAGGAGTTGAACACCTCTCTCGCCGTGTAA -3’ 
QC_XPF_P85S_rev 5’- GTGATTTCATTTGTTACACGGCGAGAGAGGTGTT -3’ 
QC_XPF_F905A_fwd 5’-GATTTCATTCACACCTCTGCTGCAGAAGTCGTATCAAA-3’ 
QC_XPF_F905A_rev 5’- CCTTTTGATACGACTTCTGCAGCAGAGGTGTGAA -3’ 
QC_XPF_F905P_fwd 5’- GATTTCATTCACACCTCTCCTGCAGAAGTCGTATCAAA -3’ 
QC_XPF_F905P_rev 5’- CCTTTTGATACGACTTCTGCAGGAGAGGTGTGAA -3’ 
QC_XPF_D731A_fwd 5’- CGTGGAGCGCAAGAGTATCAGTGCTTTAATCGGCT -3’ 
QC_XPF_D731A_rev 5’- TAAAGAGCCGATTAAAGCACTGATACTCTTGCGCT -3’ 
QC_XPF_R153P_fwd 5’- CATTCATCTTGCGCCTCTTTCCCCAGAAAAACAA -3’ 
QC_XPF_R153P_rev 5’- TTTGTTTTTCTGGGGAAAGAGGCGCAAGATGAAT -3’ 
QC_XPF_C236R_fwd 5’- CAGACTGCTATACTGGACATTTTAAATGCACGTCTAAAG -3’ 
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QC_XPF_C236R_rev 5’- ATGGGTTATGGCATTTTAGTTCCTTTAGACGTGCAT -3’ 
QC_XPF_R689S_fwd 5’- CACAGCAAAGCATAGTTGTGGATATGAGTGAATTTCGAA -3’ 
QC_XPF_R689S_rev 5’- AGATGGAAGCTCACTTCGAAATTCACTCATATCCACAA -3’ 
QC_XPF_R490Q_fwd 5’- CCAAAGAAAGAACCCTCAAAAAGAAAAAACAGAAGTTGACCTT -3’ 
QC_XPF_R490Q_rev 5’- GGTTTTCCTACCATTTGAGTTAAGGTCAACTTCTGTTTTTTCTT -3’ 
Sequencing primer 
M13 5’- TAGAAGGCACAGTCGAG -3’ 
T7 5’- TAATACGACTCACTATAGGG -3’ 
U6fwd 5’- ACTATCATATGCTTACCGTAAC -3’ 
XPFseq_exon1_fwd 5’- ATGGAGTCAGGGCAGC -3’ 
XPFseq_exon4_fwd 5’- GTTCCATGTAGCAGTAAACT -3’ 
XPFseq_exon7_fwd 5’- CAAGTGATGACCGAACATGT -3’ 
XPFseq_exon9_rev 5’- TCACTTTTTCCCTTTTCCT -3’ 
XPFseq_exon3_rev 5’- CTTGGCCACAGATACAGTT -3’ 
XPFseq_exon8_rev 5’- GCTTGGCCACAGATACAGT -3’ 
CMVpromoter_long_fwd 5’- CTGCTTAGGGTTAGGCGTTTTGCGCT -3’ 
Genomic DNA primer XPF/ERCC1 
XPFexon1_fwd 5’- CACGATCATCTCAGTCTCAGCTC -3’ 
XPFexon1_rev 5’- CCTAGCGACCCCTTACATACGTC -3’ 
XPFexon2_fwd 5’- TGTAGACTGGTTGGCTGAAGTTAC -3’ 
XPFexon2_rev 5’- TGATGTAGGGAGCTGAGTCCTTC -3’ 
XPFexon3_fwd 5’- CTCTGTTCTGTGCGTGGCTATATG -3’ 
XPFexon3_rev 5’- GAAAAGCAACCATCAAATTGCTCTC -3’ 
XPFexon4_fwd 5’- GCTTTTCGTGTTGTTTGTAGCA -3’ 
XPFexon4_rev 5’- GTGATGCTTATATGCCAATCCACAT -3’ 
XPFexon5_fwd 5’- TAGCCACTTCCTTGAATAATGCTTG -3’ 
XPFexon5_rev 5’- ACGTTAAGTAGGCGGAAACATTAGC -3’ 
XPFexon6_fwd 5’- AAGACTTGCCATGCTGTATACTTCG -3’ 
XPFexon6_rev 5’- GCCAGTTACGTATGTAGGTCATGTG -3’ 
XPFexon7_fwd 5’- TTCAGGAAAGCAGATTCCATCTAAC -3’ 
XPFexon7_rev 5’- CACTAGGATCTCAGTGTTCATTTGC -3’ 
XPFexon8_fwd 5’- GATTTAAGTAATCTTGCCAGAGAGG -3’ 
XPFexon8_rev 5’- AGCAGCATCGTAACGGATATTAAAG -3’ 
XPFexon9_fwd 5’- CCTGTGTGGTAACGAGACCTTTAAC -3’ 
XPFexon9_rev 5’- GGACAATTCAGACCACAGGTTTATC -3’ 
XPFexon10_fwd 5’- CTTCCTTTACCCATCATTTGTCTTG -3’ 
XPFexon10_rev 5’- CTGGAACATAACCCATTCTAAGCTG -3’ 
XPFexon11_fwd 5’- CTTTCCTATTAGCTCGGTTTCCTTC -3’ 
XPFexon11_rev 5’- CTGAAAAGTACAGGCATGGGATAA -3’ 
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ERCC1exon1_fwd 5’- GATGGGACTTGTGGACCTGTA -3’ 
ERCC1exon1_rev 5’- CTGCCTTAGCCCTCTCTTAGAA -3’ 
ERCC1exon2_fwd 5’- CCTCAGATGTCCTCTGCTCA -3’ 
ERCC1exon2_rev 5’- GGAGAACAAAGTGGCTGGAA -3’ 
CRISPR/Cas9 guideRNA oligonucleotides XPF/ERCC1 
XPF_Cas9-1fwd 5’- CACCgagtcagggcagccggctcgacgg -3’ 
XPF_Cas9-1rev 5’- AAACccgtcgagccggctgccctgactc -3’ 
XPF_Cas9-2fwd 5’- CACCtgctggagtacgagcgacagctgg -3’ 
XPF_Cas9-2rev 5’- AAACccagctgtcgctcgtactccagca  -3’ 
XPF_Cas9-3fwd 5’- CACCctttcgccagaaaaacaaacgtgg -3’ 
XPF_Cas9-3rev 5’- AAACccacgtttgtttttctggcgaaag -3’ 
XPF_Cas9-4fwd 5’- CACCctgtcgctcgtactccagcagcgg -3’ 
XPF_Cas9-4rev 5’- AAACccgctgctggagtacgagcgacag -3’ 
XPF_Cas9-5fwd 5’- CACCtgcagctggagaaagtggtagagg -3’ 
XPF_Cas9-5rev 5’- AAACcctctaccactttctccagctgca -3’ 
XPF_Cas9-6fwd 5’- CACCatttcatttgttacacggcgaggg -3’ 
XPF_Cas9-6rev 5’- AAACccctcgccgtgtaacaaatgaaat -3’ 
ERCC1_Cas9-1fwd 5’- CACCaatttgtgatacccctcgacgagg -3’ 
ERCC1_Cas9-1rev 5’- AAACcctcgtcgaggggtatcacaaatt -3’ 
ERCC1_Cas9-2fwd 5’- CACCcatattcggcgtaggtctgagggg -3’ 
ERCC1_Cas9-2rev 5’- AAACcccctcagacctacgccgaatatg -3’ 
ERCC1_Cas9-3fwd 5’- CACCccttgtcctaccactccaggaggg -3’ 
ERCC1_Cas9-3rev 5’- AAACccctcctggagtggtaggacaagg -3’ 
ERCC1_Cas9-4fwd 5’- CACCagggacctcatcctcgtcgagggg -3’ 
ERCC1_Cas9-4rev 5’- AAACcccctcgacgaggatgaggtccct -3’ 
ERCC1_Cas9-5fwd 5’- CACCcacaaatttcttccttgctggggc -3’ 
ERCC1_Cas9-5rev 5’- AAACgccccagcaaggaagaaatttgtg -3’ 
ERCC1_Cas9-6fwd 5’- CACCgctctgtgtagatcggaataaggg -3’ 
ERCC1_Cas9-6rev 5’- AAACcccttattccgatctacacagagc -3’ 
Oligonucleotides for quantitative real-time PCR purchased from Qiagen, Hilden GER 




XPG QT00029246  
Oligonucleotides for quantitative real-time PCR 
XPG_fwd 5’- GGATCTTCAAGTGAACATGCTGAA -3’ 
XPG_rev 5’- TGCGAATCTGAAGCACTGGT -3’ 
XP20BE_fwd 5’- CCAGTGACTCCAGGAAAACGA -3’ 
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XP20BE_rev 5’- GGTACCAACTTGGGTAAGACT -3’ 
XPGIsoII_fwd 5’- CGTCCAGTGACTCCAGGAAA  -3’ 
XPGIsoII_rev 5’- CTTTTTTAAAACTTCATCTCTAACACGACT -3’ 
XPGIsoIII_fwd 5’- GAGTTCACCAAGCGCAGAAG -3’ 
XPGIsoIII_rev 5’- GAAGAGGGCAAGGGAATGTG -3’ 
XPGIsoIV_fwd 5’- CCAAAAGGAAATGAATCAGCAA  -3’ 
XPGIsoIV_rev 5’- CCCTCTAGCTACGTCAAAAGACATG -3’ 
XPGIsoV_fwd 5‘- GAATCTGCAGGCCAGGATTT -3‘    
XPGIsoV_rev 5’- CCTACCGTTCCAGATTTCTACAAAA -3 
XPGIsoVI_fwd 5’- GAGCCACAGGAAGCTGAGAAA -3‘ 
XPGIsoVI_rev 5’- CAGCAAGAAGTCGAAACACAATG-3‘ 
XPG201_fwd 5’- CCCAAGCTGGCTAGCGTTTA -3’ 
XPG201_rev 5’- TGAGGATTATGAAAGAACTCTTCCTGTA -3’ 
XPG202_fwd 5’- CATCAGGACTCGGCATGGAA -3’ 
XPG202_rev 5’- CCCGGACTCCTTTAAGTGCT -3’ 
2.7 Ready to use reaction systems 
The following ready to use reaction systems were utilized in this work. 
Table 8: Reaction systems 
Description Manufacturer 
Attractene Transfection Reagent Qiagen, Hilden GER 
BigDye Terminator v3.1 Cycle Sequencing Kit Applied Biosystems, Foster City USA 
CellTiter 96
®
 Non-Radioactive Cell Proiferation Promega, Mannheim GER 
CloneJET PCR Cloning Kit Thermo Fisher, Waltham MA, USA 
Dual-Luciferase Reporter Assay System Promega, Mannheim GER 
Gel extraction and PCR Clean Up Machery + Nagel, Düren GER 
NucleoBond
®
 Xtra MiDi/Maxi Machery + Nagel, Düren GER 
NucleoSpin
®
 Plasmid Machery + Nagel, Düren GER 
RNA from 20 different healthy human tissues Ambion
®
, Huntington, UK (discontinued) 
RNase free DNase Set Qiagen, Hilden GER 
RNeasy Mini Kit Qiagen, Hilden GER 
RevertAid H Minus First Strand cDNA synthesis Kit Thermo Fisher Scientific, Braunschweig GER 
Surveyor Mutation Detection Kit IDT, Coralville IW, USA 
QIAamp DNA Blood Kit Qiagen, Hilden GER 
WesternBreeze Chemilumonescent Immunodetection 
Systems anti mouse/rabbit 




Table 9: Enzymes 
Description Manufacturer 
BbsI Thermo Fisher, Waltham MA, USA 
DpnI 10u/µl Thermo Fisher, Waltham MA, USA 
ExoSAP Affymetrix, Santa Clara CA, USA 
HindIII 10u/µl Thermo Fisher, Waltham MA, USA 
KpnI 10u/µl New England Biolabs, Ipswich MA, USA 
Phusion DNA Polymerase New England Biolabs, Ipswich MA, USA 
PvuI New England Biolabs, Ipswich MA, USA 
T4 DNA Ligase 1u/µl Thermo Fisher, Waltham MA, USA 
T4 Polynukleotid Kinase New England Biolabs, Ipswich MA, USA 
T7 Endonuclease I New England Biolabs, Ipswich MA, USA 
XbaI 10u/µll New England Biolabs, Ipswich MA, USA 
XhoI 10u/µl Thermo Fisher, Waltham MA, USA 
CIAP (calf intestinal alkaline phosphatase) 1u/μl New England Biolabs, Ipswich MA, USA 
2.9 Plasmids 
Table 10: Plasmids 
Description Manufacturer 
pcDNA3.1(+) Life technologies, Darmstadt GER,  
pcDNA3.1(-)mycHisA2 Life technologies, Darmstadt GER, 
pCMVluc Promega, Mannheim GER 
pRL-CMV Promega, Mannheim GER 
pX330 Addgene, Cambridge MA, USA 
pX458 Addgene, Cambridge MA, USA 
pX459 Addgene, Cambridge MA, USA 
pX462 Addgene, Cambridge MA, USA 
2.10 Antibodies 
Primary and secondary antibodies were diluted in 10% FCS in PBS and concentrations are 





Table 11: Primary antibodies 









anti- Cas9 from 
Streptococcus pyogenes 
clone 7A9-3A3 





Santa Cruz Biotechnology, 
Heidelberg GER 
1:250 
XPA anti-human XPA  mouse 













rabbit Bethyl, Montgomery USA 1:1000 
 
Table 12: Secondary antibodies 
Antibody Host Manufacturer Dilution 
Alexa-Fluor
®
 488 goat anti-rabbit  goat Dianova, Hamburg GER 1:800 
Alexa-Fluor
®
 594 goat anti-
mouse 
goat Dianova, Hamburg GER 1:800 
2.11 Software and online tools 
The following software and online tools were used during this project: 
Table 13: List of utilized software and online tools 
Label Supplier/web address application 
Chromas Lite 2.1 Technelysium, South Brisbane AUS sequence analysis 
CorelDraw Graphics 
Suits X5 
Corel Corporation, Ottawa CA, USA image editing 
Double Digest Finder New England Biolabs, Ipswich MA, USA restriction digestion 
E!ensembl http://www.ensembl.org  genome browser 
Endnote X1.01 Thomson Reuters, New York USA literature management 
Glomax
®
 Software Promega, Mannheim GER 
luciferase and cell survival 
assay 
ImageJ National Institutes of Health, Bethesda USA 




LabImage 1D Intas, Goettingen GER 
Imaging System, western 
blot 
Ligation Calculator http://www.insilico.uni-duesseldorf.de/Lig_Input.html ligation 
Microsoft Office Microsoft, Unterschleissheim GER Word, PowerPoint, Excel 
MultAlin http://multalin.toulouse.inra.fr/multalin alignments 
Pubmed http://www.ncbi.nlm.nih.gov/pubmed  literature request 
Reverse Complement http://www.bioinformatics.org/sms/rev_ 
comp.html 
in silico sequence 
translation 





Translation tool http://web.expasy.org/translate 







3.1 Molecular Biology 
3.1.1 Ethanol precipitation 
High salt sodium acetate (a tenth part of the sample volume) and 96% ethanol (2.5 times 
sample volume) was added to the sample. After 30min of high speed centrifugation  
(14 000rpm) the supernatant was discarded and 300µl 70% ethanol was added to wash the 
pellet followed by 10min 14000rpm of centrifugation. Finally, the remaining ethanol was 
removed and the pellet was resuspended in water or distinct buffer. 
3.1.2 Nucleic acid quantitation 
Nucleic acid quantitation by spectrophotometry was used to determine the average 
concentration of DNA or RNA as well as their purity. Nucleic acids absorb UV light in a 
specific pattern. The absorbance at 230, 260, and 280nm was measured using the 
NanoVuePlus
®
 according to the Lambert-Beer-Law. The ratio of the absorbance at 260 and 
280 nm (A260/280) was used to assess the purity in relation to contamination by proteins. For 
pure DNA a ration around 1.8 and for RNA a ration around 2 should be determined. 
Absorbance at 230nm was the result of other contaminations. Expected values for A260/230 are 
commonly in the range of 2.0-2.2. 
3.1.3 Extraction of nucleic acids 
3.1.3.1 Isolation of genomic DNA 
Genomic DNA was extracted from cells using the Qiagen QIAamp Blood and Tissue Kit 
according to manufacturer's specifications.  
3.1.3.2 Isolation of mRNA and cDNA synthesis 
Total RNA was isolated from MRC5Vi cells, primary WT or XP20BE fibroblasts using the 
RNeasy Mini Kit by Qiagen. Cells were harvested as described in 3.3.1.1 and disrupted using 
RLT buffer. Depending on the number of pelleted cells, either 350μl or 600μl RLT buffer was 
added to the pellet, and further steps were carried out according to the manufacturer's 
specifications. In order to remove any residual contaminating DNA, DNase treatment was 
performed. Finally, RNA quantification and its assessment of purity were determined by 
spectrophotometry using the NanoVuePlus
®
 (see 3.1.2) and the RNA was stored at -80°C 
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until further use. Subsequently, cDNA was synthesized from the isolated RNA with the help 
of the Revert Aid H Minus First Strand cDNA Synthesis Kit. This kit included a reverse 
transcriptase, an enzyme that uses RNA as a template to synthesize complementary DNA 
(cDNA) lacking a ribonuclease H activity and therefore, it does not degrade RNA in RNA-
DNA hybrids during synthesis of the first strand cDNA. To synthesize mRNA anchored Oligo 
(dT)18 primer annealing to the poly-A tail of mRNA molecules was used. In order to generate 
cDNA, 1µg of total RNA was mixed with 1µl Oligo d(T) primer, aqua bidest was added to 
12µl and incubated at 70°C for 5min. In the meantime, a premix consisting of reaction buffer, 
RNase inhibitor and dNTPs was prepared. The premix was added to the reaction mix and 
incubated at 37°C for 5min. Thereafter, 1µl reverse transcriptase was added and the cDNA 
was synthesized at 42°C for 60min. The reaction was stopped by incubation at 70°C for 
10min and the synthesized cDNA was stored at -20°C until further use. 
3.1.3.3 Alkaline lysis plasmid extraction   
Alkaline lysis was first described by Birnboim and Doly in 1979 and has, with a few 
modifications, been the preferred method for plasmid DNA extraction from bacteria ever 
since. The procedure starts with the growth of the bacterial cell culture harbouring the 
plasmid under selective conditions (ampicillin in LB-medium). Cells were pelleted by 
centrifugation to remove them from the growth medium. The pellet was then resuspended in a 





essential for DNase activity and the integrity of the bacterial cell wall. EDTA chelates 
bivalent cations in the solution preventing DNases from damaging the plasmid and also 
destabilizes the cell wall. Glucose maintains the osmotic pressure so the cells do not burst and 
RNase A is included to degrade cellular RNA when the cells are lysed. The lysis buffer 
contains sodium hydroxide (NaOH) and the detergent SDS. SDS is there to solubilize the cell 
membrane. NaOH helps to break down the cell wall, but more importantly it disrupts the 
hydrogen bonding between the DNA bases, converting the double-stranded DNA (dsDNA) in 
the cell, including the genomic DNA (gDNA) and the plasmid, to single stranded DNA 
(ssDNA). This denaturation is the central part of the procedure. Addition of potassium acetate 
(neutralization) decreases the alkalinity of the mixture. Under these conditions the hydrogen 
bonding between the bases of the single stranded DNA can be re-established, so the ssDNA 
can re-nature to dsDNA. While it is easy for the small circular plasmid DNA to re-nature it is 
impossible to properly anneal huge gDNA stretches. As the double-stranded plasmid can 
dissolve easily in solution, the single stranded genomic DNA, the SDS and the denatured 
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cellular proteins stick together through hydrophobic interactions to form a white precipitate. 
The precipitate can easily be separated from the plasmid DNA solution by centrifugation. The 
last step is to clean up the solution and concentrate the plasmid DNA. This was performed by 
binding to glass-silica membranes and ethanol precipitation (see 3.1.1). 
For isolation of smaller amounts of plasmid DNA 4ml LB medium containing ampicillin 
(100µg/ml), according to the selection marker of the plasmid were inoculated shaking 
overnight at 37°C with a single bacterial colony. According to manufacturer’s instructions of 
the NucleoSpin

 Plasmid Kit by Machery and Nagel plasmid DNA was isolated. To isolate 
lager DNA amounts the NucleoBond
®
 Xtra MiDi/Maxi Kit by Machery and Nagel was used 
according to the user’s manual. 100ml LB medium containing ampicillin (100µg/ml) were 
inoculated with bacteria and incubated shaking at 37°C overnight. 
3.1.3.4 Agarose gel electrophoresis (AGE) 
For analysis or preparative purposes DNA fragments or plasmids, generated by PCR or 
restriction digestion were subjected to agarose gel electrophoresis. In an electric field 
negatively charged DNA fragments move towards the anode ((+)-pole). Depending on 
fragment size DNA fragments exhibit different mobilities in the agarose gel matrix. Smaller 
fragments move faster than bigger ones so that they can be separated by size and visualized 
by fluorescence dyes (e.g. HD Green
®
 Safe DNA Dye) that intercalate into the double helix, 
and UV-light (254nm). Agarose gels were generated by diluting a suitable amount of agarose 
powder (e.g. 1%) in 1x TBE buffer and dissolving it by boiling using the microwave. For 
visualization, a nucleic acid stain (HD Green
®
 Safe DNA Dye) was added (5µl per 100ml 
agarose). 1x TBE buffer was used as running buffer at a current between 60-80 V. Samples 
were prepared with 6x loading buffer and compared to a molecular weight size standard. 
Visualization of fragments was performed using the gel documentation system by Intas. 
3.1.3.5 Extraction of DNA from agarose gel 
Extraction of specific DNA fragments from agarose gels was performed according to the 
instructions of the NucleoSpin

 Gel extraction and PCR clean up Kit by Machery and Nagel. 
Previously, DNA fragments were separated by agarose gel electrophoresis  
(see 3.1.3.4) and the fragment of interest was excised using a scalpel. 
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3.1.4 Enzymatic manipulation of DNA 
3.1.4.1 Polymerase chain reaction (PCR) 
Developed in 1983 by Kary Mullis, PCR is a technique to amplify a specific DNA region of a 
template DNA strand. First template DNA is denatured into single strands. Then a pair of 
specific oligonucleotides (primer), complementary to the target region anneals to the single 
stranded DNA creating free 3’ hydroxyl ends so that the DNA polymerase can start the 
synthesis. Finally, strands are elongated. These three steps are repeated 30-40 times leading to 
an exponential amplification of a single DNA molecule. For cloning, restriction site 
sequences of specific restriction enzymes can be fused to the 5’ ends of the oligonucleotides 
resulting in a PCR product, which can be inserted into a vector after restriction digestion with 
the corresponding enzymes. The utilized Phusion DNA polymerase contains a proofreading 
activity and was used to amplify template DNA for cloning purposes. In colony PCR, single 
colonies serve as template for the amplification reaction. In this thesis, the Phusion 
polymerase was used for amplification, because it has a lower error rate as it is very important 
to generate fragments without mutations. For colony PCR and single clone screening this was 
not as important, because it was only performed to check the size of the integrated fragments. 
Therefore, in that case the Taq polymerase was used. For standard PCR a GC content of the 
primers between 40-60% and a melting temperature around 50-60°C was preferred. 
Reaction mix: 
- 0.5µl Phusion/ 0,6 µl Taq polymerase 
- 1.5µl DMSO/ 1.5µl DMSO 
- 10µl high fidelity (HF) buffer/ 10µl Taq buffer + 10µl MgCl2 (25mM) 
- 1µl dNTPs/ 2µl dNTPs 
- 2.5µl forward primer/ 4µl forward primer 
- 2.5µl reverse primer/ 4µl forward primer 
- cDNA template (100-200ng)/ genomic DNA 400ng 
- H2O up to 50µl/ 100µl 
 
Cycler protocol Phusion polymerase: 
- 98°C, 30s initial denaturation 
- 98°C, 20s denaturation 
- 50-60°C, 20s primer annealing 
- 72°C, (30sec/kb) elongation  






Cycler protocol Taq polymerase: 
- 95°C, 5min 
- 95°C, 30s 
- 50-60°C, 30s  
- 72°C, 1min/kb   
- 72°C, 5min 
3.1.4.2 Quantitative Real-time PCR 
For quantitative real-time PCR (qRT-PCR), total RNA was extracted from primary human 
fibroblasts using the RNeasy Mini Kit according to manufacturer's instructions. Afterwards, 
cDNA was synthesized from 1µg of total RNA using the RevertAid H Minus First Strand 
cDNA synthesis Kit (see 3.1.3.2). Analysis of gene expression was carried out using 
EvaGreen-based real-time PCR detection. For each reaction, 50ng of cDNA was used in a 
final reaction mixture of 10µl, containing 1pmol oligonucleotides and 2μl EvaGreen
®
 qPCR 
Mix Plus. A passive reference dye (ROX) is included in this mix to normalize the fluorescent 
reporter signal. Each sample was analyzed in duplicates. Gene expression levels were 
normalized against the GAPDH housekeeping gene. For quantitative analyses and quality 
control of the applied primer pair standard curves were established. Therefore, the PCR 
product was amplified from cDNA of WT fibroblasts and serially diluted (500amol – 5ymol, 
in 1:10 steps). To ensure high quality standard curves only standards with a dissociation curve 
containing one peak, meaning no unspecific byproducts or primer dimers were applied. For a 
PCR efficiency of 100% the standard curve was supposed to have a slope of -3.32 and an 
R
2
>0.99. The non-template control (H2O) should not be detectable. For the analyses of this 
thesis slopes between -3.58 and -3.10, corresponding to a PCR efficiency of 90 – 110%, were 
accepted. Quantitative real-time PCR analyses were performed using the Applied Biosystems 
7900HT Fast Real-Time PCR System. The sequences of the PCR primer pairs are shown in 
Table 7.  
Cycling protocol: 
- 95°C, 15min initial denaturation 
- 95°C, 15sec denaturation  
- 60°C, 20sec primer annealing  
- 72°C, 20sec elongation  






3.1.4.3 Site-directed Mutagenesis (Quickchange PCR) 
Quickchange PCR is a method of site-directed mutagenesis that is used to make specific and 
intentional changes to the DNA sequence of a gene or even a plasmid. This procedure 
requires the synthesis of a DNA primer pair, which contains the desired mutation and is 
complementary to the template DNA around the mutation site (15-20bp upstream and 
downstream) in order to hybridize with the DNA at the position of interest. The single-
stranded primer is then extended using a DNA polymerase, which copies the rest of the gene 
or whole plasmid. The same cycle program as described above can be used when adjusting 
the annealing temperature of the primer and the number of cycles. Subsequently, a DpnI 
digestion leads to removal of the template plasmid, as DpnI is an enzyme that digests 
methylated DNA. 1l enzyme was added to the PCR-mix and incubated at 37°C for 2h. 
Afterwards, the enzyme was inactivated at 80°C for 20min. The gene or construct thus copied 
contained the mutated site, and could then be introduced into a host cell by transformation 
(see 3.2.3). Finally, mutants were selected. 
3.1.4.4 Plasmid vector dephosphorylation, oligonucleotide phosphorylation 
A plasmid vector dephosphorylation was performed to prevent re-ligation of the vector after 
restriction digestion. Therefore, 20g of the plasmid was mixed with 1l of calf intestinal 
alkaline phosphatase (CIAP) and 5l of the respective buffer. The volume was adjusted to 
50l with water. Then the mixture was incubated at 37°C for 1 hour. Enzyme inactivation was 
performed at 65°C for 15min. Afterwards, ethanol precipitation was performed to concentrate 
the DNA. Oligonucleotide phosphorylation was performed using the T4 Polynucleotide 
Kinase from NEB according to manufacturer’s instructions. 
3.1.4.5 Restriction digestion of DNA 
The desired sequence to be cloned into an expression vector (insert) was amplified by PCR 
(see 3.1.4.1). Restriction enzymes (KpnI/XbaI or HindIII/XhoI) were used to cut as well 
insert as plasmid vector DNA. Thereby, complementary sticky ends were generated so that 
insert and vector could be ligated and not vector and vector or insert and insert. Restriction 
enzymes were chosen according to their presence in the multiple cloning site (MCS) of the 
respective plasmid. Furthermore, it was important that there were no additional restriction 
sites in the plasmid or insert DNA. Otherwise this would have led to undesired fragments. A 
double digestion was performed according to manufacturer’s instructions over night at 37°C. 
Afterwards an ethanol precipitation (see 3.1.1) was performed, to prevent buffer components 
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from disturbing the following ligation step. For plasmid linearization PvuI was utilized 
according to manufacturer’s instructions.  
3.1.4.6 Ligation 
DNA ligases are enzymes catalyzing the formation of covalent phosphodiester bonds between 
free 3’ hydroxyl and 5’ phosphate ends of DNA molecules, fusing two fragments together. A 
DNA T4 ligase was used to insert DNA fragments into a plasmid vector according to their 
sticky ends. A vector insert ration of 1:3 (mol) according to 100ng of vector was used. Insert, 
vector, 1µl ligase, 2µl ligase buffer and H20 (up to 20µl) were incubated for 2h at room 
temperature or overnight at 16°C. 
3.1.4.7 DNA sequencing and sequence analysis 
Sequencing reactions according to Sanger’s chain-termination method (1977) were 
performed. This method requires a ssDNA template, a DNA primer, a DNA polymerase, 
normal deoxynucleotidetriphosphates (dNTPs), and modified nucleotides (dideoxyNTPs) that 
terminate DNA strand elongation. Today, these ddNTPs (in this case dye-terminating 
nucleotides) can be fluorescently labelled for detection (dye-terminator sequencing). This 
permits sequencing in a single reaction as each of the four ddNTPs is labelled differently, 
emitting light at different wavelengths. In this case, the products were separated by capillary 
gel electrophoresis by the Paediatrics Department of the University Medical Center 
Goettingen or send to Eurofins genomics. The resulting chromatogram displays the sequence. 
For this project the Big Dye Terminator v3.1 Cycle Sequencing Kit was used according to 
manufacturer’s instructions except the amount of BDs. 
Sequencing Mix: 
- 300-500ng of DNA  
- 0.5µl primer 
- 1µl BD 
- 2µl BD buffer 
- H20 ad 10µl 
 
Cycling protocol: 
- 96°C, 30sec 
- 55°C, 15sec 





The resulting product was cleaned by ethanol precipitation (see 3.1.1) and resuspended in 
10µl Hi-Di Formamide for analysis with a 3100-Avant Genetic Analyzer. The Chromas Lite 
software (Technelysium Pty Ltd, Brisbane Australia) was utilized for analysis of the resulting 
sequence. 
For single clone analysis, genomic DNA was isolated and the exonic region of interest was 
amplified using specific primers. PCR products were purified using an ExoSAP digestion and 
sequenced with the BigDye
®
 Terminator v3.1 Cycle Sequencing Kit. For allele-specific 
sequencing, exonic regions were amplified and cloned into the  pJET1.2/blunt plasmid 
according to manufacturer’s instruction of the CloneJET PCR Cloning Kit, transformed in 
DH5α cells and single colonies were sequenced as described above. 
3.1.4.8 Enzyme mismatch cleavage 
The T7 endonuclease I (T7EI) and surveyor nuclease assay were performed according to the 
suggested manufacturer’s protocol for genome targeting and surveyor mutation detection 
(NEB, IDT). These enzyme mismatch cleavage (EMC) methods make use of nucleases that 
cleave heteroduplex DNA at mismatches and extrahelical loops (single or multiple 
nucleotides). The bacteriophage T7EI cleaves cruciform DNA structures, Holliday structures 
or junctions, heteroduplex DNA and more slowly, nicked double-stranded DNA. T7EI is 
proficient at recognizing insertions and deletions of ≥2 bases that are generated by NHEJ 
activity. The surveyor nuclease is a member of the celery endonuclease (CEL) family, which 
recognizes and cleaves mismatches due to the presence of single nucleotide polymorphisms 
(SNPs) or small insertions or deletions. 
3.1.4.9 CRISPR construct generation 
The pX462 vector containing the cDNA encoding Streptococcus pyogenes Cas9 (hSpCas9) 
and a puromycin resistance cassette was purchased from Addgene (plasmid #48141) (Ran et 
al., 2013). The guide sequence oligonucleotides (Table 7) including the BbsI restriction site 
overhangs and the PAM sequence targeting exon two within XPF were annealed (95°C, 5min, 
cool down overnight) and cloned into the pX462 vector. The plasmid was digested with BbsI 
according to manufacturer’s instruction. The oligonucleotides were phosphorylated by T4 
Kinase (see 3.1.4.4) and ligated into the vector using the T4 Ligase according to 
manufacturer’s instructions. Constructs were transformed in Escherichia coli strain DH5α 
cells and selected using ampicillin (see 3.2.3). To validate the correct sequence the BigDye
®
 
Terminator v3.1 Cycle Sequencing Kit was utilized (see 3.1.4.7) applying the U6 fwd primer 
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(Table 7). The guide sequence was preselected from six different XPF guideRNA pairs using 
in silico on- and off-target predictions (http://crispr.mit.edu/, 
http://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design, http://crispr.cos.uni-
heidelberg.de/index.html) and T7EI analysis of polyclonal populations in respect of XPF gene 
targeting in MRC5Vi cells. 
3.2 Microbiology 
3.2.1 Sterilization and autoclavation 
Liquids as well as S1-waste were autoclaved at 120°C and 3bar for 20min. Plastic pipette tips 
were autoclaved at 120°C and 3bar and subsequently dried at 70°C for 4h. Glass pipettes used 
for cell culture were washed in a dish washer at 40°C. Afterwards, glass pipettes were sealed 
with cotton wool and sterilized at 180°C for at least 4h. 
3.2.2 Generation of chemically competent Escherichia coli (E. coli) DH5 
To amplify recombinant plasmid DNA, plasmids have to be inserted into bacterial cells. 
However, under normal conditions the uptake of foreign DNA by bacterial cells, like E. coli, 
is very low. Hence, bacterial cells are manipulated using physical or chemical methods to 
change their cell membrane so that foreign DNA can attach and be taken up more easily. 
Pores are opened due to the high salt conditions. This process is called production of 
competent cells. 
Competent bacterial cells were plated on LB without antibiotics. A single colony was used to 
inoculate a 10ml overnight culture (LB medium) at 37°C. On the next day the whole culture 
and 190ml fresh medium were incubated at 37°C until the optical density reached OD600= 0.5. 
Very importantly, from then on cells were kept on ice to keep them in the beginning of the 
logarithmic growth phase. Cells were centrifuged at 4°C (4000rpm, 10min). Afterwards the 
pellet was resuspended in 25ml ice-cold 100mM MgCl2 and incubated on ice for 5min. Cells 
were centrifuged again and then resuspended in 5ml ice-cold 100mM CaCl2, incubated on ice 
for 20min and centrifuged again. Finally, the pellet was resuspended in 1ml (85%CaCl2, 15% 
glycerol), aliquoted à 50µl, immediately quick-frozen in liquid nitrogen and stored at -80°C. 
3.2.3 Transformation of E. coli DH5 
In molecular biology transformation is defined as the genetic alteration of a cell resulting 
from the direct uptake and its subsequent expression of exogenous genetic material from its 
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surroundings through the cell membrane. This means uptake of recombinant plasmid-DNA 
into competent E. coli (DH5α cells, 50µl aliquots see 3.2.2). Therefore, 5µl of insert DNA 
was added to one aliquot of competent cells (thawed on ice) and incubated on ice for 30min. 
This led to the attachment of plasmid DNA to the cell membrane. Then a heat shock was 
performed (42°C for 45s, directly put the tube on ice afterwards for 2min) to improve the 
uptake of the foreign DNA. This heat shock was followed by a regeneration of the cells using 
450µl of liquid LB medium for 1h at 37°C. Subsequently, cells were plated onto an agar plate 
containing ampicillin. This led to a selection for bacterial cells carrying the plasmid with the 
resistance gene. 40% transformation efficiency was determined. Transformation efficiency is 
the number of transformed cells (transformants) generated by 1µg of plasmid DNA.  
3.3 Cell Biology 
3.3.1 Cell culture techniques 
3.3.1.1 Culture of primary human fibroblasts and immortalized cell lines 
All cell types were cultivated in 75cm
3
 culture flasks with 20ml DMEM high glucose culture 
media supplemented with 10% FBS (v/v) and 1% Penicillin and Streptomycin (v/v) in a 
humidified atmosphere at 37°C and 5% CO2. Primary fibroblasts were passaged 1:1 or 1:2 
when they had grown to confluence, while immortalized cells were passaged 1:10. Therefore, 
these adherent cells were rinsed with 10ml PBS to remove dead cells and residual FBS, and 
then dissociated from the culture flask using 4ml trypsin/EDTA and 5min incubation at 37°C. 
The reaction was stopped by addition of 10ml complete culture medium. Then cells were 
centrifuged at 1000rpm for 5min and the supernatant was discarded. Afterwards, the cells 
were distributed to an appropriate number of culture flasks to reach 10 – 50% confluence for 
immortalized and primary cells, respectively. 
3.3.1.2 Cell counting 
In order to determine the number of cells/ml, adherent cells were detached with trypsin/EDTA 
and resuspended in fresh culture medium (complete) as described before (see 3.3.1.1). 10µl 
cell suspension was mixed with 90µl trypan blue and 10µl of this suspension was applied to a 
Neubauer counting chamber. Four large squares (each 1mm
2
) were counted under a 
microscope and the number of cells was the sum of all the counted cells in all squares 




3.3.1.3 Freezing and thawing cells 
For cryo-preservation of fibroblasts, cells were sedimented at 1000rpm for 5min, the 
supernatant was discarded and the pellet was resuspended in 500µl culture medium 
(complete). Briefly, 500µl freezing medium was added and the suspension was transferred to 
cryo tubes. A cell freezing container was used to ensure a controlled cooling rate (-1°C/min) 
at -80°C. The following day, the cryo tubes were stored at -150°C in a cryogenic freezer. In 
order to cultivate frozen cells, cells were thawed under running tap water and transferred to 
10ml culture medium (complete) and centrifuged at 1000rpm for 5min. The supernatant was 
discarded and the pellet was resuspended in an appropriate volume of culture medium and re-
seeded in a culture flask. The culture medium was renewed the following day to remove any 
residual DMSO and dead cells. 
3.3.1.4 Transient Transfection 
All cell lines were transfected utilizing the Attractene Reagent, a nonliposomal lipid that 
enables transfection of not only adherent cells. It is able to form complexes with DNA 
resulting in micelles that are then absorbed by cells via endocytosis. Thus, cells were either 
seeded in 100mm tissue culture dishes at a density of 9x10
5
 for primary or 6x10
5
 for 
immortalized cells per dish, or in 24-well-plates at a density of 20000cells/well (or 15000cells 
for immortalized cells). On the next day, cells were transfected according to manufacturer’s 
instructions. DNA (4g/ 250ng) was filled up with 300l/60l of non-supplemented cell 
culture medium, 15l/1.8l/0.6l Attractene Transfection Reagent was added and the mixture 
was vortexed. This was followed by 15min incubation at room temperature, while the old 
medium of the dishes or plates was removed and 10ml/500l fresh medium was added. After 
that, the plasmid-Attractene-mix was added dropwise and cells were further incubated for 6h 
until the medium was removed and replaced again. For fast forward transfection, cells were 
directly transfected after seeding.  
3.3.1.5 CRISPR/Cas9 transfection and single clone expansion 
MRC5Vi cells were seeded in 100mm tissue culture dishes at a density of 750 000 cells and 
transfected using Attractene and the fast-forward transfection protocol according to 
manufacturer’s instructions (4µg DNA (pX462 containing the guide sequence, and a 
puromycin resistance gene, or no DNA for the control), filled up to 300µl DMEM without 
supplements and 15µl Attractene). On the next day puromycin was added to the dishes and 
cells were cultured in puromycin containing medium (0.25µg/ml puromycin) until the control 
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cells had died. For single clone selection, cells were separated using the serial dilution method 
in a 96-well plate after coating with superfibronectin and cells were further cultured in 
FibroLife
®
 fibroblast medium without puromycin. After two days the plate was evaluated 
under the microscope (Axiovert A1, Zeiss), single cells were marked, and expanded for two 
weeks to form colonies. Then, the colonies were transferred into 6-well plates and further 
expanded for genomic DNA isolation. 
3.3.2 Functional assays 
3.3.2.1 Host Cell Reactivation Assay (HCR) 
In general the HCR can be used to analyze NER repair capacity and complementation 
capabilities. In this assay a non-replicating reporter gene plasmid is either irradiated with 
UVC light (750J/m
2
 for primary cells and 1000J/m
2
 for immortalized cells), treated with cis-
diammineplatinum(II) dichloride (CP) (in a molecular ratio of 1:20 (primary cells) or 1:40 
(immortalized cells) (vector:CP)) or with 4,5’,8-trimethylpsoralen (TMP) (1:25 (primary 
cells) or 1:50 (immortalized cells) (vector:TMP)) followed by irradiation with 1 J/cm² UVA 
light. Thereby, different DNA 6-4PPs and CPDs, as well as intrastrand and interstrand 
crosslinks were generated. After transfection (see 3.3.1.4) of these damaged plasmids into a 
host cell, enzyme expression can only be detected if the DNA lesions of the transcribed strand 
of the reporter genes in the plasmid are removed. Hence, activity of the enzyme coded on the 
damaged reporter gene plasmid correlates with NER activity (see Figure 14). Cells were 
seeded in 24-well plates the day before transfection at a density of 20000cells/well. On the 
following day, cells were transiently transfected with either untreated or treated pCMVluc 
reporter gene plasmid (100ng) coding for firefly luciferase together with pCMVluc reporter 
gene plasmid (50ng) coding for Renilla luciferase for normalization plus complementation 
plasmid (100ng). The empty expression vector pcDNA3.1(+) was used as a negative 
complementation control. After 48/72h (immortalized/primary cells) of culturing, cells were 
washed with PBS and lysed with 80l of lysis buffer for 45min at room temperature. Cell 
lysates were transferred into a 96-well Glomax
TM
 96 Microplate and the enzyme expression 
was measured using the Promega’s Dual-Luciferase Reporter Assay System with the 
Glomax
® 
Discover System. Specific substrate solutions for firefly (beetle luciferase) and 
Renilla luciferase (coelenterazine) were added to the 96-well Glomax
TM
 96 Microplate. The 
enzyme activity was measured as relative light units (RLU). The mean value of a triplicate 
was determined and repair percentage was calculated. To estimate the repair efficacy firefly 












 x 100 
The assay was repeated at least four times in triplicates.  
 
Figure 14: Simplified scheme of the HCR 
Cells were transiently transfected with either a treated or untreated firefly reporter gene plasmid together with a 
Renilla reporter gene plasmid for normalization. For complementation, a plasmids coding for, e.g. full-length 
protein or one of the splice variants, was transfected. After 48/72h of incubation (37°C, 5%CO2) enzyme activity 
was measured as relative light units (RLU). 
3.3.2.2 DSB Assay 
For the measurement of HRR and NHEJ capabilities the DRGFP and pEGFP-Pem1-Ad2 
reporter gene assay were utilized (Seluanov et al., 2010). For a schematic illustration of the 
assay principle see Figure 15. Cells were seeded on glass coverslips in 24-well plates and 
transfected with 100ng DR-GFP or pEGFP-Pem1-Ad2 plasmid, 100ng pcDNA3.1(+) (used as 
empty control) or pCBAI-SceI plasmid and 50ng pcDNA3.1(+)mCherry for normalization 
using Attractene transfection reagent according to the manufacturer’s instructions. After 48h 
cells were washed with PBS three times and fixed with 4% paraformaldehyde (PFA) in PBS 
for 15min at room temperature. After fixation, the slides were washed again and then stained 
using Hoechst33342, diluted 1:1000 in PBS, for 20min at room temperature covered in 
aluminum foil. Thereafter, the slides were washed and mounted with fluoromount fluorescent 
mounting medium. Results were documented using an Axiovert A1 microscope with a 
200x/400x magnification. Subsequently, approximately 100 mCherry positive cells per 
condition were assessed (blinded) for additional GFP positivity. Hence, the repair capability 
was calculated as the percentage of GFP positive cells compared to mCherry positive cells. 
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The assay was repeated at least five times. The plasmids were a kind gift from Prof. Matthias 
Dobbelstein (Department of Molecular Oncology, Georg-August-University, Goettingen). 
 
Figure 15: Schematic illustration of the DSB assay principle 
(A) The left panel depicts the HRR assay. The GFP plasmid contains two GFP cassettes. One cassette (iGFP) 
with a deletion in the first exon of GFP combined with the insertion of I-SceI restriction sites is followed by a 
promoter-less/ATG-less first exon and intron of GFP (trGFP). The DRGFP plasmid was co-transfected with 
pCBASceI and pcDNA3.1(+)mCherry for internal normalization. Upon expression of I-SceI (from pCBAScel) a 
DSB is produced in the DRGFP plasmid. If the cells repair the DSB using the trGFP as template, a functional 
GFP cassette is formed and HRR proficient cells can express GFP, while deficient cells do not. The middle panel 
shows the way NHEJ was assessed using the pEGFP-Pem1-Ad2 plasmid. It contains a GFP gene with an 
engineered 3kb intron from the Pem1 gene with an adenoviral (AD) exon flanked by recognition sequences for 
HindIII and I-SceI to induce DSBs. The intact NHEJ cassette is GFP negative as the adenoviral exon disrupts the 
GFP ORF. We co-transfected the plasmid with pCBASceI and pcDNA3.1(+)mCherry for normalization. In 
NHEJ proficient cells, the I-Scel-induced DSBs eliminating the intron are repaired by NHEJ, so that the cell can 
transcribe and express functional GFP. Furthermore, as an additional analyses of NHEJ, we performed an in 
vitro digestion of the plasmid using HindIII and then transfected the linearized plasmid (NHEJlin) together with 
pcDNA3.1(+) (to maintain the same DNA rations) and pcDNA3.1(+)mCherry for normalization (right panel). 
(B) Representative fluorescent images acquired for the HRR (upper panel) and NHEJ (lower panel) assay in WT 
cells. For both assays approximately 100 mCherry positive cells per condition were counted (blinded) for GFP 
positive cells after 48h. Adapted from (Lehmann et al., 2017). 
3.3.2.3 Determination of post-toxin cell survival 
The colorimetric CellTiter96

 Non-Radioactive Cell Proliferation Assay, also called MTT-
assay, from Promega is a tool to measure cell viability. MTT (3-(4,5-Dimethylthiazole-2-yl)-
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2,5-diphenyl-tetrazoliumbromid) is a membrane passing dye, which is metabolized in living 
cells by mitochondrial dehydrogenases to its blue colored formazan salt (Mosmann, 1983). 
The insoluble product is dissolved into a colored solution after addition of a solubilization 
solution (=MTT stop solution), e.g. containing dimethyl sulfoxide or sodium dodecyl sulfate 
diluted in hydrochloric acid. Absorbance can be measured at 570nm using spectrometry. 
For analysis of post-toxin cell survival 2000 cells were seeded in 96-well plates and after 24h 
irradiated with UVC doses of 0 - 160J/m
2
 (UVC 500 Crosslinker at 254nm), treated with CP  
0 - 8µg/ml, TMP 0 - 364.5ng/ml (30min preincubation) followed by irradiation with 1J/cm
2
 
UVA light (Biolink BLX UVA crosslinker at 365nm), camptothecin (CPT) 0 - 512nM, 
etoposide 0 - 16µM or bleomycin 0 - 16µg/ml. After treatment cells were cultured for 48h 
until the substrate was added. As the compounds were solved in DMSO, the DMSO volume 
of the maximal toxin amount applied was used as a control and survival was set to 100%. The 
assay was repeated at least four times in quadruplicates. We analyzed the post-toxin cell 
survival method to determine the lethal dose 50 (LD50), which indicates the dose of a toxin 
that kills 50% of the cells. Therefore, this value gives an impression of the cellular sensitivity 
towards a special toxin. 
3.3.2.4 Fluorescence microscopy 
To analyze subcellular localization, HeLa cells were seeded on round glass cover slips in  
24-well-plates and transfected with the constructs containing C-terminal eGFP-tagged splice 
variants of XPF and ERCC1 on the next day (see 3.3.1.4). After 48h the wells were washed 
with PBS three times and then fixed with 4% PFA for 15min followed by three times washing 
with PBS again. Afterwards, cells were stained using DAPI or Hoechst33342 and mounted 
with fluoromount (see 3.3.2.2). Pictures were taken using the Microscope Axiovert Imager 
A1.  
3.4 Biochemical methods 
3.4.1 Preparation of protein lysates 
For whole protein lysates, cells were harvested as described in 3.3.1.1 and resulting cell 
pellets were washed twice using 10ml PBS and cells were resuspended in PBS containing 
PMSF and complete proteinase stop. Afterwards, cells were disrupted by rotational freezing 
in liquid nitrogen followed by thawing on ice for three times. Cells were sedimented by 
centrifugation (10min, 14 000rpm, 4°C). Then, the supernatant was transferred into a new 
Methods 
60 
reaction tube to get rid of cell debris. Protein lysates were adjusted to the desired 
concentration, mixed with 3% SDS splitting buffer and boiled at 95°C for 10min. Afterwards 
they were stored at -20°C. 
For preparation of cytosolic and nuclear protein extracts cells were prepared using buffer A 
and B (see Table 1). Cell pellets were resuspended in an appropriate volume of buffer A and 
incubated on ice for 15min. A tenth of the volume of 1% Nonidet NP40 in buffer A was 
added to the suspension and vortexed for 20sec. Afterwards, cells were centrifuged for 10min 
at 14000U/min. The supernatant was transferred into a new reaction tube (cytosolic fraction) 
and kept on ice. The nuclear pellet was washed three times with 500µl buffer A. Then 20-
50µl buffer B were added and the reaction tubes were put in an ultrasonic bath with ice for 
30min. Thereupon, the mixture was pelleted at 14000U/min for 30min. The supernatant was 
transferred into a new reaction tube (nuclear fraction). Protein concentration was examined 
with a ready to use Bradford solution (see 3.4.2).  
3.4.2 Bradford protein quantification  
Protein concentration was examined by Bradford assay (Bradford, 1976) using a ready to use 
Bradford solution according to the manufacturer's instructions. Protein concentration was 
photometrically measured (OD595) and quantification was determined using a BSA calibration 
curve (standard serial dilutions, 0-1500μg/ml). Each sample was diluted 1:20 and 1:40 in the 
respective buffer and 150µl Bradford solution (Roti-Quant 1:5 in aqua bidest) and incubated 




3.4.3 Polyacrylamide gel electrophoresis (SDS-PAGE) 
With the help of the SDS-Page (polyacrylamide gel electrophoresis) according to Laemmli it 
is possible to separate proteins by size in an electric field. The binding of the aliphatic tail of 
SDS to the polypeptide chain imparts an even distribution of charge per unit mass, thereby 
resulting in a fractionation by approximate size during electrophoresis. The SDS-treated 
proteins have similar charge-to-mass ratios in an electric field; hence they can be separated 
according to their molecular weight. SDS is a negatively charged strong detergent agent used 
to denature native proteins to unfolded, individual polypeptides. It binds to polypeptides in a 
constant weight ratio of 1.4g SDS/g of polypeptide. The intrinsic charges of polypeptides 
become negligible and movement in the gel depends on the size. Therefore, protein lysates 
were mixed with 3% SDS splitting buffer, containing ß-mercaptoethanol, and heated for 
10min at 95°C. SDS as a detergent, along with the reducing agent (to break down protein-
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protein disulphide bonds), disrupts the tertiary structure and coats the protein with an overall 
negative charge. Separation of proteins via gel electrophoresis was performed using 4–15% 
Mini-PROTEAN
®
 TGX™ Precast Protein Gels. Gels were loaded with 50-100µg of protein 
lysates together with a prestained protein marker. 
3.4.4 Western blotting 
Western blot technique allows protein visualization of one specific protein within a protein 
mixture by antibody detection. For semi-dry western blotting, the proteins were transferred 
onto a nitrocellulose membrane after horizontal SDS-PAGE. Blot paper as well as the 
membrane were pre-equilibrated with transfer buffer. The transfer was carried out using the 
Bio-Rad Transblot Turbo System at a current of 0.6A and maximal voltage of 12V for 30-
45min, depending on the size of the respective proteins. Successful protein transfer was 
visualized by staining with Ponceau S solution, followed by destaining of the membrane with 
aqua bidest. In order to saturate free protein binding sites, membranes were incubated with 
blocking buffer for at least 30min according to manufacturer’s instructions. Incubation with 
the respective primary antibody was performed rocking overnight at 4°C (see Table 11). The 
next day, the membranes were incubated with an appropriate secondary antibody for 45min at 
room temperature. Membranes were washed four times with washing solution for 5min and 
rinsed two times with aqua bidest. Antibody binding was detected using the WesternBreeze 
Chemiluminescent Immunodetection system, according to the manufacturer’s instructions. 
Chemiluminescence was developed and quantified using the Chemo Cam Imager 3.2 and the 
LabImage 1D software. Therefore, each band was normalized to β-actin. 
3.4.5 Membrane stripping 
Prior to reprobing, membranes were stripped in Roti
®
-Free Stripping Buffer at 56°C for 
30min, washed in PBS, and blocked in blocking buffer for 30min at room temperature. For 
normalization, membranes were reprobed with β-actin antibody as described in 3.4.4. 
3.5 Statistics analyses 
Statistics analyses were performed using the GraphPad Prism software with at least three 
independent experiments. Data are presented as the mean ± SEM. The one-tailed, unpaired 





During the course of my master thesis physiologically occurring splice variants of the XPG 
gene were identified and characterized (see Figure 12A). These variants encoding for the 
XPG endonuclease were amplified from healthy donor mRNA and cloned into a 
pcDNA3.1(+) plasmid vector, a pcDNA3.1(-) plasmid vector with a C-terminal myc/HisA2-
tag, or a pcDNA3.1(+) plasmid vector with a C-terminal eGFP-tag. Protein expression over 
time was assessed as well as subcellular localization (see Figure A1, Figure A2). As 
previously shown, the XPG endonuclease does not travel according to its molecular weight 
(136kDa) (Aracil et al., 2013; Dunand-Sauthier et al., 2005; Tillhon et al., 2012), due to an 
acidic patch in the spacer region. Therefore, endogenous full-length XPG presents with a 
band at 180kDa. However, all XPG isoforms were stably expressed over the observed time 
course. Assessment of subcellular localization showed that all isoforms localize to the nucleus 
and could therefore theoretically take part in NER. Notably, two isoforms (IsoV and IsoVI) 
led to a highly significant increase of cellular repair capability (see Figure 12B).  
The goal of my Ph.D. project was to analyze catalytic functions or negative influences of 
alternative splice variants of the three genes XPF, ERCC1 and XPG during NER and ICL 
removal. I established the CRISPR/Cas9 technique in the laboratory and utilized it to generate 
XPF and ERCC1 KO cells in order to overcome the limitations of studying the function of the 
XPF/ERCC1 complex due to the lack of an appropriate human XPF- or ERCC1-defective cell 
line.  
4.1 A novel mutation in the XPA gene results in two truncated protein 
variants and leads to a severe XP/neurological symptoms phenotype 
In addition to characterizing and testing spontaneous mRNA splice variants of XP genes, I 
also worked on the characterization of XP patients and identified a novel mutation in the XPA 
gene. The human XPA gene (OMIM: 278700) is located on chromosome nine (9q34.1), 
encodes for a 273 aa protein, and plays a major role in DNA damage demarcation as well as 
stabilization of NER factors (reviewed in Berneburg & Lehmann, 2001). In geographically 
isolated areas, like Japan, the XP frequency is about 1:22,000 with a preference for XP-A 
cases and commonly occurring founder mutations result in a severe XP plus neurological 
symptoms phenotype (see Figure 6) (Moriwaki et al., 2012; Satokata et al., 1990).  
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Two 21 and 28 year old brothers (XP31MA and XP32MA), a 17 year old Moroccan 
adolescent from a consanguineous family (XP31GO), and a 6 year old boy (XP118MA) were 
characterized. XP31MA, XP32MA, and XP31GO clinically presented with only mild XP 
symptoms together with mild mental retardation. On the other hand, XP118MA showed a 
very severe mental retardation as well as skin cancer development during early childhood. 
Primary skin fibroblasts of all patients showed strongly reduced post UV-cell survival and 
high sensitivity against UVC irradiation, assessed by MTT-assay (see Figure 16A). LD50 
values were 5 J/m
2
 UVC for all four patients compared to 80 J/m
2
 UVC for WT primary 
fibroblasts. Cellular NER capacity was analyzed using the HCR assay (see 3.3.2.1). 
Compared to WT fibroblasts (14.05%), XP-A patient cells exhibited a decreased repair 
capacity of only 0.28% (XP31MA), 0.24% (XP32MA), 0.14% (XP31GO), and 0.49% 
(XP118MA) (see Figure 16B). This effect could be rescued by co-transfection of a WT XPA 
containing expression vector (9.24% (XP31MA), 8.73% (XP32MA), 7.46% (XP31GO), and 




Figure 16: Characterization of four new XP-A patients 
(A) Post-UV cell survival of XP-A patient fibroblasts was analyzed after cells were irradiated with increasing 
UVC doses at least three times in quadruplicates. (B) Reporter gene reactivation after treatment with UVC 
determined a decrease in repair capability of all four patients (black bars) that could be rescued to wildtype 
levels (light grey bar) after complementation with an XPA encoding plasmid (dark grey bars). Data are presented 
as mean ± SEM of at least three independent experiments in triplicates. (C) XPA protein levels were assessed by 
immunoblotting of whole cell protein extracts from WT and patient primary fibroblasts. In extracts from 
XP31GO, XP31MA and XP32MA a truncated protein could be detected, while no protein was detectable for 
XP118MA. (D) Functional domains of the XPA protein (upper part) as well as the mutational spectrum found in 
the four new XP-A patients (lower part) are shown. Purple boxes: functional protein-protein interaction domains, 
yellow and blue boxes: DNA interaction domains, and green box: NLS; red arrow: XP-A patient mutation; 





In order to pinpoint the genetic defects, the entire XPA gene including exon-intron boundaries 
was sequenced on the genomic and cDNA level (see 3.1.3.1, 3.1.3.2, and 3.1.4.7). XP31MA, 
XP32MA, and XP31GO showed the already known founder mutation c.747C>T, a 
homozygous C>T transversion leading to a premature stop in exon six (p.R228X). In 
XP118MA, I identified a homozygous two nucleotide insertion mutation in exon two 
(c.268_269insAA) leading to a frameshift and a termination signal 40 nts downstream, 
resulting in a truncated protein of 103 aa with 14 non-XPA amino acids at the C-terminus 
(variant one) (see Figure 16D). Additionally, a second variant of this mutation could be 
identified. Due to in-frame skipping of exons three-four, it is missing aa 96-185 and 
containing a stretch of six foreign amino acids. Patient fibroblasts of XP31MA, XP32MA, 
and XP31GO exhibited a detectable endogenous expression of the truncated XPA protein as 
assessed by western blot analyses (see 3.4.4). The two variants of XP118MA could not be 
detected on protein level (see Figure 16C). However, mRNA decay was excluded as cell lines 
XP31MA, XP32MA, and XP31GO exhibited 83%, 140% and 45% XPA expression and even 
172% in XP118MA mRNA compared to WT (100%) (data not shown) (Lehmann et al., 
2015). 
4.2 Establishment of a complete XPF and ERCC1 CRISPR/Cas9 knockout 
in MRC5Vi cells 
To elucidate the catalytic or inhibitory function of XPF, ERCC1 and XPG alternative splice 
variants during NER and ICL removal, establishing a suitable cell line was of essential 
importance. As described before (see 1.4.3), patient cells from XP20BE represent a good 
basis for mechanistic studies of XPG and its isoforms. In contrast, a key limitation to study 
the functions of the XPF/ERCC1 complex has been the lack of an appropriate human XPF- or 
ERCC1-defective cell line. This is due to the essentialness of these genes and relatively mild 
phenotypes in XP-F patients or in the case of ERCC1 the overall limited number of known 
patients. To generate targeted XPF and ERCC1 KO cell lines with early mutations, the 
CRISPR/Cas9 technique is a great tool to study the truncated splice variants of these genes. 
4.2.1 Characterization of an XPF CRISPR/Cas9 KO single clone  
Fibroblasts from XP-F patients still retain relatively high repair activities which are reflected 
predominantly in the mild phenotype due to residual repair capabilities in full-length alleles 
with point mutations (reviewed in Matsumura et al., 1998). The aim was to create an XPF KO 
cell line from immortalized fetal lung fibroblasts (MRC5Vi), already used in DNA repair 
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studies (Ogi et al., 2010; Sertic et al., 2011), by employing the CRISPR/Cas9 nuclease system 
targeting one of the first exons (one-three) of XPF. The feasibility for a complete XPF KO in 
human fibroblasts was assumed based on a previously established Xpf-deficient mouse model 
(Tian et al., 2004).  
A transient transfection approach with a puromycin resistance cassette containing a plasmid 
for selection of positive clones was applied to circumvent long-term expression of artificial 
nucleases in the cells in order to minimize off-target effects (see 3.1.4.9 and 3.3.1.4). 
Different guide RNAs were analyzed in respect to on and off-target effects to identify suitable 
target sequences in exon two of XPF. Single clone expansion was followed by amplifying and 
sequencing exon two to verify the successful KO (see 3.1.4.7). At this point, cells were 
sensitive to puromycin again. Figure 17A shows a part of the XPF exon two sequencing 
results from a positive clone, visualizing the generation of a compound heterozygous, 
complete, and still viable XPF KO cell line. In this section, the binding of the guide RNA 
(black arrow) in XPF exon two is indicated. As expected the Cas9 nuclease induces a DSB 
~3bp upstream of the PAM sequence (Ran et al., 2013). Part of the guide sequence was 
deleted during the NHEJ process. One allele contains a seven nt deletion resulting in a 
premature stop codon nine nts downstream. In addition to this, the second allele shows an 
insertion of three nts and a premature stop after twelve nts, respectively. This is probably a 
result of a second cutting event by the Cas9 nuclease at the same position. Complete 
sequencing of the XPF gene did not reveal any additional mutations.  
Furthermore, the XPF KO clone containing the mutation, was subject to standard enzyme 
mismatch cleavage experiments (EML), the T7EI and surveyor nuclease assay (see 3.1.4.8). 
For the T7E1 assay, PCR products were generated from genomic DNA of WT and XPF KO 
MRC5Vi cells, using primers for XPF exon two as described above (see 3.1.4.1)  
(see Table 7). Subsequently, PCR products were denatured, followed by re-annealing, leading 
to a population of double strand fragments, of which some contained mismatches due to the 
afore mentioned compound heterozygous nature of the KO. These mismatches could be 
detected by T7EI and visualized on an agarose gel (see 3.1.3.4). WT cells did not yield 
amplicons susceptible to site-specific cleavage by T7EI (see Figure 17B), while XPF KO cells 
showed efficient cleavage of the endogenous chromosomal target sequence, evidenced by 
T7EI digestion products (arrows). This confirmed the presence of indels at the locus. 
Surprisingly, there was an additional cleavage product, also in the WT cells (arrow head) that 
can be explained by a physiologically appearing already described three nt deletion in exon 
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two (polymorphism rs771203473 (NCBI), deletion AGA/-, chromosome 16:13922057-
13922059). PCR amplicons from mutant (KO) and WT DNA were likewise prepared for the 
surveyor nuclease assay. Afterwards, equal amounts of KO and WT DNA were mixed and 
hybridized by heating and cooling the mixture to form hetero- and homoduplexes (see 
3.1.4.8). In accordance with the T7EI assay, the WT cells did not show cleavage products, 
whereas in the WT+KO mixture, as well as in the KO alone, cleavage products could be 
detected. This was in concurrence with the compound heterozygous state of the KO (see 
Figure 17C, arrows). As observed in the assay before, an additional cleavage product was 







Figure 17: Structural analyses of XPF CRISPR/Cas9 KO and WT MRC5Vi cells 
(A) Sanger sequencing of XPF exon two from WT (upper panel) and KO (middle and lower panel) cells. The 
start of the guide RNA binding sequence is illustrated by a black arrow, while the dashed line marks the start of 
the sequence alterations in the XPF KO cells. The green sequence represents the deletion in the KO cells, while 
the blue nts are inserted. Red nts indicate the continuation of the WT sequence after the CRISPR event up until 
the stop codon (underlined), resulting from the frameshift. Two different alleles of the KO cells originating from 
the CRISPR/Cas9 genome editing are depicted in the middle and lower panel. (B) XPF exon two was PCR 
amplified from genomic DNA of WT and KO cells, denaturated, reannealed and T7EI-digested or (C) subject to 
a surveyor nuclease assay. The positions of digested DNA are illustrated by black arrows, while the arrow head 
marks an additional digestion product that can be seen in the WT cells as well (polymorphism). (D) Horizontal 
SDS-PAGE followed by western blot analyses was used to assess protein expression. Therefore, equal amounts 
of cytosolic and nuclear extracts of WT and KO cells were loaded onto ready-to-use SDS-gels and stained with 
an anti-XPF or anti-ERCC1 antibody. The membrane was stripped and reprobed for anti-β-actin to serve as 
loading control. Representatively, one of three independent experiments is shown. (E) Subsequent to 
complementation of the XPF KO cells with a plasmid coding for XPF cDNA, the same procedure was 
performed. Adapted from (Lehmann et al., 2017). 
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Moreover, generation of a complete XPF KO on protein level was confirmed. Therefor, 
cytosolic and nuclear protein fractions of WT and KO cells were isolated (see 3.4.1). Full-
length XPF molecular weight is predicted to be 112kDa. The KO induced a premature stop 
codon after 86/87 aa, resulting in a theoretic molecular weight of approximately 10kDa. 
Protein expression was assessed using horizontal SDS-Page followed by western blotting as 
described in 3.4.3, 3.4.4, and 3.4.5. WT cells showed an accumulation of nuclear XPF 
(13.88), while in XPF KO cells XPF was below limits of detection in the cytosol as well as in 
the nucleus, verifying the total lack of the protein (see Figure 17D). This was also true for 
lower sections of the gel, where a 10kDa protein would be visible (section of the gel not 
shown). After overexpression of a plasmid containing XPF cDNA (see 3.3.1.4), XPF protein 
expression could be restored in the cytosol (3.20) as well as in the nucleus (18.32) of XPF KO 
cells (see Figure 17E). In addition, protein expression of ERCC1, XPF’s functional 
heterodimer partner necessary for the catalytic activity in DNA repair, was assessed. In the 
cytosol, ERCC1 presented as a double band at 38kDa, which is probably caused by post-
translational modifications (Nowotny & Gaur, 2016; Perez-Oliva et al., 2015). While WT 
cells displayed an accumulation of the modified form of ERCC1 in the nucleus (8.82) (Figure 
17D), ERCC1 could not be detected in the nucleus of XPF KO cells. This suggests an 
inability of ERCC1 to enter the nucleus without its binding partner XPF. Transfection of XPF 
KO cells with a plasmid containing XPF cDNA (see 3.3.1.4) rescued nuclear localization of 
ERCC1 (see Figure 17E). 
Quantitative real-time PCR was applied to analyze differences in XPF mRNA expression 
between WT and KO cells (see 3.1.3.2 and 3.1.4.2). Interestingly, there was a reduction of 
about 50% in the KO cells (WT XPF normalized to GAPDH 100 ± 4.71%, KO 54.76 ± 
13.32%), probably due to nonsense-mediated messenger decay (see Figure 18) (reviewed in 




Figure 18: Decrease in XPF expression in XPF KO cells assessed by quantitative real-
time PCR 
Comparison of XPF mRNA expression levels from MRC5Vi WT and XPF KO cells. Expression levels are 
shown as relative values and GAPDH was used as the internal control gene to normalize the expression of the 
target gene. Results represent mean values from three independent experiments in duplicates. Data are presented 
as mean ± SEM. Statistical significances were calculated by applying the one-tailed, unpaired student's t-test  
(* P < 0.05).  
4.2.2 A viable complete ERCC1 KO cannot be generated  
As described for XPF, a transient transfection approach with a puromycin resistance cassette 
containing plasmid for selection of positive clones, was applied for ERCC1 as well (see 
3.1.4.9 and 3.3.1.4). In contrast to Xpf, several different mouse models with a disruption of 
the C-terminal part of Ercc1 have been described. In one model, the last four exons are 
missing due to a mutation in exon five, disrupting the interaction between XPF and ERCC1. 
Whereas the other model contains a truncation in the HhH2 motif, as a result of an insertion of 
a neomycin cassette into exon seven of the Ercc1 gene (McWhir et al., 1993; Weeda et al., 
1997) (reviewed in Gregg et al., 2011). This implicates an essential role of ERCC1, as 
complete KO mice are not available, and challenges the creation of a complete cellular KO. 
It was possible to generate a heterozygous ERCC1 KO with a one nt insertion in exon two. 
This led to a premature stop codon only after about 400nts later, resulting in a residual protein 
of 21kDa (see Figure 19, lower band) additional to the WT protein (double band). As 
expected for a recessive disease, one functional allele was sufficient to constitute normal NER 
levels (data not shown). However, additional attempts to perform further CRISPR/Cas9 
genome editing after generation of Cas9 stable MRC5Vi WT cells, as well as the afore 
mentioned heterozygous ERCC1 KO cells, only yielded further heterozygous single clones, 
but no full KO in the first exons of ERCC1. In regard to these results, it is most likely that 
homozygous complete ERCC1 KO cells are not viable due to the essential role of the protein 
in many cellular processes. Therefore, exons further downstream (three-ten) should be 
Results 
71 
targeted. Anyhow, such KO cells would not be of value to analyze the splice variants shown 
in Figure 13 as they comprise structural changes already in early parts of the protein 
sequence.  
 
Figure 19: Generation of a heterozygous ERCC1 KO via CRISPR/Cas9 genome editing 
To assess ERCC1 protein expression, horizontal SDS-PAGE was followed by western blot analyses. Equal 
amounts of whole protein lysates from MRC5Vi WT and heterozygous ERCC1 KO cells were loaded onto a 
ready-to-use SDS-gel and stained with an anti-ERCC1 antibody. The membrane was stripped and reprobed for 
anti-β-actin to serve as loading control. One of three independent experiments is shown. 
4.2.3 XPF KO cells show an increased sensitivity to several DNA damaging toxins 
The newly generated XPF KO cells were further characterized by investigation of cell 
survival after treatment with UVC irradiation, the main trigger of NER, as well as treatment 
with ICL inducing toxins (CP and TMP plus UVA irradiation) (see 3.3.2.3). Cisplatin is a 
frequently used chemotherapeutic and predominantly produces intrastrand cross-links 
between guanine residues or adenine and guanine (90%), which in turn are also mostly 
repaired by the NER pathway. Interstrand cross-links are only formed between guanines to a 
minor extent of 2–5% (Jones et al., 1991). Psoralen and its derivatives, for example TMP, 
mainly form interstrand cross-links with the DNA after activation by irradiation with long-
wavelength UV light (UVA) (McHugh et al., 2001). The MTT method was applied to analyze 
post-toxin cell survival (Mosmann, 1983) and determine the LD50, as a means to quantify 
cellular sensitivity towards a special toxin. XPF KO cells were significantly more sensitive to 
UVC irradiation in comparison to WT cells (LD50WT = 50J/m², LD50KO< 1J/m²)  
(*** P < 0.001, n = 4, one-tailed, unpaired student’s t-test) (see Figure 20A). Similarly, 
treatment with intra- and interstrand crosslink inducing agents like CP or TMP activated by 
UVA irradiation provoked a significantly reduced survival of XPF KO cells  
(CP: LD50WT = 1.5µg/ml, LD50KO = 0.125µg/ml; TMP: LD50WT = 13.5ng/ml, LD50KO = 
Results 
72 
0.5ng/ml) (*** P < 0.001, n = 4) (see Figure 20B, C). Cell survival was not markedly affected 
by treatment with TMP or UVA alone (data not shown). 
Moreover, the XPF/ERCC1 complex is involved in different sub-pathways of mammalian 
DSB repair, therefore effects of different DSB creating toxins on cellular survival was subject 
to further analyses (Ahmad et al., 2008; McVey & Lee, 2008). Even though XPF KO cells 
were slightly more sensitive to bleomycin treatment, no significant reduction in survival in 
comparison to WT cells could be measured (LD50WT = 3µg/ml, LD50KO = 2.5µg/ml)  
(n.s. P > 0.05, n = 4) (see Figure 20D). Besides, the effects of CPT, a topoisomerase I (TOP1) 
inhibitor, as well as etoposide, a topoisomerase II (TOP2) inhibitor, were analyzed. In 
concurrence with the previously tested toxin, only a slight, but non-significant, decrease in 
cell survival was measurable after drug treatment (CPT: LD50WT = 50nM, LD50KO = 50nM; 
etoposide: LD50WT = 6µM, LD50KO = 3.5µM) (n.s. P > 0.05, n = 4) (see Figure 20E, F). 
Taken together, the results indicate that XPF is not as essential for coping with DSB inducing 




Figure 20: WT MRC5Vi and XPF KO post-toxin cell survival analyses  
Cells were seeded in 96-well plates at a density of 2000 cells/well and (A) irradiated with increasing doses of 
UVC (0 – 160J/m²), (B) treated with increasing doses of cisplatin (0 - 8µg/ml), (C) trimethylpsoralen (0 - 
364.5ng/ml) activated by 1J/cm² UVA light, (D) bleomycin (0 - 16µg/ml), (E) camptothecin (0 - 512nM), or (F) 
etoposide (0 - 16µM). After 48h, cell survival was assessed using the MTT assay, setting survival of the DMSO 
control cells to 100%. Data are presented as the mean ± SEM. At least four independent experiments in 
quadruplicates were performed. Adapted from (Lehmann et al., 2017). 
4.2.4 Loss of XPF reduces the cellular repair capability for NER, ICL, and HRR 
As the XPF/ERCC1 complex is involved in multiple repair pathways and cellular processes, 
effects of the XPF KO on NER, ICL, and DSB repair were studied in more detail by utilizing 
reporter gene assays. Therefor, the HCR assay was utilized to investigate correct repair of 
UVC induced DNA lesions (see 3.3.2.1). Expectedly, XPF KO MRC5Vi cells exhibited a 
significant reduction in NER capability (0.15 ± 0.02%) in comparison to WT cells  
(12.45 ± 0.86%) (*** P < 0.001, n = 4). Complementation with a plasmid containing the 
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cDNA of full-length XPF rescued this effect (6.87 ± 0.13%) (*** P < 0.001, n = 4), but 
neither XPG (0.35 ± 0.01%) nor ERCC1 (0.13 ± 0.21%) used as controls (n.s. P > 0.05, n = 4) 
(see Figure 21A). ICLs are more challenging to repair as they obstruct DNA replication and 
transcription (Hodskinson et al., 2014; Klein Douwel et al., 2014). Moreover, it is known that 
XPF-deficient cells are sensitive to agents inducing ICLs, e.g. CP or TMP plus UVA light 
(reviewed in Wood, 2010). To further investigate this, the HCR assay was adapted for 
plasmids treated with CP or TMP activated by UVA irradiation (see 3.3.2.1). In the XPF KO 
cells, the repair of intrastrand crosslinks caused by CP, as well as interstrand crosslinks 
produced by TMP treatment of the firefly luciferase plasmid followed by irradiation with 
UVA, was impaired, shown by a significant reduction in ICL repair capability (CP 0.78 ± 
0.08%, TMP + UVA 2.50 ± 0.15%) compared to WT cells (CP 15.43 ± 0.035%, TMP + UVA 
13.90 ± 0.81%) (*** P < 0.001, n = 4). This effect was rescued by co-transfection of a  
full-length XPF containing plasmid (CP 17.65 ± 1.13%, TMP + UVA 12.65 ± 0.37%)  
(*** P < 0.001, n = 4), but neither by XPG (CP 1.34 ± 0.02%, TMP + UVA 2.65 ± 0.07%) 
nor ERCC1 (CP 0.56 ± 0.51% TMP + UVA 2.04 ± 0.22%) (n.s. P > 0.05, n = 4)  
(see Figure 21B, C). 
 
Figure 21: Reactivation of a reporter gene after treatment with UVC, cisplatin or 
trimethylpsoralen activated by UVA light in XPF KO and WT MRC5Vi cells 
For the HCR assays, firefly plasmids were treated with (A) UVC irradiation (B) cisplatin (intrastrand crosslinks) 
or (C) trimethylpsoralen activated by 1J/cm
2
 UVA irradiation (interstrand crosslinks) to induce specific lesions, 
transfected into MRC5Vi WT and XPF KO cells, and complemented with plasmids coding for XPF, XPG or 
ERCC1. The relative repair capability was calculated as the percentage (repair %) of the reporter gene activity 
(firefly luciferase) compared to the untreated plasmid, after normalization to an internal co-transfected control 
(Renilla luciferase). Data are presented as the mean ± SEM. The one-tailed, unpaired student’s t-test was 
applied, ∗∗∗ P < 0.001. At least four independent experiments in triplicates were performed. Adapted from 
(Lehmann et al., 2017). 
To investigate DNA DSB repair, two eGFP based reporter assays were utilized. The DRGFP 
reporter assay was applied to investigate HRR capability, while a reporter gene assay using 
the pEGFP-Pem1-Ad2 plasmid was implemented to assess NHEJ (see Figure 15A, B) 
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(Seluanov et al., 2010) (see 3.3.2.2). Compared to WT cells (33.27 ± 5.52%), XPF KO cells 
showed a significant reduction in HRR capability (13.31 ± 3.07%) (* P < 0.05, n = 5)  
(see Figure 22A). On the other hand, no reduction in NHEJ activity, neither for the I-SceI 
(WT 98.29 ± 0.36%, KO 94.49 ± 2.70%) nor the in vitro HindIII digestion, used as an 
additional control, could be detected (WT 92.25 ± 3.81%, KO 93.94 ± 1.12%) (n.s. P > 0.05, 
n = 4) (see Figure 22B).  
 
Figure 22: Analyses of HRR und NHEJ repair pathways in XPF KO and WT MRC5Vi 
cells. 
For both assays, a pCBASceI and a pcDNA3.1(+)mCherry plasmid for normalization were co-transfected with 
the eGFP reporter plasmid. Furthermore, as an additional analysis of NHEJ, an in vitro digestion of the plasmid 
using HindIII was performed prior to transfection. (NHEJlin). Approximately 100 mCherry positive cells per 
condition were counted (blinded) for GFP positive cells after (A) HRR or (B) NHEJ assay. The repair capability 
was calculated as percentage (repair %) of GFP compared to mCherry positive cells. Data are presented as mean 
± SEM. The one-tailed, unpaired student’s t-test was applied, ∗ P < 0.05. At least five independent experiments 
were performed. Adapted from (Lehmann et al., 2017). 
4.3 Amplification and characterization of XPF and ERCC1 splice variants 
As previously mentioned, the expression level of splice variants in different tissues is more 
suitable to distinguish between oncogene and non-oncogene samples than the primary gene 
transcript (Zhang et al., 2013b) and could be predictive of cancer risk, disease progression 
and therapeutic success (see 1.6.2). However, not much is known about the function of 
spontaneous splice variants of XP genes. Therefore, part of my PhD thesis was to further 
characterize these variants. All until now, physiologically occurring spontaneous mRNA 
splice variants (see Figure 13) of the XPF (XPF-201, XPF-003, XPF-202) and ERCC1 
(ERCC1-002 – ERCC1-008, ERCC1-11, ERCC1-013) genes were amplified from WT 
MRC5Vi mRNA and cloned into different expression plasmids: pcDNA3.1(+),  
pcDNA3.1(-)mycHisA2, and pcDNA3.1(+)eGFP (C-terminal). In order to amplify these 
splice variants, mRNA was isolated from WT MRC5Vi and transcribed into cDNA (see 
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3.1.3.2). Specifically designed primer pairs were utilized for amplification of the different 
splice variants and are listed in Table 7. The cloning procedure was conducted as described in 
my master thesis for XPG and its splice variants (Lehmann, 2013).  
4.3.1 Protein expression and subcellular localization of XPF and ERCC1 splice 
variants 
To verify whether the generated plasmid vectors containing the different XPF and ERCC1 
mRNA splice variants result in stable expression of a protein, horizontal SDS Page (see 3.4.3) 
followed by immunoblotting was performed (see 3.4.4). For this purpose, HeLa cells were 
transiently transfected (see 3.3.1.4) with the different constructs and harvested after 24h, 48h 
and 72h. Protein extracts were isolated from total cell lysate (see 3.4.1) and separated by 
SDS-Page. For immunoblot analyses anti-XPF, anti-ERCC1, or an antibody directed against 
the myc-tag were used (see Table 11). Myc-tagged constructs were used in case of severely 
truncated variants, probably lacking the antibody epitope. Expression was normalized to anti-
-actin as a housekeeping gene and quantified by densitometric analysis using the LabImage 
1D software from Intas (Gassmann et al., 2009). 
Figure 23 shows expression patterns of full-length XPF and its isoforms. Wildtype XPF levels 
peak at 72h, while its isoform XPF-201 shows highest protein levels after 48h. On the other 
hand, protein levels of XPF-202 and XPF-003 decrease over time. Taken together, all XPF 
isoforms were successfully overexpressed over time and resulted in proteins of the expected 
size (XPF and XPF-201 ~ 112kDa, XPF-202 and XPF-003 ~ 48kDa). The same procedure 
was performed for ERCC1 and its respective splice variants (see Figure A3). Again, all 
isoforms were detectable over time. As mentioned before, ERCC1 presents as a double band 
due to posttranslational modifications (see 4.2.2). Notably, ERCC1-002 and ERCC1-008 
levels increase over time, while full-length ERCC1, ERCC1-003, ERCC1-005, ERCC1-007 




Figure 23: Immunoblot results for protein levels of XPF splice variants over time 
In order to analyze protein levels after overexpression of the splice variants in HeLa cells, horizontal SDS Page 
followed by immunoblotting was performed. Therefore, HeLa cells were transiently transfected with the 
different constructs, harvested after 24h, 48h and 72h, and stained with an anti-XPF or an antibody directed 
against the myc-tag. Anti-β-actin staining was used for normalization. Protein levels were quantified in regard to 
untransfected control cells for full-length XPF and XPF-201, or in the case of XPF-202 and XPF-003 to the 24h 
value as there is no endogenous myc-tag protein. One of three representative experiments is shown. 
Figure 13 illustrates an overview of all XPF and ERCC1 splice variants and gives an 
impression on which domains are lost due to truncating mutations. Subcellular localization of 
the proteins was of special interest, as DNA repair takes place in the nucleus and requires 
active or passive nuclear import of the respective proteins. This was analyzed by cloning the 
isoforms into an eGFP expression vector. Thereby, proteins with a C-terminal eGFP tag were 
overexpressed in HeLa cells and subcellular localization was studied by fluorescence 
microscopy (see 3.3.1.4and 3.3.2.4). 48h after overexpression, all isoforms as well as the WT 
protein, localized in the nucleus, whereas XPF-202 showed an equal distribution throughout 
the cell (see Figure 24 and Figure A4). Therefore, all isoforms could theoretically take part in 




Figure 24: Subcellular localization of eGFP-tagged XPF isoforms and patient alleles 
XPF isoforms and patient alleles were cloned into an pcDNA3.1(+)eGFP expression vector and overexpressed in 
HeLa cells for 48h to analyze subcellular localization. Additionally, DAPI staining was performed to visualize 
the nucleus. Scale bar = 50µm. 
4.4 Splice variants and their involvement in different DNA repair 
pathways 
As analyzed during my master thesis, XPG isoforms either show C-or N-terminal truncations, 
leading to full or partial loss of protein domains important for enzymatic activity or protein-
protein interactions. In order to investigate consequences on repair capability, functional 
assays were applied. Due to the lack of an ERCC1 KO cell line, no functional analyses of the 
splice variants could be performed at this time, but will be subject to further investigations. 
This thesis therefore focusses on XPG and XPF splice variants. 
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4.4.1 XPG isoforms V and VI significantly increase the repair capability of intra- and 
interstrand crosslinks 
The residual repair activity of splice variants was determined by HCR (see 3.3.2.1). 
Originally, this assay was applied to study the repair of UV induced DNA lesions (6-4PPs and 
CPDs) that are repaired by the NER. Therefor, a non-replicating reporter gene plasmid (firefly 
luciferase) was irradiated with UVC and transfected into an XPG-deficient host cell line 
(XP20BE). Under this circumstance, enzyme expression can only be detected if the DNA 
lesions of the reporter gene’s transcribed strand are removed due to activity of full-length 
XPG or residual repair capabilities of the isoform coded on the complementation plasmid (see 
Figure 14). Hence, enzyme activity correlates with NER activity and is measured as repair 
percentage. Repair activity of different XPG isoforms was already determined by HCR assay 
during my master thesis (see Figure 12) (Lehmann, 2013). Primary WT fibroblasts exhibited a 
NER repair capability of approximately 15% (15.72 ± 0.96%) (see Figure 25A). Only co-
transfection with XPG isoforms V and VI led to a significant increase of repair capability in 
comparison to the empty vector control (XPG: 4.9 ± 1.22%, IsoV: 0.40 ± 0.07%, IsoVI: 0.78 
± 0.12%) (*** P < 0.001, ** P < 0.01, or * P < 0.05 n = 4), showing a 5-fold (XP20BE) 
increase in NER-activity. The other isoforms analyzed displayed no residual NER repair 
function.  
The two endonucleases XPF/ERCC1 and XPG represent the excision complex of NER. Both 
proteins are also involved in other important cellular processes like basal transcription and 
ICL repair (reviewed in Wood, 2010). In regard to this, the HCR assay was adapted to study 
the repair of intrastrand and interstrand crosslinks by treating the firefly reporter plasmid with 
CP and TMP plus UVA light (see 3.3.2.1 and 4.2.4). WT repair levels of about 15% (CP: 
13.92 ± 1.71%, TMP + UVA: 17.25 ± 3.34%) were measured. Complementation with full-
length XPG was closer to WT levels as in the case for UVC induced lesions (UVC: 4.9 ± 
1.22%, CP: 11.61 ± 2.75%, TMP + UVA: 12.71 ± 1.55%). Again, isoform V and VI showed a 
significant increase in repair capability (IsoV: CP 5.98 ± 0.98%, TMP + UVA 8.55 ± 1.54 and 
IsoVI: CP 4.57 ± 0.76%, TMP + UVA 9.94 ± 2.32) (*** P < 0.001, ** P < 0.01, n = 4), while 
the other isoforms did not have a significant effect (n.s. P > 0.05, n = 4). However, the overall 
basic levels of repair were higher than for UVC (CP 1.98% ± 0.19, TMP + UVA 5.12 ± 0.43), 
meaning that also the difference between isoform V and VI and the other isoforms were not as 
prominent as seen in NER (see Figure 25B and C). This suggests that the involvement of 
XPG in the repair of ICL repair is not as essential as for NER. In contrast, the MRC5Vi XPF 
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KO cells showed a nearly complete ablation of ICL repair (see Figure 21). As previously 
mentioned, this implicates an essential role of the XPF/ERCC1 endonuclease in ICL repair. 
 
Figure 25: Reactivation of a reporter gene after treatment with UVC, cisplatin or 
trimethylpsoralen activated by UVA light in XP20BE patient or primary WT fibroblasts 
For the HCR assays, firefly plasmids were treated with (A) UVC irradiation (B) cisplatin (intrastrand crosslinks) 
or (C) trimethylpsoralen activated by 1J/cm
2
 UVA irradiation (interstrand crosslinks) to induce specific lesions, 
transfected into XP20BE patient or primary WT fibroblasts, and complemented with plasmids coding for the 
empty expression plasmid, full-length XPG, or the XPG splice variants. The relative repair capability is 
calculated as the percentage (repair %) of the reporter gene activity (firefly luciferase) compared to the untreated 
plasmid, after normalization to an internal co-transfected control (Renilla luciferase). Data are presented as the 
mean ± SEM. The one-tailed, unpaired student’s t-test was applied, ∗∗∗ P < 0.001 or ∗∗ P < 0.01. At least four 
independent experiments in triplicates were performed. 
Nevertheless, XPG isoform V and VI contained residual repair capabilities, but are both 
lacking essential parts of the endonuclease domains. Hence, the two isoforms seem to be able 
to fulfill at least structural functions of XPG during NER as well as ICL repair, and catalyze 
the subsequent excision performed by XPF/ERCC1 (Gary et al., 1999). 
4.4.2 XPF splice variants show residual repair capabilities during NER and ICL repair 
As the XPF/ERCC1 complex is involved in multiple repair pathways (NER, ICL, DSB repair) 
and cellular processes (see 1.4.2), residual repair capabilities of XPF splice variants  
(see Figure 13) were studied in more detail by utilizing reporter gene assays in the complete 
XPF KO cells compared to MRC5Vi WT cells as well. Therefor, the HCR assay was applied 
to investigate correct repair of UVC, CP and TMP plus UVA irradiation induced DNA lesions 
(see 3.3.2.1). The variants as well as full-length XPF or an empty expression plasmid were 
transiently overexpressed in the KO cells (see 3.3.1.4). 
As described above, XPF KO cells show a nearly complete loss of repair capabilities, but 
repair can be rescued by complementation with full-length XPF (see 4.2.4). Interestingly, two 
XPF splice variants exhibited significant residual repair capabilities in NER as well as ICL 
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repair (XPF-201: UVC 6.50 ± 0.22, CP 16.28 ± 0.51%, TMP + UVA 12.06 ± 0.22% and 
XPF-003: UVC 1.15 ± 0.02%, CP 3.17 ± 0.10%, TMP + UVA 3.89 ± 0.03%) (*** P < 0.001 
or ** P < 0.01, n = 4). XPF-201 only lacks the first 12 aa of the protein, whereas XPF-003 is 
severely C-terminally truncated, with an intronic retention of five aa lacking the endonuclease 
domain. Surprisingly, XPF-202, another variant, that only differs from XPF-003 in the first 12 
aa did not display any significant repair capability at all, neither in NER nor ICL repair  
(UVC 0.15 ± 0.02%, CP 0.58 ± 0.03%, TMP + UVA 2.17 ± 0.06%) (P > 0.05, n = 4)  
(see Figure 26). 
This implicates a high importance of those 12 N-terminal aa of the XPF protein. It could point 
towards an undescribed essential interaction domain of the protein, which may be necessary 
to communicate with other structural or catalytically active components of the DNA repair 
machinery.  
 
Figure 26: Reactivation of a reporter gene after treatment with UVC, cisplatin or 
trimethylpsoralen activated by UVA light in XPF KO cells complemented with XPF 
splice variants 
For the HCR assays, firefly plasmids were treated with (A) UVC irradiation (B) cisplatin (intrastrand crosslinks) 
or (C) trimethylpsoralen activated by 1J/cm
2
 UVA irradiation (interstrand crosslinks) to induce specific lesions, 
transfected into MRC5Vi WT and XPF KO cells, and complemented with plasmids coding for full-length XPF 
and the different splice variants. The relative repair capability is calculated as the percentage (repair %) of the 
reporter gene activity (firefly luciferase) compared to the untreated plasmid, after normalization to an internal 
co-transfected control (Renilla luciferase). Data are presented as the mean ± SEM. The one-tailed, unpaired 
student’s t-test was applied, ∗∗∗ P < 0.001 or ∗∗ P < 0.01. At least four independent experiments in triplicates 
were performed. 
4.4.3 XPG and XPF splice variants do exhibit dominant negative effects during DNA 
repair 
The interference of XPG and XPF spontaneous mRNA splice variants with endogenous DNA 
repair, exemplarily NER, in MRC5Vi WT cells was subject to further investigations. For this 
purpose, cell lines stably overexpressing these variants were generated by spontaneous 
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integration of a linearized expression plasmid into MRC5Vi WT cells. An expression plasmid 
coding for the full-length protein or one of the splice variants, e.g. pcDNA3.1(+)XPF, was 
linearized as described in 3.1.4.5, analyzed on an agarose gel (see 3.1.3.4), and purified by 
ethanol precipitation (see 3.1.1). Linearized plasmids were transiently transfected into 
MRC5Vi WT cells seeded on 10mm cell culture dishes and positive clones were selected 
using G418 (100mg/ml). Afterwards, single cell clones were generated by serial dilution and 
checked for plasmid integration by PCR using specific primer pairs for the CMV (cytomegalo 
virus)-promoter and the integrated gene (see 3.1.4.1, Table 7), as well as immunoblot analysis 
(see 3.4.4). 
In order to test the effect of an overexpression on NER capability of MRC5Vi WT cells, for 
each variant or full-length protein, three positive clones with a similar level of overexpression 
were selected and repair capability was measured using the HCR assay (see 3.3.2.1). Repair 
capabilities were averaged for statistical purposes and compared to unmodified and non-
manipulated WT cells. Figure 27A and B exemplary show, that the full-length proteins (XPG 
180kDa, XPF 112kDa) as well as their splice variants (XPG IsoV 100kDa, XPF-201 112kDa) 
can be stably overexpressed in MRC5Vi WT cells, reaching overexpression ratios of  
1.13 – 9.65 in comparison to WT cells. Regarding the impact on NER capacity of MRC5Vi 
WT cells (14.17 ± 1.20%), XPG-201, a variant that N-terminally lacks the first four exons in 
frame and therefore misses one of XPG’s endonuclease domains (N-domain), showed a 
significant dominant negative effect on repair (10.75 ± 0.50%) (∗ P < 0.05, n=4) (see Figure 
27C). This effect could also be observed for XPG IsoVI, the variant with the highest residual 
repair capability in XPG deficient cell, lacking the I-domain (7.85 ± 0.72%) (∗∗∗ P < 0.001, 
n=4). Unexpectedly, all three XPF splice variants, as well as the full-length protein, 
significantly reduced repair capabilities of MRC5Vi WT cells (XPF: 9.19 ± 0.83%, XPF-201: 




Figure 27: Immunoblot analyses and reactivation of a reporter gene after treatment 
with UVC in MRC5Vi WT cells and single clones overexpressing XPG, XPF or 
respective splice variants  
Protein expression of MRC5Vi WT cells as well as single clones overexpressing the WT protein or respective 
splice variants was assesed by horizontal SDS Page followed by immunoblotting. Antibodies for XPG (A) or (B) 
XPF were used and β-actin staining was applied for normalization after reprobing. One of three independent 
experiments is shown. Expression was quantified by densitometric analysis. Protein levels in MRC5Vi cells 
were set to one. (C) For the HCR assays, firefly plasmids were treated with UVC irradiation to induce specific 
lesions, transfected into MRC5Vi WT or single clones overexpressing XPG, XPF or respective splice variants. 
The relative repair capability is calculated as the percentage (repair %) of the reporter gene activity (firefly 
luciferase) compared to the untreated plasmid, after normalization to an internal co-transfected control (Renilla 
luciferase). Data are presented as the mean ± SEM. The one-tailed, unpaired student’s t-test was applied; 
significances are displayed with regard to WT cell repair capability, ∗ P < 0.05 or ∗∗∗ P < 0.001. At least four 
independent experiments in triplicates were performed. 
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Taken together, two XPG splice variants (XPG IsoVI and XPG-201) showed a dominant 
negative effect on MRC5Vi WT NER capabilities, as well as WT XPF and all three splice 
variants (XPF-201, XPF-003, XPF-202).  
4.4.4 Analyses of XPF point mutants in the newly generated XPF KO cells give insights 
into mechanistic aspects of XPF’s functions in different DNA repair pathways 
The newly generated viable human fibroblasts cell line, lacking the essential endonuclease 
XPF, represents a great tool for mechanistic analyses of XPF’s function in different DNA 
repair pathways. Up to this point, this has been limited to experiments in patient cells with 
extensive residual alleles, or in vitro studies. In these in vitro studies, NER is reconstructed 
using a set of 30 recombinant proteins, constituting necessary NER components. This system 
is highly artificial. Thus, in the literature, different point mutants have been described to 
change essential residues for different protein functions, according to these experiments. For 
further analyses, these variants, as well as patient alleles of diseases associated with XPF have 
been generated using site-directed mutagenesis (see 3.1.4.3). The patient alleles included an 
XP-F allele (XP3YO, p.R490Q), an XP-F/CS allele (XPCS1CD, p.C236R), a FA allele 
(FA104, p.R689S), and the severely affected XFE patient allele of XP51RO (p.R153P) (see 
Figure 28) (Bogliolo et al., 2013; Kashiyama et al., 2013). In addition, an endonuclease 
defective mutant (p.D668A), postulated to be essential for NER (Sertic et al., 2011; 
Staresincic et al., 2009) as well as a mutant affecting the residue essential for ICL unhooking 
(p.D731A) (Fisher et al., 2008; reviewed in Enzlin & Scharer, 2002), a point mutant of the 
essential residue for interaction with RPA and nuclear import (p.P85S) (Fisher et al., 2008), 
and the residues for interaction with the heterodimeric partner ERCC1 (p.F905A/P) (reviewed 




Figure 28: Overview of XPF point mutants  
The XPF gene was artificially manipulated by site-directed mutagenesis to produce different point mutants. 
Some changes were introduced on the basis of essential residues reported in the literature, while others resemble 
pathologically occurring mutations in patient alleles to study structural and functional domains of XPF. 
The residual NER and ICL repair capability of the XPF point mutants was assessed using the 
HCR assay (see 3.3.2.1). In contrast to previously described studies (Sertic et al., 2011; 
Staresincic et al., 2009), the D668A mutant significantly complemented the XPF KO cells in 
NER and ICL repair up to WT XPF levels (UVC: 6.71 ± 0.50%, CP: 16.73 ± 1.88, TMP + 
UVA: 12.31 ± 1.17%) (*** P < 0.001 or ** P < 0.01, n = 4) (see Figure 29A-C). On the other 
hand, the D731A mutant, which was reported to be essential for ICL unhooking, did not 
complement the XPF KO cells in NER as well (UVC: 0.19 ± 0.01%) (n.s. P > 0.05, n = 4) 
(see Figure 29A). Interestingly, the F905A/P mutant affecting the residue implicated for 
interaction with ERCC1, did complement the XPF KO cells (F905A UVC: 5.97 ± 0.29%, CP: 
14.19 ± 0.85%, TMP + UVA: 11.02 ± 1.05%, F905P UVC: 6.10 ± 0.39%, CP: 14.07 ± 
0.82%, TMP + UVA: 12.50 ± 1.63%) (*** P < 0.001 or ** P < 0.01, n = 4). The P85S 
mutant, as well as mutants R689S and R490Q, resembling the FA and the XP-F patient 
alleles, did fully complement the XPF KO cells in regard to both NER and ICL repair. The 
mutant, resembling the XP-F/CS patient allele C236R, as well as the XFE mutant R153P did 
show complementation in NER and ICL repair (C236R UVC: 1.76 ± 0.22%, CP: 3.76 ± 
0.32%, TMP + UVA: 5.09 ± 0.66%, R153P UVC: 3.65 ± 0.64%, CP: 4.94 ± 0.43%, TMP + 
UVA: 6.29 ± 0.54%) (*** P < 0.001 or ** P < 0.01, n = 4), but clearly to a lesser extent than 
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WT XPF or the other complementing mutants. For both mutations, problems with misfolding, 
nuclear import, protein stability and interaction with ERCC1 or SLX4 have been postulated 
(Kashiyama et al., 2013). 
Clearly, these results highlight the differences between cellular backgrounds and artificial 
systems, emphasizing the necessity of suitable model cell lines. 
 
Figure 29: Reactivation of a reporter gene after treatment with UVC, cisplatin or 
trimethylpsoralen activated by UVA light in XPF KO cells complemented with XPF 
point mutants 
For the HCR assays, firefly plasmids were treated with (A) UVC irradiation (B) cisplatin (intrastrand crosslinks) 
or (C) trimethylpsoralen activated by 1J/cm
2
 UVA irradiation (interstrand crosslinks) to induce specific lesions, 
transfected into MRC5Vi WT and XPF KO cells, and complemented with plasmids coding for full-length XPF 
and the different point mutants generated by site-directed mutagenesis. The relative repair capability was 
calculated as the percentage (repair %) of the reporter gene activity (firefly luciferase) compared to the untreated 
plasmid, after normalization to an internal co-transfected control (Renilla luciferase). Data are presented as the 
mean ± SEM. The one-tailed, unpaired student’s t-test was applied, ∗∗ P < 0.01 or ∗∗∗ P < 0.001. At least four 
independent experiments in triplicates were performed. Significances are displayed in regard to the XPF KO 
cells.  
In order to assess stable protein expression of the generated point mutants, whole cell protein 
lysates were prepared (see 3.4.1) after 48h of overexpression in MRC5Vi XPF KO cells (see 
3.3.1.4). Equal amounts of these extracts and an extract from MRC5Vi WT cells were loaded 
onto precast SDS gels, separated by horizontal SDS-Page and analyzed by immunoblotting 
for XPF and β-actin (see 3.4.3 and 3.4.4). Taken together, all XPF point mutants were 
(over)expressed over time (0.53 – 4.69) and resulted in proteins of the expected size, which 




Figure 30: Immunoblot results for XPF point mutants generated by site-directed 
mutagenesis 
In order to analyze protein levels, XPF point mutants were overexpressed in MRC5Vi XPF KO cells for 48h, 
whole protein extracts were prepared, separated by horizontal SDS Page, analyzed by immunoblotting, and 
quantified in comparison to WT expression. Blots were stained with an anti-XPF or an antibody directed against 
β-actin for normalization. Equal amounts were loaded onto the gel and one of three representative blots is 
shown. 
Selected point mutants were investigated in regard to their subcellular localization by 
preparing cytosolic and nuclear protein extracts (see 3.4.1), followed by horizontal SDS-Page 
and immunoblotting as described above. As shown in 4.2.1, in the newly generated XPF KO 
cells, ERCC1 remains in the cytosol and cannot be detected in the nucleus without its 
heterodimeric partner XPF. Therefore, subcellular localization of the point mutants F905A/P, 
comprising the essential residues for interaction with ERCC1, was analyzed. Notably, F905A 
did not conclusively lead to reduced nuclear localization of ERCC1 as well as XPF (see 
Figure 31A and B), whereas F905P showed a reduction in nuclear levels of both proteins (see 
Figure 31D and E) in comparison to WT cells, that showed a strong induction of nuclear XPF 
as well as ERCC1. Interestingly, as described in previous studies (Niedernhofer et al., 2006), 
the XFE patient allele R153P seems to result in a full-length XPF protein that is only stable in 
the cytosol but undetectable in the nucleus. In turn, also ERCC1 could not be observed in the 
nucleus (see Figure 31C). 
Therefore, the F905A mutation seems to have no influence on ERCC1 and XPF localization, 
while a stronger distortion in protein structure due to insertion of a proline (strand breaker) in 
F905P leads to a slight nuclear reduction of ERCC1 and XPF. Moreover, the artificial mutant 
generated in parallel with the XFE patient allele R153P, showed that instable XPF cannot be 
transported into the nucleus. As observed before, without nuclear XPF nuclear ERCC1 
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protein could not be detected, confirming the effect seen in the MRC5Vi XPF KO cells, even 
further aggravating the necessity to a functional and stable XPF protein. 
 
Figure 31: Immunoblot results for cytosolic and nuclear fractions of XPF point mutants 
generated by site-directed mutagenesis 
In order to analyze subcellular protein localization and levels, XPF point mutants (A + B) F905A, (C) R153P, or 
(D + E) F905P were overexpressed in MRC5Vi XPF KO cells for 48h, cytosolic and nuclear fragments were 
prepared, equal amounts were loaded onto an SDS-Page gel, separated, analyzed by immunoblotting and 
quantified in comparison to WT levels. For ERCC1 the upper and lower ERCC1 band was set to one. Blots were 
stained with an anti-XPF or an antibody directed against β-actin for normalization. One exemplary blot of three 
independent experiments is shown. 
4.5 Functionally relevant splice variants can be implicated as prognostic 
markers for individual cancer risk, therapeutic success, or disease 
outcome 
In order to assess the physiological relevance of XPG isoforms with repair catalyzing 
functions (isoform V and VI), specific primer pairs for both isoforms as well as for WT XPG 
were utilized to analyze RNA expression in 20 different healthy human tissues obtained from 
Ambion
®
 (see Table 8). Therefore, cDNA was prepared from RNA samples and quantified as 
described in 3.1.3.2 and 3.1.4.2. Specific primer pairs binding to the intronic regions of the 
isoforms were applied (see Table 7). Unfortunately, the material was only sufficient to 
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analyze XPG, but not XPF, variants and further material could not be reordered due to 
discontinuation of the Ambion
®
 product. 
Figure 32 illustrates the comparison of the three XPG species in several different tissues. All 
20 tissues expressed WT XPG, as well as both functionally relevant isoforms. Whereas heart, 
liver and skeletal muscle exhibited very low expression levels of all three XPG transcripts 
(light blue arrows), the expression of both isoforms, V and VI, was relatively high in spleen, 
testes, and thymus compared to the primary transcript (dark blue arrows).  
 
Figure 32: Comparative analysis of XPG expression in human tissues 
RNA samples from 20 tissues were transcribed into cDNA and subject to real-time PCR measurements. 
Expression levels are shown as absolute values with GAPDH used as the internal control gene to normalize the 
expression of the target gene or isoform. Results represent mean values from three independent experiments in 
duplicates. Data are presented as mean ± SEM. Colored arrows indicate groups with similar expression patterns.  
To compare the expression levels of the three XPG transcripts between human individuals, 
blood samples from 20 healthy donors (age between 22 and 61, 7 males and 13 females) were 
analyzed as described above (see Figure 33). The comparison of these 20 unrelated 
individuals displayed a unique pattern for each of them. The expression profile either 
displayed high or low expression of all three transcripts (middle blue arrows), expression of a 
predominant primary transcript (dark blue arrows), or predominance of the two isoforms V 
and VI (light blue arrows). Despite a few exceptions, isoform VI, with the highest residual 
catalytic activity in the functional experiments, was the predominantly expressed XPG 
transcript in blood samples in 80% of the investigated subjects. No relations of expression 
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between age and sex were evident in this small collective. Unfortunately, the material was 
only sufficient to analyze the XPG, but not XPF, variants. 
 
Figure 33: Analysis of XPG expression in human blood samples 
RNA samples from 20 healthy donors were transcribed into cDNA and subject to real-time PCR measurements. 
Expression levels are shown as absolute values using GAPDH as the internal control gene to normalize the 
expression of the target gene or isoform. Results represent mean values from three independent experiments in 





The endonucleases XPG and XPF/ERCC1 are central players in NER and ICL repair, but also 
in basal transcription by encompassing both, catalytic and structural roles. Mutations in both 
genes are associated with complex genotype-phenotype correlations, for instance XPG splice 
variants have already been implicated in having residual functions that lead to a milder form 
of the XP/CS phenotype (reviewed in Scharer, 2008). In 2004 Thorel et al. reported about a 
28-year-old patient with a splice variant of only minimal residual function, which resulted in a 
meaningful prolongation of the patient’s life. In contrast, a functionally dominant negative 
splice variant that reduced NER by approximately 50% has been identified in an XP-C patient 
(Khan et al., 2002). This splice variant was eventually identified in about 40% of normal 
individuals and associated with a two-fold increased melanoma risk (Blankenburg et al., 
2005). 
Thus far, little is known about the functionality, expression patterns and structural functions 
of physiologically occurring, spontaneous mRNA splice variants of XPG and XPF/ERCC1, as 
well as their potential implication as prognostic markers in skin cancer prognosis, progression 
and therapy outcome. This was the main subject of this PhD thesis. Additionally, four new 
XP-A patients were characterized and a new mutation was detected, leading to an 
alternatively spliced variant in the XPA gene 
5.1 A large deletion in the XPA gene results in XP with severe neurological 
symptoms 
A new disease-causing mutation was identified in the XP-A complementation group. This 
novel and unusually large deletion mutation (genomic deletion of exons three-four) leads to a 
severely truncated XPA protein with no functional repair activity (Lehmann et al., 2015). 
Due to geographical isolation, a higher frequency of XP-A patients can be observed in Japan 
and Northern Africa compared to the world-wide distribution. So far, three common founder 
mutations (IVS3-1G>C; p.R228X; p.Y116X) have been described (Moriwaki et al., 2012; 
Nishigori et al., 1993) (see Figure 16F). In addition, a specific mutation in the XPA gene 
(c.747 C>T) has been reported in 12% of 66 unrelated families in the Maghreb region 
(Algeria, Morocco, Tunisia) (Soufir et al., 2010; Tamura et al., 2010). As part of this thesis, 
four XP-A patients (XP31MA, XP32MA, XP31GO, and XP118MA) were characterized. All 
patient cell lines showed high sensitivity against UVC irradiation (Figure 16A). However, 
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post-UV survival only reflects the cell’s overall capability to cope with UV-induced DNA 
damages, which can involve multiple cellular mechanisms (e.g. NER, DDR, and apoptosis). 
Low viability after UV irradiation was consistent in patients with the XP plus neurological 
involvement phenotype. In order to specifically estimate the NER capacity, the HCR assay 
was applied. All four cell lines showed very low NER capability (Figure 16B), indicating a 
pivotal role of XPA during NER. For XP31MA, XP32MA, and XP31GO, stable protein 
expression was detectable, but not for XP118MA (Figure 16C). The well-known p.R228X 
mutation could be detected in XP31MA, XP32MA, and XP31GO in consistency with the 
mild XP plus neurological symptoms phenotype. As determined by epidemiological studies, 
consanguineous marriage and Northern African ancestry are promoting factors for this 
phenotype, which were evident for the siblings XP31MA and XP31GO, respectively. 
A new homozygous mutation in the XPA gene of XP118MA was identified 
(c.268_269insAA), which resulted in two different XPA protein variants, one with a large in-
frame deletion (missing exons three-four, p.P96_Q185del) and the other with a premature 
stop in exon two (p.104X). Protein expression could not be detected by western blotting, 
probably due to the missing antibody epitope within the truncated proteins (Figure 16C). 
However, XPA mRNA expression was measured excluding nonsense-mediated messenger 
decay, as well as proteasomal degradation, as no additional bands could be observed on 
protein level. Notably, this new mutation (c.268_269insAA) leads to two variants, which is 
very similar to the most common founder mutation in XPA (IVS3-1G>C). Both mutational 
events result in one truncated variant and another variant with exon skipping. The severe 
clinical phenotype of XP with severe neurological symptoms might be explained by the loss 
of important protein-protein (RPA70, TFIIH) and protein-DNA interaction domains (DNA-
binding domain) (Figure 16D), provoking an extreme loss of function during NER (reviewed 
in Berneburg & Lehmann, 2001; Scharer, 2013). 
This study in patients with DNA repair defective syndromes elucidates that not only the WT 
mRNA sequence undergoes spontaneous alternative splicing, but also inherited gene 
mutations can lead to two different mRNA variants of the mutated gene – in this case the XPA 
gene. On second note, the WT XPA gene is also predicted to result in several alternatively 
spliced variants with unknown functional relevance awaiting investigation.  
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5.2 The XPF CRISPR/Cas9 KO cells present a great tool to model XP 
Over the past years, different site-specific techniques modifying genomes of various species 
have emerged using the site-directed ZFNs or TALENs. Recently, using the new and 
customizable CRISPR/Cas9 system was preferred, especially because of its simple approach 
to program specific gene disruptions or generate knockout cells, but also its easy design and 
efficient functionality. The structure-specific endonuclease XPF is involved in numerous 
DNA repair pathways (NER, ICL, and DSB repair) by comprising multiple protein functions. 
This is also evidenced by the variety of phenotypes and diseases arising from different 
mutations in the XPF gene. Mostly, mild clinical features, such as minor sun sensitivity and 
no neurological abnormalities, can be observed in XP-F patients (Hayakawa et al., 1981). 
This is due to missense mutations in at least one allele not affecting the nuclease activity and 
therefore not completely abolishing XPF function, resulting in a residual repair capability of 
UV damage (up to 20%) (Ahmad et al., 2010; Gregg et al., 2011). On the other hand, a few 
more severe phenotypes like CS, XP/CS complex phenotype, XFE progeroid syndrome, or 
FA exist, that are caused by mutations leading to premature stop codons or missense 
mutations in essential residues (Kashiyama et al., 2013; Niedernhofer et al., 2006). 
Unfortunately, no suitable patient cells with a complete loss of the XPF protein have been 
available so far for extensive molecular and mechanistic studies. However, an Xpf-deficient 
mouse model with defective postnatal growth, a shortened life span, and hypersensitivity 
against UV irradiation and mitomycin C treatment has been described (Tian et al., 2004).  
During my PhD thesis I was able to generate the first viable human XPF KO cell line while 
applying the CRISPR/Cas9 technique targeting exon two of XPF. These cells are compound 
heterozygous and contain a premature stop codon in exon two of XPF, resulting in a 
massively truncated XPF protein with no residual activity (Figure 21). No further mutations in 
the XPF gene were detected. Protein expression, assessed by immunoblotting, was completely 
ablated, while mRNA levels were only reduced by 50% (Figure 18) in consistency with a 
subset of XP-F patients, suggesting instability of the mutant XPF protein (Matsumura et al., 
1998). Another explanation could be the loss of the antibody epitope mapping aa 629-905. 
Apparently, it is possible to generate a viable cell line of human fibroblasts lacking the 
essential endonuclease XPF, while germline mutations to this extent seem to be incompatible 
with life in humans and mice, limiting knockout strategies from studying genes critical for 
embryogenesis. As described in 4.2.2, it was not possible to generate a viable cell line with a 
full ERCC1 KO in the first exons as the cells were probably not viable due to the essential 
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role of the protein in many cellular processes. In following approaches, later exons should be 
targeted (three-ten), but these cells would not be of value to analyze the splice variants 
(Figure 13) comprising structural changes already in early parts of the protein sequence. 
Another possibility to generate an ERCC1 KO cell line would be to utilize a commercial 
approach from e.g. GE Dharmacon, offering transient as well as lentiviral systems to increase 
efficiency. A strategy to circumvent lethality could also be conditional gene inactivation, 
which has been performed using CRISPR/Cas9 in mice to generate conditional alleles before 
(Yang et al., 2013). Providing that, the CRISPR/Cas9 technique is also a useful tool to 
identify sets of essential and non-essential genes (Evers et al., 2016; Hart et al., 2014). In case 
of failure to generate a complete ERCC1 KO cell line, studies would have to focus on in vitro 
assays using recombinant proteins. 
As a structure-specific endonuclease, XPF/ERCC1 is essential for the repair of helix-
distorting DNA lesions, like UV-photoproducts, in replicating as well as non-replicating cells 
by making incisions on the damaged DNA strand on the 5‘ side of the open “denaturation-
bubble” intermediate (Sijbers et al., 1996a; reviewed in Mu et al., 1996). XPF KO cells 
showed no NER capability in functional analyses and were also highly sensitive against UVC 
irradiation and exhibited reduced host cell reactivation of an UVC-treated reporter gene 
plasmid (Figure 20A, Figure 21A). This effect could be rescued up to WT repair levels by 
complementation with full-length XPF, but neither XPG nor ERCC1. Furthermore, XPF KO 
cells showed a diminished repair activity of CP induced lesions of only 0.78%, making them 
an exquisite model system for mechanistic analysis of ICL repair (Figure 21B). Whereas the 
model previously used for this purpose, GM08437 (XP-F) cells, still containing one full-
length allele with a missense mutation, show 20% residual repair of CP crosslinks (Enoiu et 
al., 2012). Moreover, XPF KO cells exhibited a high sensitivity against TMP plus UVA 
irradiation induced lesions (Figure 20B-C, Figure 21C), that are repaired by the ICL repair 
pathway. Also, these compounds are used in the therapy of psoriasis, vitiligo, and cutaneous 
T-cell lymphoma (Cimino et al., 1985; Gupta & Anderson, 1987; Hearst, 1981). XPF is 
essential for the incision, or “unhooking” step, of ICL in an NER-independent manner (Fisher 
et al., 2008; Klein Douwel et al., 2014; Kuraoka et al., 2000; Rahn et al., 2010; reviewed in 
Wood, 2010). Whether other endonucleases like Mus81/Eme1, SLX4/SLX1, or FAN1 can 
perform incisions normally conducted by XPF, but in a much less efficient manner, merits 
further investigation (Hanada et al., 2006; Klein Douwel et al., 2014; Pizzolato et al., 2015; 
Takahashi et al., 2015; Yamamoto et al., 2011; reviewed in Zhang & Walter, 2014).  
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5.3 ERCC1 is retained in the cytosol without its heterodimeric partner 
XPF 
Analyses of protein levels in the cytosol and nucleus of the newly generated XPF KO cells 
compared to MRC5Vi WT cells, showed that ERCC1 was not detectable in the nuclear 
fraction of the KO cells (Figure 19D). However, after complementation with full-length XPF, 
ERCC1 did localize to the nucleus (Figure 19F). In previous studies, in the absence of the 
heterodimeric partner, ERCC1 and XPF have been reported to be unstable (Biggerstaff et al., 
1993; Sijbers et al., 1996b; van Vuuren et al., 1993). Moreover, low levels of ERCC1 protein 
are a common feature of total protein extracts from XP-F patients (Yagi et al., 1997). 
Furthermore, extracts from XPF- and ERCC1- defective cells do not complement one another 
in vitro (Biggerstaff et al., 1993; van Vuuren et al., 1993), highlighting the necessity of a 
functional XPF/ERCC1 complex to maintain protein stability. In the absence of either binding 
partner, the other forms aggregates respectively and will either be subject to proteolytic 
degradation, or nuclear export (Gaillard & Wood, 2001). The results of this thesis show 
contradictory results thereto. Actually, the ERCC1 protein is stable in the cytosol of the XPF 
KO cells, but could not be detected in the nucleus without its heterodimer partner. As 
assumed earlier, this effect could be explained by the lack of an NLS in ERCC1 (Boulikas, 
1997), which prohibits it from entering the nucleus by itself (Ahmad et al., 2010). In later 
studies however, the presence of an NLS was shown (reviewed in McNeil & Melton, 2012). 
Apart from that, rapid nuclear export of single ERCC1, outside the prematurely formed 
XPF/ERCC1 complex, might be the likeliest explanation. Importantly, overexpression of XPF 
in the XPF KO cells could restore the localization of ERCC1 in the nucleus. Notably, the 
previous results have been performed with whole cell protein extracts; hence it remains 
unclear, whether ERCC1 can be stabilized in the cytosol by other interaction partners than 
XPF, and requires further investigations. A study showed that application of a compound 
inhibiting XPF-ERCC1 protein-protein interaction to two different cancer cell lines sensitized 
those cells to CP, mitomycin C and UV irradiation. Thereby, removal of DSBs was decreased 
confirming the findings in the XPF KO cells (Jordheim et al., 2013).   
5.4 XPF is markedly involved in HRR but dispensable for NHEJ 
XPF/ERCC1 deficient mammalian cells exhibit a moderate sensitivity towards DSB inducing 
agents and ionizing radiation suggesting a role of XPF/ERCC1 in one or more sub-pathways 
of DSB repair in an NER-independent manner (Ahmad et al., 2008; Mogi & Oh, 2006; 
Murray et al., 1996; Wood et al., 1983). The yeast homolog Rad1/Rad10 of XPF/ERCC1 is 
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known to be involved in HRR as well as NHEJ by removing non-homologous 3’ single-
stranded flaps (Al-Minawi et al., 2008; Niedernhofer et al., 2001; Sargent et al., 1997). The 
heterodimeric complex has been accounted for the error-prone single-strand annealing (SSA) 
sub-pathway, gene conversion, and homologous gene targeting in HRR of yeast and mammals 
(Adair et al., 2000; Fishman-Lobell & Haber, 1992; Ivanov & Haber, 1995; Niedernhofer et 
al., 2001; Sargent et al., 2000), whereas in NHEJ the complex is only known to take part in 
the Rad52- and Ku70/Ku86-independent microhomology-mediated end-joining (MMEJ) sub-
pathway (Ahmad et al., 2008; Bennardo et al., 2008; Ma et al., 2003; McVey & Lee, 2008; 
Yan et al., 2007). Notably, these studies primarily focus on mice, yeast, and hamster cells, but 
only hypothesize an involvement of the human XPF/ERCC1 complex during HRR, never 
testing a complete human knockout cell line. As shown in Figure 22A, in the newly generated 
XPF KO cells, HHR capability is reduced to 60%, while no effect on NHEJ could be 
observed (Figure 22B). This strongly implicates human XPF for error-prone single-strand 
annealing, gene conversion, and homologous gene targeting, rather than microhomology-
mediated end-joining strengthening the importance of human XPF in the HRR subpathway of 
DSB repair, already indicated by the yeast based studies. Anyhow, the XPF KO cells only 
displayed a mild sensitivity against DSB inducing agents (Figure 20D-F), because 
XPF/ERCC1 is only involved in sub-pathways of HRR as well as NHEJ, loss of the protein 
may be compensated in DSB repair, unlike during NER or ICL repair, where the 
endonuclease is essential for functional repair. XPF is involved in three different HR related 
repair mechanisms and plays a key role in ICL repair not only via its endonuclease function, 
but also in the late stage of HR during ICL repair (Al-Minawi et al., 2009). Although no 
significant effect on cell survival of the XPF KO cells could be shown after treatment with 
DSB inducing drugs, these cells did show a slight decrease in survival. This could be due to 
adding effects, rendering the KO cells less capable of repair in terms of HRR substrates that 
cannot be removed by NHEJ. For bleomycin the mode of action is still unsolved, but it is 
hypothesized that it chelates metal ions forming a pseudoenzyme that reacts with oxygen 
resulting in superoxide and hydroxide free radicals cleaving DNA (reviewed in Hecht, 2000). 
CPT and etoposide are topoisomerase inhibitors. While TOP1 is irreversibly trapped to the 
DNA by CPT, resulting in replication or transcription induced DSBs (reviewed in Tomicic & 
Kaina, 2013), etoposide forms a ternary complex with TOP2 and the DNA, thus preventing 
re-ligation of the DNA strands and resulting in DSBs (reviewed in Pommier et al., 2010). 
XPF/ERCC1 is also implicated in a pathway repairing Top1-attached DNA nicks in an NER 
dependent manner (Takahata et al., 2015).  
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Interestingly, the overall level of HRR capability was lower (up to 33.27%) than the NHEJ 
activity (up to 98.92%) in the WT cells. Although, the repair template is encoded on the same 
plasmid, cell-cycle dependent expression regulation of DSB repair genes could be an 
explanation for this. Different DSB repair pathways compete for DSBs, and the balance 
between different subpathways varies among species, cell types and cell cycle phases. 
Expression of DSB repair genes of HRR and NHEJ can be regulated by phosphorylation of 
proteins, chromatin modulation of repair factor accessibility, or the availability of 
homologous repair templates. Cells actively shift from NHEJ towards HRR during cell cycle 
progression from G1 to S/G2 phase in lower and higher eukaryotes. Studies showed that 
RAD51 and RAD52 expression is low in G0/G1, and strongly increases in S and G2/M phase 
(Chen et al., 1997). 
5.5 XPF and ERCC1 splice variants could successfully be cloned from 
wildtype fibroblasts, show stable expression, and localize to the nucleus 
The major aim of this project was to functionally characterize and test physiologically 
relevant, spontaneous mRNA splice variants of the two endonucleases XPG and 
XPF/ERCC1. Therefore, it was a prerequisite to generate artificial constructs of these splice 
variants for further functional in vitro experiments. This had already been done for XPG 
during my master thesis (Lehmann, 2013), but so far except their existence (see 
www.ensembl.org) nothing more was known about XPF/ERCC1 splice variants. All 
three/eight selected splice variants of XPF/ERCC1 have successfully been amplified from WT 
cells and cloned into different expression plasmids (pcDNA3.1(+), pcDNA3.1(+)eGFP, 
pcDNA3.1(+)myc/HisA2), presenting useful tools for further functional analyses.  
Overexpression of the generated constructs lead to stable expression of proteins of the 
expected size (see Figure 23, Figure A4). Although, the XPF splice variants show different 
peak protein level over time, all three splice variants as well as the full-length protein are 
stable over the time of the functional assays (48h). In contrast, ERCC1 splice variants, as well 
as the full-length protein, generally decreased over time, except ERCC1-002 and ERCC1-008. 
Differences in expression could be explained by proteolytic degradation (Fischer et al., 2004) 
due to toxic effects of these shorter isoforms as they may constitute dominant negative effects 
on DNA repair, which will be discussed later (see 5.7). Anyhow, densitometric analysis is not 
the most resilient method of protein quantification and should only be regarded as semi-
quantitative. Many experimental factors influence the final results, as well as certain 
subjective evaluation artifacts (Gassmann et al., 2009).  
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DNA repair takes place in the nucleus; therefore it is necessary that all proteins involved are 
either passively or actively transported into the nucleus. XPF splice variants XPF-003 and 
XPF-202 both lack the C-terminal NLS (aa486-495) (see Figure 13). All ERCC1 isoforms 
still maintain the NLS (aa12-20). In general, proteins of less than 40kDa (around 350aa) are 
able to pass the nuclear pores by passive diffusion (Marfori et al., 2011). Therefore, ERCC1 
should passively diffuse into the nucleus, whereas XPF-003 and XPF-202 depend on a NLS 
as they lead to proteins of roughly 50kDa, suggesting a more inefficient transport for these 
two variants as they only contain one of two NLS. Localization was analyzed by generating 
C-terminally eGFP-tagged constructs. eGFP itself does not contain an NLS as it can passively 
be transported into the nucleus due to its small size (26.9 kDa) (Seibel et al., 2007). However, 
fusion proteins of eGFP and the different isoforms would depend on an NLS. Fluorescent 
analysis (see Figure 24, Figure A4) showed that after 48 hours all isoforms localized in the 
nucleus (see 4.3.1). This suggests that the activity of one of the two XPF NLS is sufficient for 
nuclear import of the proteins and presents a prerequisite for catalytic activity of the splice 
variants due to residual enzymatic or structural function. Interestingly, only XPF-202 
displayed a rather uniform cellular distribution with an accumulation in the nucleus. As 
already reported in the literature and shown in 4.4.4 for the XFE patient, dysfunctional or 
unstable XPF protein shows an abnormal subcellular localization (Ahmad et al., 2010; 
Kashiyama et al., 2013) (see Figure 31) suggesting that XPF-202 may not be involved in 
functional DNA repair.   
5.6 Splice variants of the two endonucleases XPG and XPF show residual 
repair capabilities in NER and ICL repair 
It is of special importance to analyze the residual catalytic or putative structural functions of 
physiologically occurring, spontaneous mRNA splice variants of DNA repair genes (see 
1.6.2). XPG splice variants II-VI lack the endonuclease activity containing I region (see 
Figure 12). During my master thesis, it was shown that isoform V and VI contain residual 
repair capabilities. In the course of this PhD project, two splice variants of XPF (XPF-201 and 
XPF-003) with residual repair capabilities were identified, but the isoform XPF-202 that only 
differs from XPF-003 in the first 12 aa did not show any complementation.  
Complementation of XPG- or XPF-deficient cells with full-length proteins only leads to 
partial restoration of repair capability and does not reach WT levels. This discrepancy has 
several reasons, e.g. transfection efficiency, synthesis and nuclear transport of the transfected 
expression plasmids, resulting in a difference in actual repair time compared to WT cells 
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containing the endogenous protein, and last but not least, posttranslational modifications that 
may influence catalytic functions. Moreover, XPG and XPF are also involved in transcription 
making the HCR assay rather useful for qualitative but not so much quantitative analyses. The 
complementation effect of splice variants is even lower than observed for full-length proteins. 
XPG isoform V and VI as well as XPF-003 only lead to a minor relative increase in NER and 
ICL repair capability, yet, clearly statistically significant in comparison to mock vector 
transfectants (see Figure 25, Figure 26). In comparison to the full-length proteins, this appears 
to be a marginal increase, but it may have a strong impact on a patient’s survival or skin 
cancer free life period. All these isoforms only contain one NLS, which results in a decreased 
activity of nuclear import, partially explaining the low increase in repair capability. The effect 
might be stronger if these variants could be transported into the nucleus more efficiently. 
Emmert et al. examined a 14 year old Caucasian girl (XP65BE) with sun sensitivity, but no 
neurological abnormalities that had not suffered of skin cancer so far (Emmert et al., 2002). 
XPG mRNA expression was nearly normal. She had inherited one allele with an early stop 
codon mutation from her father, while the maternal allele only showed a single base missense 
mutation with a residual repair activity of 10%. Therefore, this residual functional activity in 
one allele could be accounted for the mild clinical features without neurological 
abnormalities, emphasizing that a rise in repair activity up to 10% can greatly influence the 
severity of disease progression and skin cancer free survival time up to 20 years. This 
indicates that also minor repair activities of splice variants may have a huge influence on the 
cell’s repair capabilities. Furthermore, Thorel et al. (Thorel et al., 2004) reported about a 28 
year old patient with advanced XP/CS symptoms that had two XPG alleles producing a 
severely truncated protein. Interestingly, an XPG protein lacking seven internal amino acids, 
leading to residual endonuclease activity in vitro and weak TFIIH interaction ability, was 
generated by alternative splicing. The residual effects of this protein prolonged the patient’s 
life for several years.  
Commonly, all three splice variants of XPF and XPG evolve from alternative splicing and 
intron retention (five to eleven aa) (Emmert et al., 2001). XPG isoform V shows a motif 
implicating the involvement of disulfide bonds in the protein-protein interaction surface (T-C-
L-C-F-C-R). Numerous functions of intron retention have been explored over the last years, 
ranging from enhancing proteome diversity and gene expression to regulatory functions 
(reviewed in Graveley, 2001; Le Hir et al., 2003). Intron gain or loss has been an important 
evolutionary engine over time (reviewed in Rogers, 1985). Large-scale analyses regarding 
intron retention in a set of 21,106 human genes, revealed at least one intron retention in 
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14.8% of the investigated genes, suggesting a biological function (Galante et al., 2004). The 
question remains, whether there is evidence for functional introns influencing enzyme 
activity, for example in DNA repair gene splice variants. This has not been reported in the 
literature so far. However, intron-retaining splice variants of transcription factors have been 
postulated to be risk factors for different types of cancer, e.g. breast cancer, lymphoma or 
melanoma (Busse et al., 2009; Honda et al., 2012; Whiley et al., 2011).  
Notably, loss of ICL repair capability was not as prominent in XPG-deficient (XP20BE) as it 
was in XPF-deficient cells (see Figure 25B, C and Figure 26B, C). Thus, complementation 
effects of functional splice variants were not as strong for XPG IsoV and VI as they were for 
XPF-201 and XPF-003 compared to non-functional splice variants. There is a long and 
ongoing discussion about the importance of XPG during ICL repair, while it is essential for 
NER. Anyhow, discussion of ICL repair presents a major challenge. Up until now, 
understanding of the process is still poor. Indeed, there are many inconsistencies, 
contradictions, and uncertainties regarding the literature due to the numerous crosslinking 
agents with differing properties and products. Dual incision of an ICL is much more difficult 
to investigate. In prokaryotes, like E. coli, the UvrABC system, using a mechanism involving 
an ATP-dependent strand separation step, is able to cleave on both sides of an ICL (reviewed 
in Batty & Wood, 2000). In mammalian cells the mechanism is still unclear. Unhooking is a 
key step during ICL repair; therefore identification of the critical factors is clearly important. 
In regard to the NER pathway, roles of XPG (3' incision) and XPF/ERCC1 (5' incision), are 
of special interest. Unwinding could take place on both or only one side of an ICL, creating 
an open structure for endonucleases to access the lesion. Depending on the position of an ICL, 
XPF/ERCC1 is able to cleave on either side (Kuraoka et al., 2000), but also XPG may be 
involved in cutting 3′ to a junction between duplex and single-stranded DNA (Evans et al., 
1997a). Moreover, additional nucleases could be implicated in ICL unhooking depending on 
the situation. Cells deficient in XPF or ERCC1 are hypersensitive to crosslinking agents, but 
cells with defective XPG or other NER genes, generally only display modest sensitivity 
(Andersson et al., 1996; Clingen et al., 2007; Damia et al., 1996; De Silva et al., 2002; Hoy et 
al., 1985). Furthermore, as shown in Figure 25 and Figure 26 reduction in repair capability 
compared to WT cells was lower in XPG (CP 6-fold, TMP + UVA 3-fold) compared to XPF-
deficient cells (CP 20 fold, TMP + UVA 6 fold). This emphasizes the essential role of the 
XPF/ERCC1 endonuclease in ICL repair due to dual involvement in ICL unhooking.  
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Additionally, it seems as if there is a more important role for both endonucleases in removal 
of CP induced crosslinks, which are known to be rather intra- than interstrand crosslinks. For 
the experiments the HCR was adapted to CP and TMP + UVA induced lesions and only 
represent replication-independent removal of ICLs, as there is no origin of replication located 
on the pCMVluc plasmid (see Table 10). Previous studies showed that human cells deficient 
in XPG nearly showed WT unhooking kinetics of psoralen + UVA induced ICLs (De Silva et 
al., 2000; Rothfuss & Grompe, 2004), while XPF/ERCC1 deficient cells were unable to 
unhook these lesions clearly indicating a necessity of the XPF/ERCC1 complex (De Silva et 
al., 2000; De Silva et al., 2002). Trimethylpsoralen that was used during this thesis is a 
psoralen derivative, but seems to be more efficient in producing ICLs. It was able to reduce 
repair levels of XPG- and XPF-deficient cells (5.12%, 2.50%) (see Figure 21 and Figure 25), 
but much less efficient than UVC or CP. Interestingly, CP induced ICLs rendered cells much 
more sensitive and also impaired unhooking in XPG-deficient cells in other experiments as 
well (De Silva et al., 2002). This again raises the question, how to handle compounds minorly 
producing ICLs, but rather single strand adducts which are NER substrates, like CP, changing 
the dynamics of ICL repair.  
However, current models of ICL repair propose a fundamental role of the XPF/ERCC1 
complex during the unhooking step of ICL repair, which is in concurrence with the results of 
this thesis where both lesions result in nearly no residual repair capability in our XPF KO 
cells. Furthermore, there are studies implicating XPF/ERCC1 in an NER-independent ICL 
unhooking at stalled replication forks, which could not be examined using the experimental 
set up of this thesis (Fisher et al., 2008). As proposed before, XPF/ERCC1 may associate with 
the scaffold protein SLX4 and two other structure specific endonucleases Mus81/Eme1 and 
SLX1, when SLX4 enhances their nuclease activity (Andersen et al., 2009; Fekairi et al., 
2009; Munoz et al., 2009). An siRNA knockdown of SLX4 rendered cells sensitive to 
crosslinking agents, but not UV irradiation, implicating an interaction of XPF/ERCC1 and 
SLX4 outside of NER (Munoz et al., 2009). In regard to these results, a double knockout of 
XPF and SLX4 is of special importance to test the complementation ability of the XPF-003 
splice variant. The above mentioned results suggested an important protein interaction domain 
of the very N-terminal part of the XPF protein. SLX4 is supposed as one interaction 
candidate, therefore, a double knockout should diminish XPF-003’s complementation ability 
at least in regard to CP and TMP + UVA induced lesions. Moreover, XPF-202 that only 
differs from XPF-003 in the first 12 aa did not show any complementation and subcellular 
localization showed a less distinct accumulation in the nucleus, but rather a distribution all 
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over the cell (see Figure 24). This could also be explained by the disrupted interaction with 
SLX4 that is an important platform and scaffold protein to organize DNA repair factors. 
Apart from this, XPF/ERCC1 is also involved in recombination and DSB repair (Adair et al., 
2000; Ahmad et al., 2008; Niedernhofer et al., 2001; Sargent et al., 1997), so it remains to be 
elucidated whether the interaction between XPF and SLX4 is important for unhooking or 
other crosslink repair associated pathways. However, there is strong evidence that 
XPF/ERCC1 and SLX4 simultaneously load onto the ICL (Klein Douwel et al., 2014). 
Additionally, SLX4 functions as a SUMO E3 ligase and sumoylates itself, as well as XPF 
(Guervilly et al., 2015). 
It remains to be elucidated, by which mechanisms, apart from protein-protein interactions 
with other repair factors, splice variants are able to confer residual repair capabilities. As 
mentioned before, XPG IsoV and VI as well as XPF-003 lack at least parts of the 
endonuclease domains (see Figure 12 and Figure 13). The existence of a cellular backup 
mechanism for the XPG endonuclease was subject to the PhD thesis of Dr. rer. nat Steffen 
Schubert, where he demonstrated that endonuclease defective XPG was able to perform 
accurate NER in living cells. He proposed that severely truncated XPG splice variants can 
structurally complement an XPG defect and lead to functional NER by recruitment of other 
structure-specific endonucleases like Fen1. These endonucleases can then cleave the DNA 
and repair can proceed (Schubert, 2014). A similar mechanism could be implicated for the 
XPF/ERCC1 endonuclease complex, but was not subject of this thesis and will therefore not 
be further discussed. 
5.7 XPG and XPF splice variants exert a dominant negative effect on wild 
type NER capacities 
Dominant negative inhibition describes the manifestation of an impaired WT gene product 
function by co-expression of a mutant variant, originating from the same gene product 
(reviewed in Herskowitz, 1987). Interference of splice variants with endogenous DNA repair 
in regard to dominant negative effects has been investigated in 4.4.3. Therefore, exemplarily 
effects on NER have been analyzed after generation of cell lines stably overexpressing XPG 
and XPF splice variants as well as full-length proteins. Overall, two XPG splice variants 
(XPG IsoVI and XPG-201), as well as WT XPF and all three splice variants (XPF-201, XPF-
003, XPF-202), exhibited a dominant negative effect on MRC5Vi WT NER capabilities (see 
Figure 27).  
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In the human genome, the majority of protein-encoding genes are subject to physiological 
splicing. Interestingly, pathological splicing has been reported in cancer tissue (reviewed in 
(Srebrow & Kornblihtt, 2006; Zhao et al., 2016)). For example, a negative effect of Chk2 
splice variants and their effect on downstream substrates like p53, and Cdc25A/C that are 
involved in cell cycle arrest and apoptosis have been reported, suggesting alternative splicing 
as a mechanism for repression of WT protein function (Berge et al., 2010). Interestingly, a 
polymorphism of the splice acceptor site in intron 11 of the XPC gene, a central player in 
NER, results in the expression of a functionally dominant negative splice variant that reduces 
NER by about 50% (Khan et al., 2002). This polymorphism occurs as a haplotype with 
another polymorphism in the XPC gene (Khan et al., 2000) and could be associated with an 
increased risk for SCCs of head and neck, as well as melanoma development (Blankenburg et 
al., 2005; Shen et al., 2001). Dominant negative effects have already been observed for other 
enzymes besides XPG and XPF/ERCC1, like the telomerase catalytic subunit (hTERT). 
Although lacking telomerase activity, low levels of hTERT mRNA has been shown in 
different human tissues. Furthermore, six splice variants, among which one deletion variant 
missing parts of the catalytic core, have been described (Kilian et al., 1997). This particular 
splice variant inhibits endogenous telomerase activity in developing tissues, thereby leading 
to telomere shortening and chromosome end-to-end fusions (Colgin et al., 2000). This is in 
concurrence with XPF-202, XPF-003, and XPG-201, which also lack parts of the catalytic 
protein domains. Moreover, dominant negative inhibition is often seen in splice variants of 
multisubunit proteins, e.g. isoleucyl-tRNA synthetase. If the variant is co-expressed with the 
WT protein, assembly of a functional complex might be impaired due to formation of 
dysfunctional complexes as the variant and the WT protein compete for binding partners 
(Michaels et al., 1996). This could also be the case for XPF splice variants in view of 
heterodimer formation with ERCC1. Anyhow, this would only apply for XPF-201, as XPF-
202 and XPF-003 lack the HhH2 motif important for ERCC1 interaction. 
The observed effects could also be due to simple protein overload in the cell, due to the strong 
and artificial overexpression, leading to unproductive protein interactions of splice variants 
with a repair capability lower than the WT protein. Furthermore, protein ratios between XPG 
and XPF could be disturbed. As mentioned before the excision process is highly coordinated 
between XPF/ERCC1 and XPG following subsequent binding and cutting steps. However, it 
is possible that the results only represent gene dose effects. Interestingly, effects were much 
more significant and extensive for XPF than for XPG, suggesting that XPF protein ratios, 
interactions and functions are more sensitive to changes than XPG. Milne and Weaver already 
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reported about the disruption of DSB repair through nonfunctional interactions of Rad52 
splice variants and proposed the formation of a higher order repair/recombination complex, 
potentially containing other yet unidentified components (Milne & Weaver, 1993). Taken 
together, interpretation of dominant negative effects is difficult due to experimental 
challenges and merit further investigations. 
5.8 Artificially generated XPF point mutants behave differently in the 
newly generated XPF KO cells  
In vitro reconstituted NER using purified recombinant proteins (~30 proteins), as well as dual 
incision assays with constructs containing defined lesions, have been applied over the past 
decade to analyze interactions between the endonucleases XPF/ERCC1 and XPG during the 
excision step of NER and ICL unhooking (Lindsey-Boltz et al., 2014; Moggs et al., 1996; 
Tapias et al., 2004). In course of these experiments, several essential residues of those 
endonucleases have been postulated and were subject to further in vivo analyses using the 
newly generated XPF KO cells in this thesis (see 4.4.4). 
In the fully reconstituted in vitro NER system, the mutant XPF D668A (designated D676A in 
older publications) was devoid any NER activity and only lead to a marginal increase of 3’ 
incision in the dual incision assay. Therefore, this variant is often used as an endonuclease 
defective XPF control (Sertic et al., 2011). Addition of XPF D668A to XP-F patient cells only 
resulted in an UDS (unscheduled DNA synthesis), another readout for functional NER, of 8% 
of WT cells (Staresincic et al., 2009; Tapias et al., 2004). In conflict with these results, the 
D668A mutant showed complementation like WT cells or full-length XPF protein using the 
HCR assay, whilst D731A did show neither NER nor ICL repair capabilities. In the literature, 
this variant, also known as D720A, was only implicated to be essential for ICL unhooking. 
Fisher et al. (Fisher et al., 2008) performed ICL specific in vitro studies and postulated a role 
of this residue in a 3’-5’ exonuclease activity of XPF, which is also present in the yeast 
homolog Rad1/Rad10 (Guzder et al., 2004; Mu et al., 2000). Other in vitro studies also 
reported about residual NER capabilities of D720A (Tapias et al., 2004), while Staresincic et 
al. could not confirm this in their dual incision assays (Staresincic et al., 2009). This clearly 
illustrates the differences between artificially reconstituted and physiological test systems and 
the need for suitable model cell lines with a full protein reservoir. 
The HhH2 domain is highly conserved in XPF and ERCC1 (Gaillard & Wood, 2001; Sgouros 
et al., 1999) and is essential for the dimerization of the hydrophobic C-terminal parts of the 
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proteins in order to function as a stable heterodimer (Tripsianes et al., 2005; Tsodikov et al., 
2005). XPF Phe905 and ERCC1 Phe293 are thought to be residues essential for interaction, 
anchoring the proteins together (Figure 8). This has been confirmed by mutational studies for 
ERCC1 Phe293, which resulted in abolition of dimerization and enzyme activity (de Laat et 
al., 1998c; Sijbers et al., 1996b). However, despite identical biochemical features this has not 
been shown for XPF. A general dogma implicates that neither protein is stable without its 
heterodimeric partner and will rapidly be degraded due to aggregation (Choi et al., 2005; 
Tripsianes et al., 2005). Functional assays determined complementation abilities of two 
artificially generated XPF Phe905 point mutants, F905A/P, like full-length XPF during NER 
and ICL repair (see Figure 29). In this new setting, these residues do not seem to be essential 
for repair, and interaction with ERCC1. Furthermore, XPF and ERCC1 proteins could be 
detected after overexpression of the mutant variants in the XPF KO cells. Anyhow, protein 
stability seemed to be affected in the F905P variant, because nuclear levels of ERCC1 
appeared to be lower compared to WT cells (Figure 31). This suggests that XPF Phe905 is 
involved in XPF ERCC1 protein-protein interaction, but not essentially, and that interaction 
between XPF and ERCC1 might be established by a larger interaction patch including several 
residues (Choi et al., 2005). 
Moreover, protein stability and mislocalization play an important role in regard to 
physiological DNA repair activity. The P85S mutant was described to retain normal ERCC1 
binding in dual incision assays and an intact nuclease function comparable to the WT protein 
in vitro. Anyhow, this residue is important for the interaction with RPA70 and critically 
associated with nuclear import as it compromises the NLS. Although defective interaction 
with RPA showed little impact and seemed to be dispensable in vitro, CHO cells with this 
mutation were sensitive to UV irradiation and showed a decrease in 6-4PP removal (Fisher et 
al., 2011a). The picture does not seem this black and white, as the P85S mutant contains a 
high complementation capability in the new experimental setting, though not as high as WT 
or full-length protein levels (Figure 29). It is possible that the expression of one functional 
NLS is enough for a full-length protein to reach sufficient nuclear protein levels, and could be 
investigated further using the XPF KO cells. Furthermore, RPA is also involved in 
positioning and stimulating the catalytic activities of XPF (Matsunaga et al., 1996). In 
contrast, the R153P allele of an XFE patient showed a decrease in complementation ability of 
about 5% for UVC induced lesions (also reported in (Niedernhofer et al., 2006)). In vitro this 
mutation lead to a catalytically active recombinant protein, while in vivo the XPF/ERCC1 
heterodimer could only be observed in the cytoplasm. Microinjection could rescue nuclear 
Discussion 
106 
localization (Ahmad et al., 2010). Analyses of protein localization performed in the course of 
this thesis, showed no nuclear XPF or ERCC1 in the XPF KO cells after overexpression of 
the R153P variant (Figure 31). This corroborated the finding that ERCC1 is not stable in the 
cytosol without its heterodimeric partner (Lehmann et al., 2017), and further aggravates to a 
functional XPF protein. Indeed, this emphasized that correct sub-compartmentalization of 
DNA repair and mislocalization of the XPF protein to the cytoplasm, as well as protein 
misfolding, seem to regulate NER as well as ICL repair. This could lead to severe symptoms 
like XP/CS or XFE, rather than only a catalytic impairment of the protein. In addition, studies 
of the XFE patient with the p.R153 mutation exhibited a global attenuation of the 
somatotrophic axis with an upregulation of Ppar α/γ to rescue energy storage. This implicates 
a link between genome maintenance and systemic dampening of the growth hormone/IGF1 
hormonal axis, connecting DNA damage and aging (Niedernhofer et al., 2006). Therefore, the 
XPF KO cells might also present an interesting model to study accumulated aging processes.  
In line with the literature, the patient allele C236R showed a lower complementation 
capability than the full-length protein, confirming in vitro results that reported reduced 
endonuclease activities. This leads to an XP/CS complex phenotype (Kashiyama et al., 2013). 
Full complementation could also be observed for the XP patient allele R490Q, as expected for 
a mildly affected patient. On the other hand, the FA patient allele R689S only showed 
complete NER complementation abilities, while ICL repair was decreased. This is confirmed 
by the literature, as patient cells are sensitive to the ICL inducing agent mitomycin C, but not 
UV irradiation and show nearly normal UDS levels. Moreover, in vitro studies showed that 
cells are proficient in NER excision, but impaired in ICL unhooking (Bogliolo et al., 2013).  
To summarize this, it becomes clear that this new cellular background is a tantalizing tool for 
further mechanistic analyses. Reconstituted systems present good models, but are limited by 
the artificial combination of recombinant proteins, while in vivo even until now unknown 
components could be involved and discovered.  
5.9 Importance of XPG isoforms for personalized medicine and further  
perspectives  
Personalized medicine has been in the focus of research over the past decade. Differential 
expression of XP splice variants between individuals and even different tissues may be 
determining patient specific overall repair capacity, and thereby resistance to different 
therapies could be clarified. Resistance, e.g. in chemotherapy against cancer, arises from 
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different levels of DNA repair and has been shown to be a target for small molecule inhibitors 
(Gentile et al., 2016). NER and ICL repair eliminate various types of DNA lesions including 
UV irradiation and platinum-based therapy induced lesions. Furthermore, personal expression 
levels of DNA repair genes are of special interest, as it was shown that resistances to 
platinum-based therapy correlate with high expression of ERCC1 (Barakat et al., 2012). 
Interaction between ERCC1 and XPA is essential for NER regulation, and XPF/ERCC1 
activity can be inhibited by blocking this interaction, sensitizing cancer cells to UV 
irradiation. Additionally, in silico drug screens have identified inhibitors of the XPF-ERCC1 
interaction domain, disrupting the complex (Jordheim et al., 2013). Moreover, high ERCC1 
expression has been correlated with poor response in different cancer entities like e.g. non-
small cell lung cancer, esophageal cancer, breast cancer, colorectal cancer, as well as head 
and neck cancer (Bilen et al., 2014; Choueiri et al., 2015; Gerhard et al., 2013; Hayes et al., 
2011). Notably, testis tumors with reduced protein levels of XPF, ERCC1, and XPA could be 
cured using cisplatin-based chemotherapy even in advanced metastasis stages (Welsh et al., 
2004). Expression levels of splice variants in different tissues have been shown to be more 
suitable to distinguish between oncogene and non-oncogene samples than the primary gene 
transcript itself (Zhang et al., 2013b). Besides, tumor-specific splice variants are often 
overexpressed (Blair & Zi, 2011; Brinkman, 2004; Yi & Tang, 2011). In regard to this, the 
abundance of splice variants with residual repair functions could be used as prognostic factors 
for therapy outcome, as well as for personalized and targeted medicine. Therefore, repair 
increasing functions and duration of skin-cancer free survival time in patients with a lack of 
the primary transcript (see 4.4.1) (Thorel et al., 2004) as well as dominant negative functions 
(see 4.4.3) in healthy individuals have to be weighed and evaluated in larger collectives.  
Due to a limited amount of material inter-individual differences in a small collective of 20 
healthy donors as well as expression differences in 20 tissues have been assessed by qRT-
PCR only for XPG and its two splice variants with residual repair function (IsoV and VI), 
whereas IsoVI also displayed dominant negative effects in wildtype cells (see 4.5). 
Interestingly, individuals with a high expression of isoform VI showed a low expression level 
of the primary transcript, implicating a dominant negative effect of this variant on full-length 
XPG expression, which could also be seen in functional repair assays (see Figure 27). In the 
future, XPG mRNA levels of splice variants could be quantified in special, e.g. high-risk 
cancer populations (patients with multiple dysplastic nevi and high melanoma risk, or organ 
transplant recipients with high SCC risk). Clinically, as well as epidemiologically, this would 
be of high importance in order to investigate beneficial or negative influences of these 
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variants on tumor development, disease outcome, therapeutic efficacies, and side effects. 
Inter-individual variations of DNA repair levels and association with cancer is well 
documented. Therefore, implication of differences in expression levels of isoforms displays a 
great prognostic value as cancer biomarker (Zhang et al., 2013b). Taken together, the 
uniqueness of personal and tissue-specific expression levels, as seen in Figure 32 and Figure 
33, of functionally active, alternatively spliced mRNA variants may thus be implicated in 
cancer susceptibility, responses to chemotherapeutics and therapeutic success (Colmegna et 
al., 2015; Hu et al., 2014; Li et al., 2013a; Sun et al., 2015). 
5.10 Summary and conclusions 
In conclusion, the novel and innovative CRISPR/Cas9 technique was established in the 
laboratory and applied to successfully generate a viable human XPF KO cell line. A markedly 
increased sensitivity to UVC, cisplatin, and psoralen activated by UVA, as well as reduced 
repair capabilities for NER and ICL repair were determined. This cell line can now be used as 
a valuable tool for further analyses regarding XPF’s various functions in different cellular 
processes. It was shown that XPF is dispensable for ERCC1 protein stability but essential for 
ERCC1 nuclear localization. Moreover, besides its essential role in NER and ICL repair, 
XPF’s endonuclease activity appears to be partially essential in the HRR subpathway of DSB 
repair. In the future, it might be possible to further investigate more general questions in DNA 
repair, like the ongoing discussion about the essential nuclease for incising the DNA around 
an ICL. This cell line could be utilized to clarify whether or not it might exclusively be XPF. 
Other detailed mechanistic questions of repair pathways like NER can be studied in a setting 
without residual XPF activity, as it has already been done for XPF point mutants in this thesis. 
Moreover, the proposed method could be expanded to other genes of the DNA repair 
machinery and in vitro as well as in vivo studies.  
Furthermore, the residual repair capabilities lead to following questions regarding mechanistic 
studies, for which the XPF KO cells present an excellent model cell line. The 12 N-terminal 
missing aa of the inactive superfamily2 helicase-like domain of XPF may interact with the 
SLX4 platform for DNA repair, as it is already described for Mus81 (Nowotny & Gaur, 2016; 
Wyatt et al., 2013). In a follow-up research grant the interaction between XPF and SLX4 
could be investigated by creating SLX4 CRISPR KO cells and even XPF/SLX4 double 
mutants for functional repair assays. Moreover, additional interaction partner could be 
identified applying proteomics and BRET analyses. 
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Additionally, splice variants of XPF and XPG with residual repair capabilities, but also 
dominant negative effects in NER and ICL repair, were identified. These variants show inter-
individual expression differences as well as expression differences in various tissues making 
them promising prognostic marker for individual repair capability, disease outcome, and 
therapy success. As these are preliminary results from a small collective of healthy donors, 
analyses should be expanded to screening of a larger collective to identify actual prognostic 
marker. As the same splice variants showed residual repair activity in a KO background, but 
also dominant negative effects if overexpressed in a WT background, one would expect a 
high expression of such splice variants to be associated with rather unfavorable disease 






Figure A1: Immunoblot results for wildtype XPG, the seven isoforms and two patient 
alleles after overexpression in HeLa cells 
Protein expression was assesed by horizontal SDS Page followed by immunoblotting after transient transfection 
of HeLa cells with the different constructs (24-72h). Two different antibodies for XPG, one spanning the epitope 
from amino acid 151-190 (Abcam) and the other from 650-700 (Bethyl), or an antibody directed against the 






Figure A2: Subcellular localization of eGFP-tagged XPG isoforms and patient alleles 
XPG isoforms and patient alleles were cloned into an pcDNA3.1(+)eGFP expression vector and overexpressed 
in HeLa cells for 48h to analyze subcellular localization. Additionally, DAPI staining was performed to visualize 




Figure A3: Immunoblot results for protein levels of ERCC1 splice variants over time 
In order to analyze protein levels after overexpression of the splice variants in HeLa cells, horizontal SDS Page 
followed by Immunoblotting was performed. Therefore, HeLa cells were transiently transfected with the 
different constructs and harvested after 24h, 48h and 72h and stained with an anti- myc-tag antibody. Anti-β-
actin staining was used for normalization. Protein levels were quantified in regard to the 24h value as there is no 





Figure A4: Subcellular localization of eGFP-tagged ERCC1 isoforms and patient alleles 
ERCC1 isoforms were cloned into an pcDNA3.1(+)eGFP expression vector and overexpressed in HeLa cells for 
48h to analyze subcellular localization. Additionally, DAPI staining was performed to visualize the nucleus. 






Adair GM, Rolig RL, Moore-Faver D, Zabelshansky M, Wilson JH, Nairn RS (2000) Role of ERCC1 in removal 
of long non-homologous tails during targeted homologous recombination. The EMBO journal 19: 5552-5561 
Ahmad A, Enzlin JH, Bhagwat NR, Wijgers N, Raams A, Appledoorn E, Theil AF, JH JH, Vermeulen W, NG 
JJ, Scharer OD, Niedernhofer LJ (2010) Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA 
repair in XP-F patients. PLoS genetics 6: e1000871 
Ahmad A, Robinson AR, Duensing A, van Drunen E, Beverloo HB, Weisberg DB, Hasty P, Hoeijmakers JH, 
Niedernhofer LJ (2008) ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Molecular and 
cellular biology 28: 5082-5092 
Al-Minawi AZ, Lee YF, Hakansson D, Johansson F, Lundin C, Saleh-Gohari N, Schultz N, Jenssen D, Bryant 
HE, Meuth M, Hinz JM, Helleday T (2009) The ERCC1/XPF endonuclease is required for completion of 
homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic acids research 
37: 6400-6413 
Al-Minawi AZ, Saleh-Gohari N, Helleday T (2008) The ERCC1/XPF endonuclease is required for efficient 
single-strand annealing and gene conversion in mammalian cells. Nucleic acids research 36: 1-9 
Andersen SL, Bergstralh DT, Kohl KP, LaRocque JR, Moore CB, Sekelsky J (2009) Drosophila MUS312 and 
the vertebrate ortholog BTBD12 interact with DNA structure-specific endonucleases in DNA repair and 
recombination. Molecular cell 35: 128-135 
Andersson BS, Sadeghi T, Siciliano MJ, Legerski R, Murray D (1996) Nucleotide excision repair genes as 
determinants of cellular sensitivity to cyclophosphamide analogs. Cancer chemotherapy and pharmacology 38: 
406-416 
Arab HH, Wani G, Ray A, Shah ZI, Zhu Q, Wani AA (2010) Dissociation of CAK from core TFIIH reveals a 
functional link between XP-G/CS and the TFIIH disassembly state. PloS one 5: e11007 
Aracil M, Dauffenbach LM, Diez MM, Richeh R, Moneo V, Leal JF, Fernandez LF, Kerfoot CA, Galmarini CM 
(2013) Expression of XPG protein in human normal and tumor tissues. International journal of clinical and 
experimental pathology 6: 199-211 
Araki M, Masutani C, Takemura M, Uchida A, Sugasawa K, Kondoh J, Ohkuma Y, Hanaoka F (2001) 
Centrosome protein centrin 2/caltractin 1 is part of the xeroderma pigmentosum group C complex that initiates 
global genome nucleotide excision repair. The Journal of biological chemistry 276: 18665-18672 
Athar M, Li C, Kim AL, Spiegelman VS, Bickers DR (2014) Sonic hedgehog signaling in Basal cell nevus 
syndrome. Cancer research 74: 4967-4975 
Baker BS, Carpenter AT, Ripoll P (1978) The Utilization during Mitotic Cell Division of Loci Controlling 
Meiotic Recombination and Disjunction in DROSOPHILA MELANOGASTER. Genetics 90: 531-578 
Barakat KH, Jordheim LP, Perez-Pineiro R, Wishart D, Dumontet C, Tuszynski JA (2012) Virtual screening and 
biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. PloS one 7: e51329 
Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P (2007) 
CRISPR provides acquired resistance against viruses in prokaryotes. Science (New York, NY) 315: 1709-1712 
Bartek J, Lukas J (2007) DNA damage checkpoints: from initiation to recovery or adaptation. Current opinion in 
cell biology 19: 238-245 
Batty DP, Wood RD (2000) Damage recognition in nucleotide excision repair of DNA. Gene 241: 193-204 
Ben Rekaya M, Messaoud O, Talmoudi F, Nouira S, Ouragini H, Amouri A, Boussen H, Boubaker S, Mokni M, 
Mokthar I, Abdelhak S, Zghal M (2009) High frequency of the V548A fs X572 XPC mutation in Tunisia: 
implication for molecular diagnosis. Journal of human genetics 54: 426-429 
Bennardo N, Cheng A, Huang N, Stark JM (2008) Alternative-NHEJ is a mechanistically distinct pathway of 
mammalian chromosome break repair. PLoS genetics 4: e1000110 
Bibliography 
115 
Bentley D (2002) The mRNA assembly line: transcription and processing machines in the same factory. Current 
opinion in cell biology 14: 336-342 
Berge EO, Staalesen V, Straume AH, Lillehaug JR, Lonning PE (2010) Chk2 splice variants express a dominant-
negative effect on the wild-type Chk2 kinase activity. Biochimica et biophysica acta 1803: 386-395 
Berneburg M, Lehmann AR (2001) Xeroderma pigmentosum and related disorders: defects in DNA repair and 
transcription. Advances in genetics 43: 71-102 
Berquist BR, Wilson DM, 3rd (2012) Pathways for repairing and tolerating the spectrum of oxidative DNA 
lesions. Cancer letters 327: 61-72 
Bertram JS (2000) The molecular biology of cancer. Molecular aspects of medicine 21: 167-223 
Bessho T, Sancar A, Thompson LH, Thelen MP (1997) Reconstitution of human excision nuclease with 
recombinant XPF-ERCC1 complex. The Journal of biological chemistry 272: 3833-3837 
Bhagwat N, Olsen AL, Wang AT, Hanada K, Stuckert P, Kanaar R, D'Andrea A, Niedernhofer LJ, McHugh PJ 
(2009) XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. Molecular and cellular 
biology 29: 6427-6437 
Biggerstaff M, Szymkowski DE, Wood RD (1993) Co-correction of the ERCC1, ERCC4 and xeroderma 
pigmentosum group F DNA repair defects in vitro. The EMBO journal 12: 3685-3692 
Bilen N, Tekin SB, Topdagi O (2014) ERCC1 Expression in Non-Small Cell Lung and Esophageal Cancer. The 
Eurasian journal of medicine 46: 84-88 
Bitinaite J, Wah DA, Aggarwal AK, Schildkraut I (1998) FokI dimerization is required for DNA cleavage. 
Proceedings of the National Academy of Sciences of the United States of America 95: 10570-10575 
Blair CA, Zi X (2011) Potential molecular targeting of splice variants for cancer treatment. Indian journal of 
experimental biology 49: 836-839 
Blankenburg S, Konig IR, Moessner R, Laspe P, Thoms KM, Krueger U, Khan SG, Westphal G, Berking C, 
Volkenandt M, Reich K, Neumann C, Ziegler A, Kraemer KH, Emmert S (2005) Assessment of 3 xeroderma 
pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study. 
Carcinogenesis 26: 1085-1090 
Boettcher M, McManus MT (2015) Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR. Molecular 
cell 58: 575-585 
Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, Raams A, Trujillo JP, Minguillon J, Ramirez MJ, Pujol 
R, Casado JA, Banos R, Rio P, Knies K, Zuniga S, Benitez J, Bueren JA, Jaspers NG, Scharer OD, de Winter JP, 
Schindler D, Surralles J (2013) Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause 
Fanconi anemia. American journal of human genetics 92: 800-806 
Bohr VA, Smith CA, Okumoto DS, Hanawalt PC (1985) DNA repair in an active gene: removal of pyrimidine 
dimers from the DHFR gene of CHO cells is much more efficient than in the genome overall. Cell 40: 359-369 
Bohr VA, Stevnsner T, de Souza-Pinto NC (2002) Mitochondrial DNA repair of oxidative damage in 
mammalian cells. Gene 286: 127-134 
Boulikas T (1997) Nuclear import of DNA repair proteins. Anticancer research 17: 843-863 
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein 
utilizing the principle of protein-dye binding. Analytical biochemistry 72: 248-254 
Bradford PT, Goldstein AM, Tamura D, Khan SG, Ueda T, Boyle J, Oh KS, Imoto K, Inui H, Moriwaki S, 
Emmert S, Pike KM, Raziuddin A, Plona TM, DiGiovanna JJ, Tucker MA, Kraemer KH (2011) Cancer and 
neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. 
Journal of medical genetics 48: 168-176 
Bibliography 
116 
Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J (1991) A role for 
sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proceedings of the National 
Academy of Sciences of the United States of America 88: 10124-10128 
Brinkman BM (2004) Splice variants as cancer biomarkers. Clinical biochemistry 37: 584-594 
Brookman KW, Lamerdin JE, Thelen MP, Hwang M, Reardon JT, Sancar A, Zhou ZQ, Walter CA, Parris CN, 
Thompson LH (1996) ERCC4 (XPF) encodes a human nucleotide excision repair protein with eukaryotic 
recombination homologs. Molecular and cellular biology 16: 6553-6562 
Brugmans L, Kanaar R, Essers J (2007) Analysis of DNA double-strand break repair pathways in mice. 
Mutation research 614: 95-108 
Busse A, Rietz A, Schwartz S, Thiel E, Keilholz U (2009) An intron 9 containing splice variant of PAX2. 
Journal of translational medicine 7: 36 
Campisi J, d'Adda di Fagagna F (2007) Cellular senescence: when bad things happen to good cells. Nature 
reviews Molecular cell biology 8: 729-740 
Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, Baller JA, Somia NV, Bogdanove AJ, Voytas 
DF (2011) Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA 
targeting. Nucleic acids research 39: e82 
Chang YF, Imam JS, Wilkinson MF (2007) The nonsense-mediated decay RNA surveillance pathway. Annual 
review of biochemistry 76: 51-74 
Chen F, Nastasi A, Shen Z, Brenneman M, Crissman H, Chen DJ (1997) Cell cycle-dependent protein 
expression of mammalian homologs of yeast DNA double-strand break repair genes Rad51 and Rad52. Mutation 
research 384: 205-211 
Chen J, Larochelle S, Li X, Suter B (2003) Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature 
424: 228-232 
Cheo DL, Meira LB, Burns DK, Reis AM, Issac T, Friedberg EC (2000) Ultraviolet B radiation-induced skin 
cancer in mice defective in the Xpc, Trp53, and Apex (HAP1) genes: genotype-specific effects on cancer 
predisposition and pathology of tumors. Cancer research 60: 1580-1584 
Chevalier BS, Stoddard BL (2001) Homing endonucleases: structural and functional insight into the catalysts of 
intron/intein mobility. Nucleic acids research 29: 3757-3774 
Chiara MD, Palandjian L, Feld Kramer R, Reed R (1997) Evidence that U5 snRNP recognizes the 3' splice site 
for catalytic step II in mammals. The EMBO journal 16: 4746-4759 
Choi YJ, Ryu KS, Ko YM, Chae YK, Pelton JG, Wemmer DE, Choi BS (2005) Biophysical characterization of 
the interaction domains and mapping of the contact residues in the XPF-ERCC1 complex. The Journal of 
biological chemistry 280: 28644-28652 
Choueiri MB, Shen JP, Gross AM, Huang JK, Ideker T, Fanta P (2015) ERCC1 and TS Expression as 
Prognostic and Predictive Biomarkers in Metastatic Colon Cancer. PloS one 10: e0126898 
Cimino GD, Gamper HB, Isaacs ST, Hearst JE (1985) Psoralens as photoactive probes of nucleic acid structure 
and function: organic chemistry, photochemistry, and biochemistry. Annual review of biochemistry 54: 1151-
1193 
Cimprich KA, Cortez D (2008) ATR: an essential regulator of genome integrity. Nature reviews Molecular cell 
biology 9: 616-627 
Clauson C, Scharer OD, Niedernhofer L (2013) Advances in understanding the complex mechanisms of DNA 
interstrand cross-link repair. Cold Spring Harbor perspectives in biology 5: a012732 
Cleaver JE, Lam ET, Revet I (2009) Disorders of nucleotide excision repair: the genetic and molecular basis of 
heterogeneity. Nature reviews Genetics 10: 756-768 
Bibliography 
117 
Cleaver JE, Thompson LH, Richardson AS, States JC (1999) A summary of mutations in the UV-sensitive 
disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Human mutation 14: 9-22 
Clingen PH, Arlett CF, Hartley JA, Parris CN (2007) Chemosensitivity of primary human fibroblasts with 
defective unhooking of DNA interstrand cross-links. Experimental cell research 313: 753-760 
Cockayne EA (1936) Dwarfism with retinal atrophy and deafness. Archives of disease in childhood 11: 1-8 
Coin F, Oksenych V, Egly JM (2007) Distinct roles for the XPB/p52 and XPD/p44 subcomplexes of TFIIH in 
damaged DNA opening during nucleotide excision repair. Molecular cell 26: 245-256 
Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR (2000) The hTERTalpha splice 
variant is a dominant negative inhibitor of telomerase activity. Neoplasia (New York, NY) 2: 426-432 
Colmegna B, Uboldi S, Frapolli R, Licandro SA, Panini N, Galmarini CM, Badri N, Spanswick VJ, Bingham JP, 
Kiakos K, Erba E, Hartley JA, D'Incalci M (2015) Increased sensitivity to platinum drugs of cancer cells with 
acquired resistance to trabectedin. British journal of cancer 113: 1687-1693 
Compe E, Egly JM (2012) TFIIH: when transcription met DNA repair. Nature reviews Molecular cell biology 
13: 343-354 
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) 
Multiplex genome engineering using CRISPR/Cas systems. Science (New York, NY) 339: 819-823 
Cornu TI, Thibodeau-Beganny S, Guhl E, Alwin S, Eichtinger M, Joung JK, Cathomen T (2008) DNA-binding 
specificity is a major determinant of the activity and toxicity of zinc-finger nucleases. Molecular therapy : the 
journal of the American Society of Gene Therapy 16: 352-358 
Couve-Privat S, Le Bret M, Traiffort E, Queille S, Coulombe J, Bouadjar B, Avril MF, Ruat M, Sarasin A, 
Daya-Grosjean L (2004) Functional analysis of novel sonic hedgehog gene mutations identified in basal cell 
carcinomas from xeroderma pigmentosum patients. Cancer research 64: 3559-3565 
Crick F (1970) Central dogma of molecular biology. Nature 227: 561-563 
Damia G, Imperatori L, Stefanini M, D'Incalci M (1996) Sensitivity of CHO mutant cell lines with specific 
defects in nucleotide excision repair to different anti-cancer agents. International journal of cancer 66: 779-783 
Daya-Grosjean L (2008) Xeroderma pigmentosum and skin cancer. Advances in experimental medicine and 
biology 637: 19-27 
de Buendia PG (1998) Search for DNA repair pathways in Drosophila melanogaster. Mutation research 407: 67-
84 
de Laat WL, Appeldoorn E, Jaspers NG, Hoeijmakers JH (1998a) DNA structural elements required for ERCC1-
XPF endonuclease activity. The Journal of biological chemistry 273: 7835-7842 
de Laat WL, Appeldoorn E, Sugasawa K, Weterings E, Jaspers NG, Hoeijmakers JH (1998b) DNA-binding 
polarity of human replication protein A positions nucleases in nucleotide excision repair. Genes & development 
12: 2598-2609 
de Laat WL, Sijbers AM, Odijk H, Jaspers NG, Hoeijmakers JH (1998c) Mapping of interaction domains 
between human repair proteins ERCC1 and XPF. Nucleic acids research 26: 4146-4152 
De Silva IU, McHugh PJ, Clingen PH, Hartley JA (2000) Defining the roles of nucleotide excision repair and 
recombination in the repair of DNA interstrand cross-links in mammalian cells. Molecular and cellular biology 
20: 7980-7990 
De Silva IU, McHugh PJ, Clingen PH, Hartley JA (2002) Defects in interstrand cross-link uncoupling do not 
account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic acids research 30: 3848-3856 
de Vries E, Coebergh JW (2004) Cutaneous malignant melanoma in Europe. European journal of cancer 
(Oxford, England : 1990) 40: 2355-2366 
Bibliography 
118 
Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, Charpentier E 
(2011) CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471: 602-607 
Deng D, Yan C, Pan X, Mahfouz M, Wang J, Zhu JK, Shi Y, Yan N (2012) Structural basis for sequence-
specific recognition of DNA by TAL effectors. Science (New York, NY) 335: 720-723 
DiGiovanna JJ, Patronas N, Katz D, Abangan D, Kraemer KH (1998) Xeroderma pigmentosum: spinal cord 
astrocytoma with 9-year survival after radiation and isotretinoin therapy. Journal of cutaneous medicine and 
surgery 2: 153-158 
Doherty AJ, Serpell LC, Ponting CP (1996) The helix-hairpin-helix DNA-binding motif: a structural basis for 
non-sequence-specific recognition of DNA. Nucleic acids research 24: 2488-2497 
Dunand-Sauthier I, Hohl M, Thorel F, Jaquier-Gubler P, Clarkson SG, Scharer OD (2005) The spacer region of 
XPG mediates recruitment to nucleotide excision repair complexes and determines substrate specificity. The 
Journal of biological chemistry 280: 7030-7037 
Dupuy A, Valton J, Leduc S, Armier J, Galetto R, Gouble A, Lebuhotel C, Stary A, Paques F, Duchateau P, 
Sarasin A, Daboussi F (2013) Targeted gene therapy of xeroderma pigmentosum cells using meganuclease and 
TALEN. PloS one 8: e78678 
Egly JM, Coin F (2011) A history of TFIIH: two decades of molecular biology on a pivotal transcription/repair 
factor. DNA repair 10: 714-721 
Ehrhart JC, Gosselet FP, Culerrier RM, Sarasin A (2003) UVB-induced mutations in human key gatekeeper 
genes governing signalling pathways and consequences for skin tumourigenesis. Photochemical & 
photobiological sciences : Official journal of the European Photochemistry Association and the European 
Society for Photobiology 2: 825-834 
Emmert S, Leibeling D, Runger TM (2006) Syndromes with genetic instability: model diseases for (skin) 
cancerogenesis. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of 
Dermatology : JDDG 4: 721-731 
Emmert S, Schneider TD, Khan SG, Kraemer KH (2001) The human XPG gene: gene architecture, alternative 
splicing and single nucleotide polymorphisms. Nucleic acids research 29: 1443-1452 
Emmert S, Schon MP, Haenssle HA (2014) Molecular biology of basal and squamous cell carcinomas. Advances 
in experimental medicine and biology 810: 234-252 
Emmert S, Slor H, Busch DB, Batko S, Albert RB, Coleman D, Khan SG, Abu-Libdeh B, DiGiovanna JJ, 
Cunningham BB, Lee MM, Crollick J, Inui H, Ueda T, Hedayati M, Grossman L, Shahlavi T, Cleaver JE, 
Kraemer KH (2002) Relationship of neurologic degeneration to genotype in three xeroderma pigmentosum 
group G patients. The Journal of investigative dermatology 118: 972-982 
Enoiu M, Jiricny J, Scharer OD (2012) Repair of cisplatin-induced DNA interstrand crosslinks by a replication-
independent pathway involving transcription-coupled repair and translesion synthesis. Nucleic acids research 
40: 8953-8964 
Enzlin JH, Scharer OD (2002) The active site of the DNA repair endonuclease XPF-ERCC1 forms a highly 
conserved nuclease motif. The EMBO journal 21: 2045-2053 
Evans E, Fellows J, Coffer A, Wood RD (1997a) Open complex formation around a lesion during nucleotide 
excision repair provides a structure for cleavage by human XPG protein. The EMBO journal 16: 625-638 
Evans E, Moggs JG, Hwang JR, Egly JM, Wood RD (1997b) Mechanism of open complex and dual incision 
formation by human nucleotide excision repair factors. The EMBO journal 16: 6559-6573 
Evers B, Jastrzebski K, Heijmans JP, Grernrum W, Beijersbergen RL, Bernards R (2016) CRISPR knockout 
screening outperforms shRNA and CRISPRi in identifying essential genes.  34: 631-633 
Fadda E (2016) Role of the XPA protein in the NER pathway: A perspective on the function of structural 
disorder in macromolecular assembly. Computational and structural biotechnology journal 14: 78-85 
Bibliography 
119 
Faridounnia M, Wienk H, Kovacic L, Folkers GE, Jaspers NG, Kaptein R, Hoeijmakers JH, Boelens R (2015) 
The Cerebro-oculo-facio-skeletal Syndrome Point Mutation F231L in the ERCC1 DNA Repair Protein Causes 
Dissociation of the ERCC1-XPF Complex. The Journal of biological chemistry 290: 20541-20555 
Fekairi S, Scaglione S, Chahwan C, Taylor ER, Tissier A, Coulon S, Dong MQ, Ruse C, Yates JR, 3rd, Russell 
P, Fuchs RP, McGowan CH, Gaillard PH (2009) Human SLX4 is a Holliday junction resolvase subunit that 
binds multiple DNA repair/recombination endonucleases. Cell 138: 78-89 
Field LL, Bonnevie-Nielsen V, Pociot F, Lu S, Nielsen TB, Beck-Nielsen H (2005) OAS1 splice site 
polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes. Diabetes 54: 
1588-1591 
Fischer JA, Muller-Weeks S, Caradonna S (2004) Proteolytic degradation of the nuclear isoform of uracil-DNA 
glycosylase occurs during the S phase of the cell cycle. DNA repair 3: 505-513 
Fisher LA, Bessho M, Bessho T (2008) Processing of a psoralen DNA interstrand cross-link by XPF-ERCC1 
complex in vitro. The Journal of biological chemistry 283: 1275-1281 
Fisher LA, Bessho M, Wakasugi M, Matsunaga T, Bessho T (2011a) Role of interaction of XPF with RPA in 
nucleotide excision repair. Journal of molecular biology 413: 337-346 
Fisher LA, Samson L, Bessho T (2011b) Removal of reactive oxygen species-induced 3'-blocked ends by XPF-
ERCC1. Chemical research in toxicology 24: 1876-1881 
Fishman-Lobell J, Haber JE (1992) Removal of nonhomologous DNA ends in double-strand break 
recombination: the role of the yeast ultraviolet repair gene RAD1. Science (New York, NY) 258: 480-484 
Fox-Walsh KL, Dou Y, Lam BJ, Hung SP, Baldi PF, Hertel KJ (2005) The architecture of pre-mRNAs affects 
mechanisms of splice-site pairing. Proceedings of the National Academy of Sciences of the United States of 
America 102: 16176-16181 
Friboulet L, Postel-Vinay S, Sourisseau T, Adam J, Stoclin A, Ponsonnailles F, Dorvault N, Commo F, Saulnier 
P, Salome-Desmoulez S, Pottier G, Andre F, Kroemer G, Soria JC, Olaussen KA (2013) ERCC1 function in 
nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. 
Cell cycle (Georgetown, Tex) 12: 3298-3306 
Fridman JS, Lowe SW (2003) Control of apoptosis by p53. Oncogene 22: 9030-9040 
Fujiwara Y, Masutani C, Mizukoshi T, Kondo J, Hanaoka F, Iwai S (1999) Characterization of DNA recognition 
by the human UV-damaged DNA-binding protein. The Journal of biological chemistry 274: 20027-20033 
Gaillard PH, Wood RD (2001) Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision 
repair. Nucleic acids research 29: 872-879 
Gaj T, Gersbach CA, Barbas CF, 3rd (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome 
engineering. Trends in biotechnology 31: 397-405 
Galante PA, Sakabe NJ, Kirschbaum-Slager N, de Souza SJ (2004) Detection and evaluation of intron retention 
events in the human transcriptome. RNA (New York, NY) 10: 757-765 
Gary R, Kim K, Cornelius HL, Park MS, Matsumoto Y (1999) Proliferating cell nuclear antigen facilitates 
excision in long-patch base excision repair. The Journal of biological chemistry 274: 4354-4363 
Gary R, Ludwig DL, Cornelius HL, MacInnes MA, Park MS (1997) The DNA repair endonuclease XPG binds 
to proliferating cell nuclear antigen (PCNA) and shares sequence elements with the PCNA-binding regions of 
FEN-1 and cyclin-dependent kinase inhibitor p21. The Journal of biological chemistry 272: 24522-24529 
Gassmann M, Grenacher B, Rohde B, Vogel J (2009) Quantifying Western blots: pitfalls of densitometry. 
Electrophoresis 30: 1845-1855 
Gentile F, Tuszynski JA, Barakat KH (2016) New design of nucleotide excision repair (NER) inhibitors for 
combination cancer therapy. Journal of molecular graphics & modelling 65: 71-82 
Bibliography 
120 
Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good 
P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, 
Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, 
Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant 
TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami 
K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei 
CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, 
Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, 
Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard 
GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield 
YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus 
DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak 
S, Malek J (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene 
Collection (MGC). Genome research 14: 2121-2127 
Gerhard R, Carvalho A, Carneiro V, Bento RS, Uemura G, Gomes M, Albergaria A, Schmitt F (2013) 
Clinicopathological significance of ERCC1 expression in breast cancer. Pathology, research and practice 209: 
331-336 
Gervais V, Lamour V, Jawhari A, Frindel F, Wasielewski E, Dubaele S, Egly JM, Thierry JC, Kieffer B, 
Poterszman A (2004) TFIIH contains a PH domain involved in DNA nucleotide excision repair. Nature 
structural & molecular biology 11: 616-622 
Giannattasio M, Follonier C, Tourriere H, Puddu F, Lazzaro F, Pasero P, Lopes M, Plevani P, Muzi-Falconi M 
(2010) Exo1 competes with repair synthesis, converts NER intermediates to long ssDNA gaps, and promotes 
checkpoint activation. Molecular cell 40: 50-62 
Giannelli F, Avery J, Polani PE, Terrell C, Giammusso V (1981) Xeroderma Pigmentosum and 
medulloblastoma: chromosomal damage to lymphocytes during radiotherapy. Radiation research 88: 194-208 
Giglia-Mari G, Zotter A, Vermeulen W (2011) DNA damage response. Cold Spring Harbor perspectives in 
biology 3: a000745 
Giglia G, Dumaz N, Drougard C, Avril MF, Daya-Grosjean L, Sarasin A (1998) p53 mutations in skin and 
internal tumors of xeroderma pigmentosum patients belonging to the complementation group C. Cancer 
research 58: 4402-4409 
Gilljam KM, Muller R, Liabakk NB, Otterlei M (2012) Nucleotide excision repair is associated with the 
replisome and its efficiency depends on a direct interaction between XPA and PCNA. PloS one 7: e49199 
Goh AM, Coffill CR, Lane DP (2011) The role of mutant p53 in human cancer. The Journal of pathology 223: 
116-126 
Graveley BR (2001) Alternative splicing: increasing diversity in the proteomic world. Trends in genetics : TIG 
17: 100-107 
Greenblatt MS, Beaudet JG, Gump JR, Godin KS, Trombley L, Koh J, Bond JP (2003) Detailed computational 
study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the 
functional consequences of allelic variants. Oncogene 22: 1150-1163 
Gregg SQ, Robinson AR, Niedernhofer LJ (2011) Physiological consequences of defects in ERCC1-XPF DNA 
repair endonuclease. DNA repair 10: 781-791 
Guervilly JH, Takedachi A, Naim V, Scaglione S, Chawhan C, Lovera Y, Despras E, Kuraoka I, Kannouche P, 
Rosselli F, Gaillard PH (2015) The SLX4 complex is a SUMO E3 ligase that impacts on replication stress 
outcome and genome stability. Molecular cell 57: 123-137 
Gupta AK, Anderson TF (1987) Psoralen photochemotherapy. Journal of the American Academy of 
Dermatology 17: 703-734 
Guzder SN, Torres-Ramos C, Johnson RE, Haracska L, Prakash L, Prakash S (2004) Requirement of yeast 
Rad1-Rad10 nuclease for the removal of 3'-blocked termini from DNA strand breaks induced by reactive oxygen 
species. Genes & development 18: 2283-2291 
Bibliography 
121 
Habraken Y, Sung P, Prakash L, Prakash S (1993) Yeast excision repair gene RAD2 encodes a single-stranded 
DNA endonuclease. Nature 366: 365-368 
Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer 
development. Science (New York, NY) 319: 1352-1355 
Hanada K, Budzowska M, Modesti M, Maas A, Wyman C, Essers J, Kanaar R (2006) The structure-specific 
endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks. The 
EMBO journal 25: 4921-4932 
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70 
Hart T, Brown KR, Sircoulomb F, Rottapel R, Moffat J (2014) Measuring error rates in genomic perturbation 
screens: gold standards for human functional genomics. Molecular systems biology 10: 733 
Hayakawa H, Ishizaki K, Inoue M, Yagi T, Sekiguchi M, Takebe H (1981) Repair of ultraviolet radiation 
damage in xeroderma pigmentosum cells belonging to complementation group F. Mutation research 80: 381-
388 
Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE (2011) ERCC1 expression and outcomes in 
head and neck cancer treated with concurrent cisplatin and radiation. Anticancer research 31: 4135-4139 
Hearst JE (1981) Psoralen photochemistry and nucleic acid structure. The Journal of investigative dermatology 
77: 39-44 
Hebra F, Kaposi M (1874) On diseases of the skin including exanthemata. The New Sydenham Society 61: 252-
258 
Hecht SM (2000) Bleomycin: new perspectives on the mechanism of action. Journal of natural products 63: 
158-168 
Herskowitz I (1987) Functional inactivation of genes by dominant negative mutations. Nature 329: 219-222 
Heyer WD (2004) Recombination: Holliday junction resolution and crossover formation. Current biology : CB 
14: R56-58 
Hirai Y, Kodama Y, Moriwaki S, Noda A, Cullings HM, Macphee DG, Kodama K, Mabuchi K, Kraemer KH, 
Land CE, Nakamura N (2006) Heterozygous individuals bearing a founder mutation in the XPA DNA repair 
gene comprise nearly 1% of the Japanese population. Mutation research 601: 171-178 
Hodskinson MR, Silhan J, Crossan GP, Garaycoechea JI, Mukherjee S, Johnson CM, Scharer OD, Patel KJ 
(2014) Mouse SLX4 is a tumor suppressor that stimulates the activity of the nuclease XPF-ERCC1 in DNA 
crosslink repair. Molecular cell 54: 472-484 
Hoeijmakers JH (2009) DNA damage, aging, and cancer. The New England journal of medicine 361: 1475-1485 
Hohl M, Thorel F, Clarkson SG, Scharer OD (2003) Structural determinants for substrate binding and catalysis 
by the structure-specific endonuclease XPG. The Journal of biological chemistry 278: 19500-19508 
Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science (New York, 
NY) 253: 49-53 
Honda A, Valogne Y, Bou Nader M, Brechot C, Faivre J (2012) An intron-retaining splice variant of human 
cyclin A2, expressed in adult differentiated tissues, induces a G1/S cell cycle arrest in vitro. PloS one 7: e39249 
Hoy CA, Thompson LH, Mooney CL, Salazar EP (1985) Defective DNA cross-link removal in Chinese hamster 
cell mutants hypersensitive to bifunctional alkylating agents. Cancer research 45: 1737-1743 
Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, Cradick 
TJ, Marraffini LA, Bao G, Zhang F (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nature 
biotechnology 31: 827-832 
Bibliography 
122 
Hu W, Pan J, Zhao P, Yang G, Yang S (2014) Genetic polymorphisms in XPG could predict clinical outcome of 
platinum-based chemotherapy for advanced non-small cell lung cancer. Tumour biology : the journal of the 
International Society for Oncodevelopmental Biology and Medicine 35: 5561-5567 
Huen MS, Chen J (2008) The DNA damage response pathways: at the crossroad of protein modifications. Cell 
research 18: 8-16 
Inciarte MR, Lazaro JM, Salas M, Vinuela E (1976) Physical map of bacteriophage phi29 DNA. Virology 74: 
314-323 
Ito S, Kuraoka I, Chymkowitch P, Compe E, Takedachi A, Ishigami C, Coin F, Egly JM, Tanaka K (2007) XPG 
stabilizes TFIIH, allowing transactivation of nuclear receptors: implications for Cockayne syndrome in XP-G/CS 
patients. Molecular cell 26: 231-243 
Ivanov EL, Haber JE (1995) RAD1 and RAD10, but not other excision repair genes, are required for double-
strand break-induced recombination in Saccharomyces cerevisiae. Molecular and cellular biology 15: 2245-
2251 
Iwao M, Morisaki H, Morisaki T (2004) Single-nucleotide polymorphism g.1548G > A (E469K) in human 
ICAM-1 gene affects mRNA splicing pattern and TPA-induced apoptosis. Biochemical and biophysical research 
communications 317: 729-735 
Jaakkola E, Mustonen A, Olsen P, Miettinen S, Savuoja T, Raams A, Jaspers NG, Shao H, Wu BL, Ignatius J 
(2010) ERCC6 founder mutation identified in Finnish patients with COFS syndrome. Clinical genetics 78: 541-
547 
Jamison SF, Crow A, Garcia-Blanco MA (1992) The spliceosome assembly pathway in mammalian extracts. 
Molecular and cellular biology 12: 4279-4287 
Jaspers NG, Raams A, Silengo MC, Wijgers N, Niedernhofer LJ, Robinson AR, Giglia-Mari G, Hoogstraten D, 
Kleijer WJ, Hoeijmakers JH, Vermeulen W (2007) First reported patient with human ERCC1 deficiency has 
cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental 
failure. American journal of human genetics 80: 457-466 
Jeppesen DK, Bohr VA, Stevnsner T (2011) DNA repair deficiency in neurodegeneration. Progress in 
neurobiology 94: 166-200 
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-
guided DNA endonuclease in adaptive bacterial immunity. Science (New York, NY) 337: 816-821 
Jones JC, Zhen WP, Reed E, Parker RJ, Sancar A, Bohr VA (1991) Gene-specific formation and repair of 
cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. The Journal of biological 
chemistry 266: 7101-7107 
Jordheim LP, Barakat KH, Heinrich-Balard L, Matera EL, Cros-Perrial E, Bouledrak K, El Sabeh R, Perez-
Pineiro R, Wishart DS, Cohen R, Tuszynski J, Dumontet C (2013) Small molecule inhibitors of ERCC1-XPF 
protein-protein interaction synergize alkylating agents in cancer cells. Molecular pharmacology 84: 12-24 
Karran P (2000) DNA double strand break repair in mammalian cells. Current opinion in genetics & 
development 10: 144-150 
Kashiyama K, Nakazawa Y, Pilz DT, Guo C, Shimada M, Sasaki K, Fawcett H, Wing JF, Lewin SO, Carr L, Li 
TS, Yoshiura K, Utani A, Hirano A, Yamashita S, Greenblatt D, Nardo T, Stefanini M, McGibbon D, Sarkany 
R, Fassihi H, Takahashi Y, Nagayama Y, Mitsutake N, Lehmann AR, Ogi T (2013) Malfunction of nuclease 
ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, 
and Fanconi anemia. American journal of human genetics 92: 807-819 
Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432: 316-323 
Khan SG, Metter EJ, Tarone RE, Bohr VA, Grossman L, Hedayati M, Bale SJ, Emmert S, Kraemer KH (2000) 




Khan SG, Muniz-Medina V, Shahlavi T, Baker CC, Inui H, Ueda T, Emmert S, Schneider TD, Kraemer KH 
(2002) The human XPC DNA repair gene: arrangement, splice site information content and influence of a single 
nucleotide polymorphism in a splice acceptor site on alternative splicing and function. Nucleic acids research 
30: 3624-3631 
Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR, Jefferson RA (1997) 
Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in 
different cell types. Human molecular genetics 6: 2011-2019 
Kim JS, Lee HJ, Carroll D (2010) Genome editing with modularly assembled zinc-finger nucleases. Nature 
methods 7: 91; author reply 91-92 
Kim Y, Kweon J, Kim A, Chon JK, Yoo JY, Kim HJ, Kim S, Lee C, Jeong E, Chung E, Kim D, Lee MS, Go 
EM, Song HJ, Kim H, Cho N, Bang D, Kim S, Kim JS (2013) A library of TAL effector nucleases spanning the 
human genome. Nature biotechnology 31: 251-258 
Kim YG, Cha J, Chandrasegaran S (1996) Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage 
domain. Proceedings of the National Academy of Sciences of the United States of America 93: 1156-1160 
Kisker C, Kuper J, Van Houten B (2013) Prokaryotic nucleotide excision repair. Cold Spring Harbor 
perspectives in biology 5: a012591 
Kleijer WJ, Laugel V, Berneburg M, Nardo T, Fawcett H, Gratchev A, Jaspers NG, Sarasin A, Stefanini M, 
Lehmann AR (2008) Incidence of DNA repair deficiency disorders in western Europe: Xeroderma 
pigmentosum, Cockayne syndrome and trichothiodystrophy. DNA repair 7: 744-750 
Klein Douwel D, Boonen RA, Long DT, Szypowska AA, Raschle M, Walter JC, Knipscheer P (2014) XPF-
ERCC1 acts in Unhooking DNA interstrand crosslinks in cooperation with FANCD2 and FANCP/SLX4. 
Molecular cell 54: 460-471 
Klungland A, Hoss M, Gunz D, Constantinou A, Clarkson SG, Doetsch PW, Bolton PH, Wood RD, Lindahl T 
(1999) Base excision repair of oxidative DNA damage activated by XPG protein. Molecular cell 3: 33-42 
Knauf JA, Pendergrass SH, Marrone BL, Strniste GF, MacInnes MA, Park MS (1996) Multiple nuclear 
localization signals in XPG nuclease. Mutation research 363: 67-75 
Kobayashi N, Katsumi S, Imoto K, Nakagawa A, Miyagawa S, Furumura M, Mori T (2001) Quantitation and 
visualization of ultraviolet-induced DNA damage using specific antibodies: application to pigment cell biology. 
Pigment cell research 14: 94-102 
Kottemann MC, Smogorzewska A (2013) Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. 
Nature 493: 356-363 
Kozak M (1983) Comparison of initiation of protein synthesis in procaryotes, eucaryotes, and organelles. 
Microbiological reviews 47: 1-45 
Kraemer KH, Coon HG, Petinga RA, Barrett SF, Rahe AE, Robbins JH (1975a) Genetic heterogeneity in 
xeroderma pigmentosum: complementation groups and their relationship to DNA repair rates. Proceedings of the 
National Academy of Sciences of the United States of America 72: 59-63 
Kraemer KH, De Weerd-Kastelein EA, Robbins JH, Keijzer W, Barrett SF, Petinga RA, Bootsma D (1975b) 
Five complementation groups in xeroderma pigmentosum. Mutation research 33: 327-340 
Kraemer KH, Lee MM, Andrews AD, Lambert WC (1994) The role of sunlight and DNA repair in melanoma 
and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Archives of dermatology 130: 1018-
1021 
Kraemer KH, Lee MM, Scotto J (1987) Xeroderma pigmentosum. Cutaneous, ocular, and neurologic 
abnormalities in 830 published cases. Archives of dermatology 123: 241-250 
Kraemer KH, Patronas NJ, Schiffmann R, Brooks BP, Tamura D, DiGiovanna JJ (2007) Xeroderma 
pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. 
Neuroscience 145: 1388-1396 
Bibliography 
124 
Kraemer KH, Slor H (1985) Xeroderma pigmentosum. Clinics in dermatology 3: 33-69 
Krasikova YS, Rechkunova NI, Maltseva EA, Craescu CT, Petruseva IO, Lavrik OI (2012) Influence of centrin 
2 on the interaction of nucleotide excision repair factors with damaged DNA. Biochemistry Biokhimiia 77: 346-
353 
Krasikova YS, Rechkunova NI, Maltseva EA, Petruseva IO, Silnikov VN, Zatsepin TS, Oretskaya TS, Scharer 
OD, Lavrik OI (2008) Interaction of nucleotide excision repair factors XPC-HR23B, XPA, and RPA with 
damaged DNA. Biochemistry Biokhimiia 73: 886-896 
Krawczak M, Reiss J, Cooper DN (1992) The mutational spectrum of single base-pair substitutions in mRNA 
splice junctions of human genes: causes and consequences. Human genetics 90: 41-54 
Kuraoka I, Kobertz WR, Ariza RR, Biggerstaff M, Essigmann JM, Wood RD (2000) Repair of an interstrand 
DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. The Journal of biological chemistry 
275: 26632-26636 
Laugel V (1993) Cockayne Syndrome. In GeneReviews(R), Pagon RA, Adam MP, Ardinger HH, Wallace SE, 
Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K (eds). Seattle (WA): 
University of Washington, Seattle University of Washington, Seattle. GeneReviews is a registered trademark of 
the University of Washington, Seattle.  
Le Hir H, Nott A, Moore MJ (2003) How introns influence and enhance eukaryotic gene expression. Trends in 
biochemical sciences 28: 215-220 
Le May N, Fradin D, Iltis I, Bougneres P, Egly JM (2012) XPG and XPF endonucleases trigger chromatin 
looping and DNA demethylation for accurate expression of activated genes. Molecular cell 47: 622-632 
Lee JH, Park CJ, Arunkumar AI, Chazin WJ, Choi BS (2003) NMR study on the interaction between RPA and 
DNA decamer containing cis-syn cyclobutane pyrimidine dimer in the presence of XPA: implication for damage 
verification and strand-specific dual incision in nucleotide excision repair. Nucleic acids research 31: 4747-4754 
Lehmann AR, McGibbon D, Stefanini M (2011) Xeroderma pigmentosum. Orphanet journal of rare diseases 6: 
70 
Lehmann J (2013) Characterization of novel Xeroderma pigmentosum Group G spontaneous mRNA 
splicevariants. [Master thesis]; Department of Dermatology, Venereology and Allergology, Georg-August-
University Goettingen.  
Lehmann J, Schubert S, Emmert S (2014a) Xeroderma pigmentosum: diagnostic procedures, interdisciplinary 
patient care, and novel therapeutic approaches. Journal der Deutschen Dermatologischen Gesellschaft = Journal 
of the German Society of Dermatology : JDDG 12: 867-872 
Lehmann J, Schubert S, Schafer A, Apel A, Laspe P, Schiller S, Ohlenbusch A, Gratchev A, Emmert S (2014b) 
An unusual mutation in the XPG gene leads to an internal in-frame deletion and a XP/CS complex phenotype. 
The British journal of dermatology 171: 903-905 
Lehmann J, Schubert S, Schafer A, Laspe P, Haenssle HA, Ohlenbusch A, Gratchev A, Emmert S (2015) A 
novel mutation in the XPA gene results in two truncated protein variants and leads to a severe XP/neurological 
symptoms phenotype. Journal of the European Academy of Dermatology and Venereology : JEADV 29: 2479-
2482 
Lehmann J, Seebode C, Smolorz S, Schubert S, Emmert S (2017) XPF knockout via CRISPR/Cas9 reveals that 
ERCC1 is retained in the cytoplasm without its heterodimer partner XPF. Cellular and Molecular Life Sciences 
doi: 10.1007/s00018-017-2455-7 
Li C, Yin M, Wang LE, Amos CI, Zhu D, Lee JE, Gershenwald JE, Grimm EA, Wei Q (2013a) Polymorphisms 
of nucleotide excision repair genes predict melanoma survival. The Journal of investigative dermatology 133: 
1813-1821 
Li J, Zhang Y, Chen KL, Shan QW, Wang YP, Liang Z, Gao CX (2013b) [CRISPR/Cas: a novel way of RNA-
guided genome editing]. Yi chuan = Hereditas 35: 1265-1273 
Bibliography 
125 
Li L, Peterson CA, Lu X, Legerski RJ (1995) Mutations in XPA that prevent association with ERCC1 are 
defective in nucleotide excision repair. Molecular and cellular biology 15: 1993-1998 
Lindsey-Boltz LA, Kemp MG, Reardon JT, DeRocco V, Iyer RR, Modrich P, Sancar A (2014) Coupling of 
human DNA excision repair and the DNA damage checkpoint in a defined in vitro system. The Journal of 
biological chemistry 289: 5074-5082 
Lippke JA, Gordon LK, Brash DE, Haseltine WA (1981) Distribution of UV light-induced damage in a defined 
sequence of human DNA: detection of alkaline-sensitive lesions at pyrimidine nucleoside-cytidine sequences. 
Proceedings of the National Academy of Sciences of the United States of America 78: 3388-3392 
Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, Alt FW (2005) DNA repair, genome stability, 
and aging. Cell 120: 497-512 
Ma JL, Kim EM, Haber JE, Lee SE (2003) Yeast Mre11 and Rad1 proteins define a Ku-independent mechanism 
to repair double-strand breaks lacking overlapping end sequences. Molecular and cellular biology 23: 8820-
8828 
MacInnes MA, Mudgett JS (1990) Cloning of the functional human excision repair gene ERCC-5: potential gene 
regulatory features conserved with other human repair genes. Progress in clinical and biological research 340a: 
265-274 
Madan V, Lear JT, Szeimies RM (2010) Non-melanoma skin cancer. Lancet (London, England) 375: 673-685 
Mak AN, Bradley P, Cernadas RA, Bogdanove AJ, Stoddard BL (2012) The crystal structure of TAL effector 
PthXo1 bound to its DNA target. Science (New York, NY) 335: 716-719 
Marfori M, Mynott A, Ellis JJ, Mehdi AM, Saunders NF, Curmi PM, Forwood JK, Boden M, Kobe B (2011) 
Molecular basis for specificity of nuclear import and prediction of nuclear localization. Biochimica et biophysica 
acta 1813: 1562-1577 
Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y (2008) RNA-seq: an assessment of technical 
reproducibility and comparison with gene expression arrays. Genome research 18: 1509-1517 
Matlin AJ, Clark F, Smith CW (2005) Understanding alternative splicing: towards a cellular code. Nature 
reviews Molecular cell biology 6: 386-398 
Matsumura Y, Ananthaswamy HN (2002) Short-term and long-term cellular and molecular events following UV 
irradiation of skin: implications for molecular medicine. Expert reviews in molecular medicine 4: 1-22 
Matsumura Y, Nishigori C, Yagi T, Imamura S, Takebe H (1998) Characterization of molecular defects in 
xeroderma pigmentosum group F in relation to its clinically mild symptoms. Human molecular genetics 7: 969-
974 
Matsunaga T, Park CH, Bessho T, Mu D, Sancar A (1996) Replication protein A confers structure-specific 
endonuclease activities to the XPF-ERCC1 and XPG subunits of human DNA repair excision nuclease. The 
Journal of biological chemistry 271: 11047-11050 
McHugh PJ, Spanswick VJ, Hartley JA (2001) Repair of DNA interstrand crosslinks: molecular mechanisms and 
clinical relevance. The Lancet Oncology 2: 483-490 
McManus CJ, Graveley BR (2011) RNA structure and the mechanisms of alternative splicing. Current opinion 
in genetics & development 21: 373-379 
McNeil EM, Melton DW (2012) DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to 
overcome chemoresistance in cancer therapy. Nucleic acids research 40: 9990-10004 
McVey M, Lee SE (2008) MMEJ repair of double-strand breaks (director's cut): deleted sequences and 
alternative endings. Trends in genetics : TIG 24: 529-538 
McWhir J, Selfridge J, Harrison DJ, Squires S, Melton DW (1993) Mice with DNA repair gene (ERCC-1) 




Melis JP, van Steeg H, Luijten M (2013) Oxidative DNA damage and nucleotide excision repair. Antioxidants & 
redox signaling 18: 2409-2419 
Mellon I, Spivak G, Hanawalt PC (1987) Selective removal of transcription-blocking DNA damage from the 
transcribed strand of the mammalian DHFR gene. Cell 51: 241-249 
Melnikova VO, Ananthaswamy HN (2005) Cellular and molecular events leading to the development of skin 
cancer. Mutation research 571: 91-106 
Messaoud O, Ben Rekaya M, Kefi R, Chebel S, Boughammoura-Bouatay A, Bel Hadj Ali H, Gouider-Khouja N, 
Zili J, Frih-Ayed M, Mokhtar I, Abdelhak S, Zghal M (2010) Identification of a primarily neurological 
phenotypic expression of xeroderma pigmentosum complementation group A in a Tunisian family. The British 
journal of dermatology 162: 883-886 
Michaels JE, Schimmel P, Shiba K, Miller WT (1996) Dominant negative inhibition by fragments of a 
monomeric enzyme. Proceedings of the National Academy of Sciences of the United States of America 93: 
14452-14455 
Milne GT, Weaver DT (1993) Dominant negative alleles of RAD52 reveal a DNA repair/recombination complex 
including Rad51 and Rad52. Genes & development 7: 1755-1765 
Mitchell DL, Nairn RS (1989) The biology of the (6-4) photoproduct. Photochemistry and photobiology 49: 
805-819 
Moggs JG, Yarema KJ, Essigmann JM, Wood RD (1996) Analysis of incision sites produced by human cell 
extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct. 
The Journal of biological chemistry 271: 7177-7186 
Mogi S, Oh DH (2006) gamma-H2AX formation in response to interstrand crosslinks requires XPF in human 
cells. DNA repair 5: 731-740 
Moldovan GL, D'Andrea AD (2009) How the fanconi anemia pathway guards the genome. Annual review of 
genetics 43: 223-249 
Moriwaki S, Stefanini M, Lehmann AR, Hoeijmakers JH, Robbins JH, Rapin I, Botta E, Tanganelli B, 
Vermeulen W, Broughton BC, Kraemer KH (1996) DNA repair and ultraviolet mutagenesis in cells from a new 
patient with xeroderma pigmentosum group G and cockayne syndrome resemble xeroderma pigmentosum cells. 
The Journal of investigative dermatology 107: 647-653 
Moriwaki S, Yamashita Y, Nakamura S, Fujita D, Kohyama J, Takigawa M, Ohmichi M (2012) Prenatal 
diagnosis of xeroderma pigmentosum group A in Japan. The Journal of dermatology 39: 516-519 
Moser J, Kool H, Giakzidis I, Caldecott K, Mullenders LH, Fousteri MI (2007) Sealing of chromosomal DNA 
nicks during nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific 
manner. Molecular cell 27: 311-323 
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and 
cytotoxicity assays. Journal of immunological methods 65: 55-63 
Mu D, Bessho T, Nechev LV, Chen DJ, Harris TM, Hearst JE, Sancar A (2000) DNA interstrand cross-links 
induce futile repair synthesis in mammalian cell extracts. Molecular and cellular biology 20: 2446-2454 
Mu D, Hsu DS, Sancar A (1996) Reaction mechanism of human DNA repair excision nuclease. The Journal of 
biological chemistry 271: 8285-8294 
Mu D, Sancar A (1997) Model for XPC-independent transcription-coupled repair of pyrimidine dimers in 
humans. The Journal of biological chemistry 272: 7570-7573 
Mulkidjanian AY, Bychkov AY, Dibrova DV, Galperin MY, Koonin EV (2012) Origin of first cells at 
terrestrial, anoxic geothermal fields. Proceedings of the National Academy of Sciences of the United States of 
America 109: E821-830 
Bibliography 
127 
Munoz IM, Hain K, Declais AC, Gardiner M, Toh GW, Sanchez-Pulido L, Heuckmann JM, Toth R, Macartney 
T, Eppink B, Kanaar R, Ponting CP, Lilley DM, Rouse J (2009) Coordination of structure-specific nucleases by 
human SLX4/BTBD12 is required for DNA repair. Molecular cell 35: 116-127 
Munoz P, Blanco R, Flores JM, Blasco MA (2005) XPF nuclease-dependent telomere loss and increased DNA 
damage in mice overexpressing TRF2 result in premature aging and cancer. Nature genetics 37: 1063-1071 
Murray D, Macann A, Hanson J, Rosenberg E (1996) ERCC1/ERCC4 5'-endonuclease activity as a determinant 
of hypoxic cell radiosensitivity. International journal of radiation biology 69: 319-327 
Nakai K, Sakamoto H (1994) Construction of a novel database containing aberrant splicing mutations of 
mammalian genes. Gene 141: 171-177 
Newby MI, Greenbaum NL (2002) Sculpting of the spliceosomal branch site recognition motif by a conserved 
pseudouridine. Nature structural biology 9: 958-965 
Niedernhofer LJ, Essers J, Weeda G, Beverloo B, de Wit J, Muijtjens M, Odijk H, Hoeijmakers JH, Kanaar R 
(2001) The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic 
stem cells. The EMBO journal 20: 6540-6549 
Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E, Odijk H, Oostendorp R, 
Ahmad A, van Leeuwen W, Theil AF, Vermeulen W, van der Horst GT, Meinecke P, Kleijer WJ, Vijg J, Jaspers 
NG, Hoeijmakers JH (2006) A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph 
axis. Nature 444: 1038-1043 
Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NG, Beverloo 
HB, Hoeijmakers JH, Kanaar R (2004) The structure-specific endonuclease Ercc1-Xpf is required to resolve 
DNA interstrand cross-link-induced double-strand breaks. Molecular and cellular biology 24: 5776-5787 
Nishigori C, Zghal M, Yagi T, Imamura S, Komoun MR, Takebe H (1993) High prevalence of the point 
mutation in exon 6 of the xeroderma pigmentosum group A-complementing (XPAC) gene in xeroderma 
pigmentosum group A patients in Tunisia. American journal of human genetics 53: 1001-1006 
Nouspikel T (2009) DNA repair in mammalian cells : Nucleotide excision repair: variations on versatility. 
Cellular and molecular life sciences : CMLS 66: 994-1009 
Nowotny M, Gaur V (2016) Structure and mechanism of nucleases regulated by SLX4. Current opinion in 
structural biology 36: 97-105 
O'Donovan A, Davies AA, Moggs JG, West SC, Wood RD (1994) XPG endonuclease makes the 3' incision in 
human DNA nucleotide excision repair. Nature 371: 432-435 
Ogi T, Limsirichaikul S, Overmeer RM, Volker M, Takenaka K, Cloney R, Nakazawa Y, Niimi A, Miki Y, 
Jaspers NG, Mullenders LH, Yamashita S, Fousteri MI, Lehmann AR (2010) Three DNA polymerases, recruited 
by different mechanisms, carry out NER repair synthesis in human cells. Molecular cell 37: 714-727 
Okinaka RT, Perez-Castro AV, Sena A, Laubscher K, Strniste GF, Park MS, Hernandez R, MacInnes MA, 
Kraemer KH (1997) Heritable genetic alterations in a xeroderma pigmentosum group G/Cockayne syndrome 
pedigree. Mutation research 385: 107-114 
Orelli B, McClendon TB, Tsodikov OV, Ellenberger T, Niedernhofer LJ, Scharer OD (2010) The XPA-binding 
domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways. The Journal of 
biological chemistry 285: 3705-3712 
Oren M (1999) Regulation of the p53 tumor suppressor protein. The Journal of biological chemistry 274: 36031-
36034 
Overmeer RM, Moser J, Volker M, Kool H, Tomkinson AE, van Zeeland AA, Mullenders LH, Fousteri M 
(2011) Replication protein A safeguards genome integrity by controlling NER incision events. The Journal of 
cell biology 192: 401-415 
Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ (2008) Deep surveying of alternative splicing complexity in the 
human transcriptome by high-throughput sequencing. Nature genetics 40: 1413-1415 
Bibliography 
128 
Park CH, Mu D, Reardon JT, Sancar A (1995) The general transcription-repair factor TFIIH is recruited to the 
excision repair complex by the XPA protein independent of the TFIIE transcription factor. The Journal of 
biological chemistry 270: 4896-4902 
Pellagatti A, Dolatshad H, Valletta S, Boultwood J (2015) Application of CRISPR/Cas9 genome editing to the 
study and treatment of disease. Archives of toxicology 89: 1023-1034 
Pena SD, Shokeir MH (1974) Syndrome of camptodactyly, multiple ankyloses, facial anomalies, and pulmonary 
hypoplasia: a lethal condition. The Journal of pediatrics 85: 373-375 
Perez-Oliva AB, Lachaud C, Szyniarowski P, Munoz I, Macartney T, Hickson I, Rouse J, Alessi DR (2015) 
USP45 deubiquitylase controls ERCC1-XPF endonuclease-mediated DNA damage responses. The EMBO 
journal 34: 326-343 
Pessa HK, Will CL, Meng X, Schneider C, Watkins NJ, Perala N, Nymark M, Turunen JJ, Luhrmann R, 
Frilander MJ (2008) Minor spliceosome components are predominantly localized in the nucleus. Proceedings of 
the National Academy of Sciences of the United States of America 105: 8655-8660 
Pizzolato J, Mukherjee S, Scharer OD, Jiricny J (2015) FANCD2-associated nuclease 1, but not exonuclease 1 or 
flap endonuclease 1, is able to unhook DNA interstrand cross-links in vitro. The Journal of biological chemistry 
290: 22602-22611 
Pommier Y, Leo E, Zhang H, Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and 
antibacterial drugs. Chemistry & biology 17: 421-433 
Query CC, Moore MJ, Sharp PA (1994) Branch nucleophile selection in pre-mRNA splicing: evidence for the 
bulged duplex model. Genes & development 8: 587-597 
Rahn JJ, Adair GM, Nairn RS (2010) Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair. 
Environmental and molecular mutagenesis 51: 567-581 
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-
Cas9 system. Nature protocols 8: 2281-2308 
Rastogi RP, Richa, Kumar A, Tyagi MB, Sinha RP (2010) Molecular mechanisms of ultraviolet radiation-
induced DNA damage and repair. Journal of nucleic acids 2010: 592980 
Riedl T, Hanaoka F, Egly JM (2003) The comings and goings of nucleotide excision repair factors on damaged 
DNA. The EMBO journal 22: 5293-5303 
Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nature 
reviews Molecular cell biology 9: 402-412 
Roca X, Olson AJ, Rao AR, Enerly E, Kristensen VN, Borresen-Dale AL, Andresen BS, Krainer AR, 
Sachidanandam R (2008) Features of 5'-splice-site efficiency derived from disease-causing mutations and 
comparative genomics. Genome research 18: 77-87 
Rogers J (1985) Exon shuffling and intron insertion in serine protease genes. Nature 315: 458-459 
Rothfuss A, Grompe M (2004) Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA 
double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Molecular and cellular 
biology 24: 123-134 
Sancar A, Rupp WD (1983) A novel repair enzyme: UVRABC excision nuclease of Escherichia coli cuts a DNA 
strand on both sides of the damaged region. Cell 33: 249-260 
Sargent RG, Meservy JL, Perkins BD, Kilburn AE, Intody Z, Adair GM, Nairn RS, Wilson JH (2000) Role of 
the nucleotide excision repair gene ERCC1 in formation of recombination-dependent rearrangements in 
mammalian cells. Nucleic acids research 28: 3771-3778 
Sargent RG, Rolig RL, Kilburn AE, Adair GM, Wilson JH, Nairn RS (1997) Recombination-dependent deletion 
formation in mammalian cells deficient in the nucleotide excision repair gene ERCC1. Proceedings of the 
National Academy of Sciences of the United States of America 94: 13122-13127 
Bibliography 
129 
Saridaki Z, Liloglou T, Zafiropoulos A, Koumantaki E, Zoras O, Spandidos DA (2003) Mutational analysis of 
CDKN2A genes in patients with squamous cell carcinoma of the skin. The British journal of dermatology 148: 
638-648 
Satokata I, Tanaka K, Miura N, Miyamoto I, Satoh Y, Kondo S, Okada Y (1990) Characterization of a splicing 
mutation in group A xeroderma pigmentosum. Proceedings of the National Academy of Sciences of the United 
States of America 87: 9908-9912 
Schafer A, Schubert S, Gratchev A, Seebode C, Apel A, Laspe P, Hofmann L, Ohlenbusch A, Mori T, 
Kobayashi N, Schurer A, Schon MP, Emmert S (2013) Characterization of three XPG-defective patients 
identifies three missense mutations that impair repair and transcription. The Journal of investigative dermatology 
133: 1841-1849 
Scharer OD (2008) XPG: its products and biological roles. Advances in experimental medicine and biology 637: 
83-92 
Scharer OD (2013) Nucleotide excision repair in eukaryotes. Cold Spring Harbor perspectives in biology 5: 
a012609 
Scherly D, Nouspikel T, Corlet J, Ucla C, Bairoch A, Clarkson SG (1993) Complementation of the DNA repair 
defect in xeroderma pigmentosum group G cells by a human cDNA related to yeast RAD2. Nature 363: 182-185 
Schubert S (2014) Characterization of the multifunctional XPG protein during Nucleotide-excision-repair. 
[Doctoral thesis]; Department of Dermatology, Venereology and Allergology, Georg-August-University 
Goettingen 
Schubert S, Emmert S (2016) Xeroderma Pigmentosum and related diseases. In: Harper’s Textbook of Pediatric 
Dermatology: Chapter 29.1  
Schubert S, Lehmann J, Kalfon L, Slor H, Falik-Zaccai TC, Emmert S (2014) Clinical utility gene card for: 
Xeroderma pigmentosum. European journal of human genetics : EJHG 22 doi: 10.1038/ejhg.2013.233 
Seebode C, Lehmann J, Emmert S (2016) Photocarcinogenesis and Skin Cancer Prevention Strategies. 
Anticancer research 36: 1371-1378 
Seibel NM, Eljouni J, Nalaskowski MM, Hampe W (2007) Nuclear localization of enhanced green fluorescent 
protein homomultimers. Analytical biochemistry 368: 95-99 
Seluanov A, Mao Z, Gorbunova V (2010) Analysis of DNA double-strand break (DSB) repair in mammalian 
cells. Journal of visualized experiments : JoVE 
Sengerova B, Wang AT, McHugh PJ (2011) Orchestrating the nucleases involved in DNA interstrand cross-link 
(ICL) repair. Cell cycle (Georgetown, Tex) 10: 3999-4008 
Sertic S, Pizzi S, Cloney R, Lehmann AR, Marini F, Plevani P, Muzi-Falconi M (2011) Human exonuclease 1 
connects nucleotide excision repair (NER) processing with checkpoint activation in response to UV irradiation. 
Proceedings of the National Academy of Sciences of the United States of America 108: 13647-13652 
Sgouros J, Gaillard PH, Wood RD (1999) A relationship betweena DNA-repair/recombination nuclease family 
and archaeal helicases. Trends in biochemical sciences 24: 95-97 
Sharpless E, Chin L (2003) The INK4a/ARF locus and melanoma. Oncogene 22: 3092-3098 
Shen H, Sturgis EM, Khan SG, Qiao Y, Shahlavi T, Eicher SA, Xu Y, Wang X, Strom SS, Spitz MR, Kraemer 
KH, Wei Q (2001) An intronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell 
carcinoma of the head and neck: a case-control study. Cancer research 61: 3321-3325 
Shiloh Y (2003) ATM and related protein kinases: safeguarding genome integrity. Nature reviews Cancer 3: 
155-168 
Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei YF, Moggs JG, Carter KC, Shell BK, Evans E, de Jong 
MC, Rademakers S, de Rooij J, Jaspers NG, Hoeijmakers JH, Wood RD (1996a) Xeroderma pigmentosum 
group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 86: 811-822 
Bibliography 
130 
Sijbers AM, van der Spek PJ, Odijk H, van den Berg J, van Duin M, Westerveld A, Jaspers NG, Bootsma D, 
Hoeijmakers JH (1996b) Mutational analysis of the human nucleotide excision repair gene ERCC1. Nucleic 
acids research 24: 3370-3380 
Slupphaug G, Kavli B, Krokan HE (2003) The interacting pathways for prevention and repair of oxidative DNA 
damage. Mutation research 531: 231-251 
Soehnge H, Ouhtit A, Ananthaswamy ON (1997) Mechanisms of induction of skin cancer by UV radiation. 
Frontiers in bioscience : a journal and virtual library 2: d538-551 
Soltys DT, Rocha CR, Lerner LK, de Souza TA, Munford V, Cabral F, Nardo T, Stefanini M, Sarasin A, Cabral-
Neto JB, Menck CF (2013) Novel XPG (ERCC5) mutations affect DNA repair and cell survival after ultraviolet 
but not oxidative stress. Human mutation 34: 481-489 
Soufir N, Ged C, Bourillon A, Austerlitz F, Chemin C, Stary A, Armier J, Pham D, Khadir K, Roume J, Hadj-
Rabia S, Bouadjar B, Taieb A, de Verneuil H, Benchiki H, Grandchamp B, Sarasin A (2010) A prevalent 
mutation with founder effect in xeroderma pigmentosum group C from north Africa. The Journal of investigative 
dermatology 130: 1537-1542 
Sperling J, Azubel M, Sperling R (2008) Structure and function of the Pre-mRNA splicing machine. Structure 
(London, England : 1993) 16: 1605-1615 
Srebrow A, Kornblihtt AR (2006) The connection between splicing and cancer. Journal of cell science 119: 
2635-2641 
Staresincic L, Fagbemi AF, Enzlin JH, Gourdin AM, Wijgers N, Dunand-Sauthier I, Giglia-Mari G, Clarkson 
SG, Vermeulen W, Scharer OD (2009) Coordination of dual incision and repair synthesis in human nucleotide 
excision repair. The EMBO journal 28: 1111-1120 
Su Y, Orelli B, Madireddy A, Niedernhofer LJ, Scharer OD (2012) Multiple DNA binding domains mediate the 
function of the ERCC1-XPF protein in nucleotide excision repair. The Journal of biological chemistry 287: 
21846-21855 
Sugasawa K, Ng JM, Masutani C, Iwai S, van der Spek PJ, Eker AP, Hanaoka F, Bootsma D, Hoeijmakers JH 
(1998) Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision 
repair. Molecular cell 2: 223-232 
Sugasawa K, Okuda Y, Saijo M, Nishi R, Matsuda N, Chu G, Mori T, Iwai S, Tanaka K, Tanaka K, Hanaoka F 
(2005) UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex. Cell 121: 
387-400 
Sun K, Gong A, Liang P (2015) Predictive impact of genetic polymorphisms in DNA repair genes on 
susceptibility and therapeutic outcomes to colorectal cancer patients. Tumour biology : the journal of the 
International Society for Oncodevelopmental Biology and Medicine 36: 1549-1559 
Suzuki K, Yu C, Qu J, Li M, Yao X, Yuan T, Goebl A, Tang S, Ren R, Aizawa E, Zhang F, Xu X, Soligalla RD, 
Chen F, Kim J, Kim NY, Liao HK, Benner C, Esteban CR, Jin Y, Liu GH, Li Y, Izpisua Belmonte JC (2014) 
Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced 
pluripotent stem cell clones. Cell stem cell 15: 31-36 
Szostak JW, Orr-Weaver TL, Rothstein RJ, Stahl FW (1983) The double-strand-break repair model for 
recombination. Cell 33: 25-35 
Takahashi D, Sato K, Hirayama E, Takata M, Kurumizaka H (2015) Human FAN1 promotes strand incision in 
5'-flapped DNA complexed with RPA. Journal of biochemistry 158: 263-270 
Takahata C, Masuda Y, Takedachi A, Tanaka K, Iwai S, Kuraoka I (2015) Repair synthesis step involving 
ERCC1-XPF participates in DNA repair of the Top1-DNA damage complex. Carcinogenesis 36: 841-851 
Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto M, Utsumi H, Yamaguchi-Iwai Y, Shinohara A, 
Takeda S (1998) Homologous recombination and non-homologous end-joining pathways of DNA double-strand 
break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. The EMBO 
journal 17: 5497-5508 
Bibliography 
131 
Tamura D, DiGiovanna JJ, Kraemer KH (2010) Founder mutations in xeroderma pigmentosum. The Journal of 
investigative dermatology 130: 1491-1493 
Tapias A, Auriol J, Forget D, Enzlin JH, Scharer OD, Coin F, Coulombe B, Egly JM (2004) Ordered 
conformational changes in damaged DNA induced by nucleotide excision repair factors. The Journal of 
biological chemistry 279: 19074-19083 
Thoma F (1999) Light and dark in chromatin repair: repair of UV-induced DNA lesions by photolyase and 
nucleotide excision repair. The EMBO journal 18: 6585-6598 
Thorel F, Constantinou A, Dunand-Sauthier I, Nouspikel T, Lalle P, Raams A, Jaspers NG, Vermeulen W, Shivji 
MK, Wood RD, Clarkson SG (2004) Definition of a short region of XPG necessary for TFIIH interaction and 
stable recruitment to sites of UV damage. Molecular and cellular biology 24: 10670-10680 
Tian M, Shinkura R, Shinkura N, Alt FW (2004) Growth retardation, early death, and DNA repair defects in 
mice deficient for the nucleotide excision repair enzyme XPF. Molecular and cellular biology 24: 1200-1205 
Tillhon M, Cazzalini O, Nardo T, Necchi D, Sommatis S, Stivala LA, Scovassi AI, Prosperi E (2012) p300/CBP 
acetyl transferases interact with and acetylate the nucleotide excision repair factor XPG. DNA repair 11: 844-
852 
Tomicic MT, Kaina B (2013) Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to 
camptothecin-like topoisomerase I inhibitors. Biochimica et biophysica acta 1835: 11-27 
Tripsianes K, Folkers G, Ab E, Das D, Odijk H, Jaspers NG, Hoeijmakers JH, Kaptein R, Boelens R (2005) The 
structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in 
nucleotide excision repair. Structure (London, England : 1993) 13: 1849-1858 
Truglio JJ, Croteau DL, Van Houten B, Kisker C (2006) Prokaryotic nucleotide excision repair: the UvrABC 
system. Chemical reviews 106: 233-252 
Tsodikov OV, Enzlin JH, Scharer OD, Ellenberger T (2005) Crystal structure and DNA binding functions of 
ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1. Proceedings of the National 
Academy of Sciences of the United States of America 102: 11236-11241 
van Duin M, de Wit J, Odijk H, Westerveld A, Yasui A, Koken MH, Hoeijmakers JH, Bootsma D (1986) 
Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology 
with the yeast DNA repair gene RAD10. Cell 44: 913-923 
van Gool AJ, van der Horst GT, Citterio E, Hoeijmakers JH (1997) Cockayne syndrome: defective repair of 
transcription? The EMBO journal 16: 4155-4162 
van Vuuren AJ, Appeldoorn E, Odijk H, Yasui A, Jaspers NG, Bootsma D, Hoeijmakers JH (1993) Evidence for 
a repair enzyme complex involving ERCC1 and complementing activities of ERCC4, ERCC11 and xeroderma 
pigmentosum group F. The EMBO journal 12: 3693-3701 
Veres A, Gosis BS, Ding Q, Collins R, Ragavendran A, Brand H, Erdin S, Cowan CA, Talkowski ME, 
Musunuru K (2014) Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted 
human stem cell clones detected by whole-genome sequencing. Cell stem cell 15: 27-30 
Vink AA, Roza L (2001) Biological consequences of cyclobutane pyrimidine dimers. Journal of photochemistry 
and photobiology B, Biology 65: 101-104 
Wahl MC, Will CL, Luhrmann R (2009) The spliceosome: design principles of a dynamic RNP machine. Cell 
136: 701-718 
Wakasugi M, Reardon JT, Sancar A (1997) The non-catalytic function of XPG protein during dual incision in 
human nucleotide excision repair. The Journal of biological chemistry 272: 16030-16034 
Wan B, Yin J, Horvath K, Sarkar J, Chen Y, Wu J, Wan K, Lu J, Gu P, Yu EY, Lue NF, Chang S, Liu Y, Lei M 
(2013) SLX4 assembles a telomere maintenance toolkit by bridging multiple endonucleases with telomeres. Cell 
reports 4: 861-869 
Bibliography 
132 
Wang Y, Digiovanna JJ, Stern JB, Hornyak TJ, Raffeld M, Khan SG, Oh KS, Hollander MC, Dennis PA, 
Kraemer KH (2009a) Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. 
Proceedings of the National Academy of Sciences of the United States of America 106: 6279-6284 
Wang Z, Burge CB (2008) Splicing regulation: from a parts list of regulatory elements to an integrated splicing 
code. RNA (New York, NY) 14: 802-813 
Wang Z, Gerstein M, Snyder M (2009b) RNA-Seq: a revolutionary tool for transcriptomics. Nature reviews 
Genetics 10: 57-63 
Weeda G, Donker I, de Wit J, Morreau H, Janssens R, Vissers CJ, Nigg A, van Steeg H, Bootsma D, 
Hoeijmakers JH (1997) Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, 
nuclear abnormalities and senescence. Current biology : CB 7: 427-439 
Wei C, Liu J, Yu Z, Zhang B, Gao G, Jiao R (2013) TALEN or Cas9 - rapid, efficient and specific choices for 
genome modifications. Journal of genetics and genomics = Yi chuan xue bao 40: 281-289 
Wei J, Zaika E, Zaika A (2012) p53 Family: Role of Protein Isoforms in Human Cancer. Journal of nucleic acids 
2012: 687359 
Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B (2004) Reduced levels of XPA, ERCC1 and 
XPF DNA repair proteins in testis tumor cell lines. International journal of cancer 110: 352-361 
Whiley PJ, Guidugli L, Walker LC, Healey S, Thompson BA, Lakhani SR, Da Silva LM, Tavtigian SV, Goldgar 
DE, Brown MA, Couch FJ, Spurdle AB (2011) Splicing and multifactorial analysis of intronic BRCA1 and 
BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the 
intron/exon boundary. Human mutation 32: 678-687 
Will CL, Luhrmann R (2011) Spliceosome structure and function. Cold Spring Harbor perspectives in biology 3 
Wood AJ, Lo TW, Zeitler B, Pickle CS, Ralston EJ, Lee AH, Amora R, Miller JC, Leung E, Meng X, Zhang L, 
Rebar EJ, Gregory PD, Urnov FD, Meyer BJ (2011) Targeted genome editing across species using ZFNs and 
TALENs. Science (New York, NY) 333: 307 
Wood RD (2010) Mammalian nucleotide excision repair proteins and interstrand crosslink repair. Environmental 
and molecular mutagenesis 51: 520-526 
Wood RD, Burki HJ, Hughes M, Poley A (1983) Radiation-induced lethality and mutation in a repair-deficient 
CHO cell line. International journal of radiation biology and related studies in physics, chemistry, and medicine 
43: 207-213 
Wu Y, Mitchell TR, Zhu XD (2008) Human XPF controls TRF2 and telomere length maintenance through 
distinctive mechanisms. Mechanisms of ageing and development 129: 602-610 
Wyatt HD, Sarbajna S, Matos J, West SC (2013) Coordinated actions of SLX1-SLX4 and MUS81-EME1 for 
Holliday junction resolution in human cells. Molecular cell 52: 234-247 
Yagi T, Wood RD, Takebe H (1997) A low content of ERCC1 and a 120 kDa protein is a frequent feature of 
group F xeroderma pigmentosum fibroblast cells. Mutagenesis 12: 41-44 
Yamamoto KN, Kobayashi S, Tsuda M, Kurumizaka H, Takata M, Kono K, Jiricny J, Takeda S, Hirota K (2011) 
Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. Proceedings 
of the National Academy of Sciences of the United States of America 108: 6492-6496 
Yan CT, Boboila C, Souza EK, Franco S, Hickernell TR, Murphy M, Gumaste S, Geyer M, Zarrin AA, Manis 
JP, Rajewsky K, Alt FW (2007) IgH class switching and translocations use a robust non-classical end-joining 
pathway. Nature 449: 478-482 
Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R (2013) One-step generation of mice carrying 
reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154: 1370-1379 




Yokoyama H, Mizutani R, Satow Y, Sato K, Komatsu Y, Ohtsuka E, Nikaido O (2012) Structure of the DNA (6-
4) photoproduct dTT(6-4)TT in complex with the 64M-2 antibody Fab fragment implies increased antibody-
binding affinity by the flanking nucleotides. Acta crystallographica Section D, Biological crystallography 68: 
232-238 
You YH, Lee DH, Yoon JH, Nakajima S, Yasui A, Pfeifer GP (2001) Cyclobutane pyrimidine dimers are 
responsible for the vast majority of mutations induced by UVB irradiation in mammalian cells. The Journal of 
biological chemistry 276: 44688-44694 
Zhang F, Scheerer P, Oberpichler I, Lamparter T, Krauss N (2013a) Crystal structure of a prokaryotic (6-4) 
photolyase with an Fe-S cluster and a 6,7-dimethyl-8-ribityllumazine antenna chromophore. Proceedings of the 
National Academy of Sciences of the United States of America 110: 7217-7222 
Zhang J, Walter JC (2014) Mechanism and regulation of incisions during DNA interstrand cross-link repair. 
DNA repair 19: 135-142 
Zhang Z, Pal S, Bi Y, Tchou J, Davuluri RV (2013b) Isoform level expression profiles provide better cancer 
signatures than gene level expression profiles. Genome medicine 5: 33 
Zhao S, Liu W, Li Y, Liu P, Li S, Dou D, Wang Y, Yang R, Xiang R, Liu F (2016) Alternative Splice Variants 
Modulates Dominant-Negative Function of Helios in T-Cell Leukemia. PloS one 11: e0163328 
Zhu XD, Niedernhofer L, Kuster B, Mann M, Hoeijmakers JH, de Lange T (2003) ERCC1/XPF removes the 3' 
overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute 




8 Curriculum vitae 
Personal details  
Name   Janin Lehmann 
  born 21
st
 March 1989 in Westerstede, Germany 
Address Clinic and Policlinic for Dermatology and Venereology  




02/2016 – today Continuation of PhD thesis after laboratory move: “Functional relevance of 
spontaneous alternative splice variants of xeroderma pigmentosum genes: 
prognostic markers for skin cancer risk and disease outcome?”; Clinic and 
Policlinic for Dermatology and Venerology, University Medical Center Rostock 
12/2015 – 01/2016 Organization and execution of laboratory move 
03/2014 – 11/2015 PhD thesis at the Department of Dermatology, Venereology and Allergology, 
University Medical Center Goettingen, supervised by Prof. Dr. med. Steffen 
Emmert with the title: "Functional relevance of spontaneous alternative splice 
variants of xeroderma pigmentosum genes: Prognostic marker for skin cancer risk 
and disease outcome?". 
05/2013 – 02/2014 Research assistant at the Department of Dermatology, Venereology and 
Allergology, University Medical Center Goettingen working on “Characterization 
of xeroderma pigmentosum patients”. 
10/2012 – 04/2013 Master thesis at the Department of Dermatology, Venereology and Allergology, 
University Medical Center Goettingen, supervised by  Prof. Dr. med. Steffen 
Emmert with the title: "Characterization of novel xeroderma pigmentosum group G 
spontaneous mRNA splice variants." 
10/2011 – 04/2013 Master of Science in Molecular Medicine, Georg-August-University Goettingen, 
Germany  
03/2011 – 07/2011 Bachelor thesis at the Department of Dermatology, University of Luebeck, 
supervised by Prof. Dr. med. Ralf Paus with the title: "The influence of nestin+ 
progenitor cells on wound healing in human skin."  
10/2008 – 09/2011 Bachelor of Science in Molecular Life Science, University of Luebeck, Germany  
05/2008 High School Diploma at the Europaschule-Gymnasium Westerstede, Germany 
 
 
